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Abstract  
Malaria is a pestilent disease associated with massive socioeconomic burden of 
sub-Saharan Africa. This disease is caused by a blood infection of the single cellular 
parasite of the Plasmodium genus. Two enzymes of this parasite have been identified to be 
essential to the survival of this parasite, notably Spermidine Synthase and Protein 
Farnesyltransferase. The goal of this dissertation was to search for and synthesise novel 
inhibitors of these two enzymes with a strong focus towards understanding their 
structure/activity relationships.  
To achieve the first goal, molecular modelling was employed. An in-depth discussion is 
presented to describe the underlying principles relevant to this branch of computational 
chemistry. This ensures that the experiments using these methods are set-up correctly and 
results are interpreted within context. Two virtual high-throughput screens were then 
performed using prepared crystallographic structures of Spermidine Synthase. The first was 
pharmacophore based method and the second based on LibDock. The database used, 
containing 7.1 million compounds, was filtered using a custom developed tool prior to 
screening. Finally, CDOCKER was then used to investigate the activity of potential hit 
compounds.  
Spermidine Synthase has a natural affinity for adenosine and this trait was exploited by 
derivatising analogues to synthesise potential inhibitors of the enzyme. This was to be 
achieved by the incorporation of both electrophilic and nucleophilic moieties at selected 
positions, including the use of a high yielding Mitsunobu reaction. A number of additional 
residues were then synthesised and joined to the adenosine which were proposed to 
increase the active site occupancy and increase affinity to the enzyme. 
For the second enzyme targeted for inhibition, Protein Farnesyltransferase, indole was used 
as a starting scaffold to synthesise potential hits de novo. It was aimed to derivatise the 
indole at the Nʹ and 3ʹ positions. The crystal structure of one of the intermediates was 
published. Furthermore, a synthetic sequence which culminated in a palladium catalysed 
Suzuki coupling was performed. 
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Opsomming (max. 500 words) 
Malaria is ‘n peslike siekte wat geassosieer word met beduinde sosio-ekonomiese 
implikasies vir sub-Sahara Afrika. Die siekte word veroorsaak deur ‘n bloed infeksie van die 
enkel sellulêre parasiet van die Plasmodium genus. Twee ensieme, naamlik Spermidien 
Sintetase en Protein Farnesieltransferase,  is geïdentifiseer  om noodsaaklik te wees vir die 
oorlewing van die parasiet. Die doelwit van hierdie verhandeling is die soektog en sintese 
van oorspronklike inhibeerders van hierdie twee ensieme met ‘n sterk fokus daarop om 
struktuur/aktiwiteit interaksies te verstaan. 
Om die eerste doelwit te bereik is molekulêre modellering toegepas. ‘n Indiepte ondersoek 
word voorgestel om die onderliggende beginsels relevant tot hierdie tak van berekenkundige 
chemie te beskryf. Dit verseker dat eksperimente wat op hierdie tegnieke berus korrek 
opgestel word en dat die resultate binne konteks geïnterpreteer word. Twee virtuele 
hoë-deurset skerms was deurgevoer op voorbereide kristallografiese strukture van 
Spermidien Sintetase. Die eerste het berus op ‘n pharmakoforiese metode en die tweede op 
LibDock. ‘n Self-ontwikkelde sagteware gereedskap stuk is gebruik om a databasis van 
7.1 miljoen verbindings te filtreer voor dit gebruik is in hoë-deurset skerms. Uiteindelik is 
CDOCKER gebruik om die potensiele aktiwiteit van “treffer” verbindings te beraam.  
Spermidien syntetase het ‘n natuurlike affiniteit vir adenosien en hierdie eienskap is benut 
deur analoeë af te lei na potensiële inhibeerders teen die ensiem. Dit is bewerkstellig deur 
die insluiting van beide elektrofiliese asook nukleifielese funksionele groepe op gekose 
posisies. Dit het die gebruik van ‘n hoë opbrengs Mitsunobu reaksie ingesluit. ‘n Aantal 
ander addisionele residueë is toe gesintetiseer en geheg aan die afgeleide adenosien om 
die ensiem setel te vul en sodoende die affinitieit te verhoog. 
Vir die tweede ensiem wat geteiken is vir inhibisie, Protein Farnesieltransferase, is indool 
benuttig as ‘n begin steier te dien om potensiële treffers  de novo te sintetiseer. Dit is 
geteiken om die indool af te lei op die Nʹ en 3ʹ posisies en die kristal struktuur van een van 
hierdie tussengangers is gepubliseer. Verder is ‘n sintetiese weg, wat uitgeloop het  op ‘n 
palladium gekataliseerde Suzuki koppeling, uitgevoer. 
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GPCR ................................. G-protein coupled receptor 
HMPA ................................. Hexamethylphosphoramide 
LAH .................................... lithium aluminium hydride (LiAlH4) 
4MCHA ............................... 4-methylcyclohexylamine 
MMFF ................................. Merck molecular force field 
MTA.................................... 5’-methylthioadenosine 
NME ................................... new molecular entity 
NMR ................................... nuclear magnetic resonance 
ODC ................................... ornithine decarboxylase 
PAO.................................... polyamine oxidase 
PBSA .................................. Poisson-Boltzmann with non-polar surface area  
PDB .................................... protein databank 
pfAdoMetDC/ODC .............. Plasmodium falciparum adenosine methionine decarboxylase / ornithine decarboxylase 
PME ................................... Particle Mesh Ewald 
PFT .................................... Protein Farnesyltransferase 
PTSA .................................. p-toluene sulfonic acid 
Putrescine .......................... 1,4-diaminobutane 
SAR .................................... structure activity relationship 
SpdSyn ............................... spermidine synthase 
hsSpdSyn ........................... Homo sapiens spermidine synthase 
pfSpdSyn ............................ Plasmodium falciparum spermidine synthase 
QSAR ................................. Quantitative structure-activity relationship 
SBDD ................................. Structure based drug design 
SD ...................................... steepest descent (minimisation algorithm) 
SpmSyn .............................. spermine synthase 
TBDMS(Cl) ......................... tert-butyl dimethyl silyl(chloride) 
TEA .................................... triethylamine 
THF .................................... tetrahydrofuran 
THQ.................................... tetrahydroquinoline 
TLC .................................... thin layer chromatography 
vHTS .................................. virtual high throughput screen 
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Conventions used throughout this dissertation 
3D Structures are presented as follows (unless specified otherwise): 
Atoms 
Carbon: ......................... Grey (or orange for highlighting).    
Oxygen:  ........................ Red  
Nitrogen:  ...................... Blue 
Hydrogen:  .................... White 
Sulfur:  ........................... Yellow 
 
Protein structures 
Alpha-helixes................. Red and  
Beta-sheets  .................. Light blue. 
 
Other 
Hydrogen bonding ......... Dotted green lines 
Pi-stacking .................... Orange lines 
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1. Introduction 
Medicinal chemistry 
The use of medicine has been around since records began. In ancient Egypt, people 
consumed extracts of the poppy plant to alleviate pain, not knowing how or why they worked. 
This extract is still widely used today, which is more commonly known as morphine.2 In 
ancient Greece, women dilated their pupils to beautify themselves with Solanaceae plants 
which contained atropine.3 Aztec and Mayan civilisations used the ipecac root, which 
contained emetine, to treat infections and induce vomiting.4 The extract of the Willow tree’s 
bark, rich in salicylic acid, was described by Hippocrates to reduce pain and fever.5 In 1928 
Alexander Fleming made the Nobel Prize winning discovery of Penicillium and so ushered 
humanity into the antibiotic era.6, 7  
Throughout the twentieth century, our brightest minds have modified natural product isolates 
to create life altering pharmaceuticals. Although we still look towards Nature for inspiration, 
newer methods are being developed. Today, modern drug discovery programmes rely on ab 
initio principles to rationally design pharmaceuticals. This is the field of modern medicinal 
chemistry.  
The drug discovery process 
Modern drug discovery is an extended, complicated and extremely expensive process – the 
average cost to bring a drug to market after a hit compound has been identified is estimated 
to be $1.8 Billion.8 However, the profit incentives are equally lucrative, in addition there is 
satisfaction of being involved in a project which may benefit the lives of millions of people. To 
bring the entire project to fruition, the skills of multiple disciplines are required – those of 
science, medicine, law and business economics.  
The first step in the endeavour is the selection of a disease. Different diseases present 
different difficulties, incentives, success rates and capital requirements (both financial and 
human). For example, diseases of the third world affect many millions of people who can 
barely afford food – let alone expensive pharmaceuticals. This demands that the cost for 
each therapeutic administration be very inexpensive. In this case, the main incentive would 
be the humanitarian effort. However, drugs which alleviate ailments of the first world can 
command wide profit margins. Pills which offer weight loss are marketed towards patients 
who can typically pay for expensive, tailor-made pharmaceuticals. In this case, the main 
incentive is profit.  
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Key to the industry are patents: Patent protection only lasts 20 years whereas drug 
development typically lasts roughly 13 years – meaning there are only 7 years to recoup the 
massive expenditures and still turn a profit.8 Sometimes, development takes longer and the 
project may be cancelled. In light of this, countries (including USA) have realised that this is 
stifling the output of new drugs and now offer market exclusivity periods (5 years for a New 
Chemical Entity) to incentivise new innovators.9  
After a disease has been selected, the biological target for manipulation needs to be decided 
upon. Following this, a number of compounds are tested for activity. Once a compound 
exhibiting a measure of desired activity is discovered, known as a “hit”, it becomes the 
subject of intense further development. This hit is then developed in the “hit to lead” phase: 
This involves significant synthetic work which is performed in parallel with animal studies to 
optimise binding characteristics and assess toxicity. If these succeed, human clinical trials 
may commence. The clinical trials are notoriously rigorous and most candidates fail them.10 
However, should the drug candidate succeed the clinical trials, the drug is registered and 
placed on the market.  
Concurrent with the trials, large scale industrial syntheses of the drugs are developed. 
During this time, costs soar. Strategic business decisions need to be made; shareholder 
equity is diluted to ensure that liquid capital is always on tap. This while keeping in mind that 
at any time, the drug candidate may fail a step. At best, the process may be moved back 
several steps. At worst, the entire project may be terminated and all investments made are 
forfeit.11 Indeed, the road to launch a new drug is fraught with significant hurdles which 
require careful consideration. One of the first ones is the selection of an appropriate target. 
Targets 
In order for a pharmaceutical to exert its action, it interacts with the naturally occurring 
physiological effectors. These effectors, deemed drug targets, are chosen for their key 
involvements in cellular processes. The major targets for pharmaceuticals and their 
prevalence are presented in Figure 1-1. The largest group of targets are receptors.12 These 
proteins are key components in signal transduction. They are embedded within the cellular 
membrane where they are stimulated by extracellular, chemical messenger molecules, 
hormones, and relay these messages into the cell. Within this class, the G-protein coupled 
receptors (GPCR’s) form the largest subset. Other receptors include the enzyme linked 
tyrosine kinases and ion-channels.13-16 The next biggest target for pharmaceuticals are 
enzymes. Enzymes are the main effectors of regulating the cellular environment, being 
intricately involved in the conversion of metabolites. Other targets include nucleic acids or 
the factors which govern their transcription. 
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Figure 1-1 Pie chart of the main biomolecule classes which are targeted by current 
pharmaceuticals.
12
 
Although there are exceptions, there are 2 major strategies to modulate the cellular 
environment for a wanted physiological response: Either through the decrease or increase in 
the activity of these mentioned targets.17 Compounds which have these effects on targets 
are termed antagonists and agonists, respectively. Typically, this is achieved through the 
use of molecules which resemble the natural substrates which are termed substrate 
analogues.18 
In the former case, inhibitors are effectively used to occupy the active site. This blocks the 
natural substrate from entering and so limits product formation. Take for example, the 
sulfonamides: These antibiotics inhibit the enzyme dihydropteroate synthetase, stopping 
folate biosynthesis. The effect is that the bacterium becomes starved of essential folates, 
dies and so the infection is ended. Because humans do not have this enzyme and folates 
are acquired though the diet, only the bacterium is affected.19 Inhibition can be classed into 
three major categories. Firstly, there is competitive inhibition. This is when the drug 
competes with the natural substrate for the active site of the target. Secondly, uncompetitive 
inhibition requires that the natural substrate be bound prior to the drug’s interaction. Thirdly, 
there is the case of irreversible inhibition. In this case, a covalent bond is formed between 
the drug and enzyme, which permanently disables the enzyme. Typically, nucleophilic 
residues (serine and cysteine, with hydroxyls and thiols, respectively) in the active site 
perform nucleophilic attack on the drug’s electrophilic centrums. Penicillin and aspirin are 
well known examples which fall within this category.20, 21 
In contrast to inhibiting targets, it is also possible to stimulate them. Agonists can exert their 
effects either by direct or allosteric interaction with the active site.  
Classes of drug targets 
(45%) Receptors
(28%) Enzymes
(11%) Hormones and factors
(7%) Unknown
(5%) Ion channels
(2%) Nuclear receptors
(2%) Nucleic acids
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When deciding upon a target to treat a particular disease, careful consideration should be 
used. Altering a biological pathway or signal cascade may incur numerous unwanted side 
effects and the implications thereof must be fully understood. For example, in the design of 
cholesterol medication, an unforeseen problem arose. Although cholesterol is supplemented 
from diet, it is also synthesised by the body. A number of enzymes are involved in the 
biosynthetic pathway and any one of them can be subjected to inhibition. One effort to block 
this cholesterol producing pathway was to inhibit one of the final enzymes in the pathway. 
Although the enzyme was successfully inhibited and cholesterol production within the body 
was significantly lowered, toxicity issues were reported. It was soon determined that the 
substrate to the enzyme that was being inhibited was, similar to cholesterol itself, a very 
hydrophobic molecule. This led to the accumulation of the insoluble intermediates which, in 
turn, led to the reported toxicity issues. By choosing an earlier step in this pathway, the 
accumulating intermediates were much more water soluble and did not exhibit the toxicity 
issues. Ultimately, this second strategy led to the statins, one of the most profitable class of 
pharmaceuticals on the market, some of which can be seen in Figure 1-2.18 
 
Figure 1-2 Three of the statins 
Hit discovery strategies 
After having selected a target in the drug discovery pipeline, the next step entails finding a 
molecule which has some sort of modulating activity against the target. This requires the 
discovery of a hit. A hit is a compound which shows notable activity towards a particular 
target. To obtain a hit, there are a number of strategies.  
Rational drug design 
Rational drug design entails tailoring a compound to interact with a specific target. This can 
either be accomplished by ligand based drug design (LBDD) or receptor based drug design, 
more commonly known as structure based drug design (SBDD). The former case requires a 
set of active ligands. These ligands are systematically modified and their activities measured 
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to build a map of the functional chemical space around the target. By compiling this 
information into a statistical model, it is possible to predict which compounds would also be 
active. This is known as a quantitative structure activity relationship (QSAR) strategy.22 The 
successful QSAR application relies on the two parameters regarding the input training set. 
The training set should be large, preferably above 100 compounds. Secondly, the set should 
include ligands which are as structurally diverse as possible. Failure of incorporating diverse 
ligands would lead to diminished possibility of finding a novel structure with a significant 
increase in pharmacological activity.  
On the other hand, SBDD requires the 3D co-ordinates of the target protein, obtained by X-
ray crystallography or NMR spectroscopy. This strategy is most likely to yield novel drug 
classes as the structural features of the target site can be thoroughly and accurately 
explored. A recent success using this method is exemplified in the marketed anti-HIV 
pharmaceuticals Saquinavir, Ritonavir, Indinavir and Nelfinavir (see Figure 1-3).23 These 
inhibitors target the retroviral protease of the human immunodeficiency (HIV) virus type 1. 
Using structures which were obtained from X-ray crystallography, it was observed that the 
HIV protease cleaves an amide bond between Tyr-Pro and Phe-Pro peptide sequences. The 
designers then incorporated a structural motif which has a similar interaction to the protein, 
without proteolytic susceptibility. This then led to a high degree of affinity for the key enzyme 
and significantly reduced viral reproductive capability. 
 
Figure 1-3 Saquinavir 
If a structure is unavailable, a homology model can be constructed. A homology model is a 
protein model which is constructed piecewise from other known protein segments. Although 
there is less certainty in these models, compared to that of an experimental observation, 
these models have successfully been used in the design of pharmaceuticals.18  
One of the most significant methods available in SBDD is the idea of fragment growing. 
Small molecule fragments are placed within the active site. These fragments are then linked 
together to grow a complete molecule. This method has the advantage that new scaffolds 
are more likely to be introduced. Programs which do this include CAVEAT, SPROUT and 
LUDI.24-26  
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In light of the importance which knowledge of the target structure may bring, the protein 
databank (PDB) was founded.27 The PDB is a global database of protein structures which 
have been determined either through crystallography or NMR. Since it was founded, the 
PDB has grown tremendously – a testimony to the importance of its existence (see Figure 
1-4). Further, 92% of marketed drugs have targets which are similar to proteins found within 
the PDB.28  
 
Figure 1-4 Graph of the total number of PDB entries per year.  
Virtual High Throughput Screening 
The other main hit discovery strategy which uses the 3D structure of a protein in silico, is 
virtual high throughput screening (vHTS). In contrast to the piecewise construction of new 
molecules de novo, vHTS attempts to place whole molecules in the active site and then use 
scoring algorithms to measure how well they fit.29, 30 Using pre-compiled databases, many 
millions of compounds may be screened for possible activity.31-33 This topic is discussed in 
more detail in chapter 4.    
High throughput screening 
High throughput screening (HTS) entails physically testing large compound libraries for 
possible bioactive qualities in vitro. These tests are performed by autonomous robots which 
are able to screen over a thousand micro assays on a single multiwell plate. Aside from the 
robotic requirements, there are two main caveats of this technology: The availability of a 
suitable bioassay and the libraries themselves.  
Firstly, the assay should lend itself to high throughput implementation. Typically, UV/Vis 
spectroscopy and radioactivity measurements are employed. Secondly, the libraries should 
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
1970 1975 1980 1985 1990 1995 2000 2005 2010 2015
Protein Databank entries per year 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 1 – Introduction 
 
7 
be both sufficiently large (>10 000 compounds) and diverse to thoroughly explore the 
chemical space of the target. In industry, these libraries may comprise previously 
synthesised molecules or be obtained through synthesis.18 
Selective optimisation of side affects 
Selective optimisation of side effects (SOSA) attempts to capitalise on an unexpected but 
useful side effect in one drug making it the primary in another. Ideally, the original activity of 
the drug is minimised by optimisation of the drug molecule.34 The drug sildenafil, more 
popularly known as Viagra®, was developed by this method.  
“Me too” drugs 
By starting with an already marketed drug, a competing company may attempt producing its 
own analogue of similar structure. The newly developed drug may offer improvements over 
the current market leader. It is interesting to note that between 1989 and 2000, 76% of new 
molecular entities (NME) were targeting already targeted protein domains, compared to only 
6% which targeted new protein domains.28 Sir James Black, a Nobel laureate in medicine, 
once said: “The most fruitful basis for the discovery of a new drug is to start with an old 
drug.”35  
Hit to lead 
Once a hit has been discovered, it becomes the subject of intense development. A number 
of properties need to be optimised. First and foremost, the lead candidate needs to a have 
maximum affinity to the target and this needs to be developed. The study of how the drug 
interacts with a target site is defined as pharmacodynamics. But also, having successfully 
developed a compound with maximal activity in vitro is most definitely not a final 
pharmaceutical product. Delivering a chemical compound into someone’s body is fraught 
with complexity. The body also affects the drug in numerous ways. As is often the case, it is 
not the most potent compound which is placed on the market, but a compound which also 
satisfies numerous other criteria. These criteria are categorised under pharmacokinetics. 
Firstly, we shall discuss pharmacodynamics. 
Pharmacodynamics 
Pharmacodynamics concerns the aspects which allow a drug to bind to its target. Before we 
can discuss drug binding, we need a way to quantify the interaction. The majority of drugs 
have reversible interactions with their targets. The equilibrium between the enzyme and the 
inhibitor can be depicted as follows: 
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Where [T] & [I] are the free target & inhibitor concentrations; [TI] is the concentration of the 
complex formed; and K & Ki are the forward & reverse equilibrium constants, respectively. 
As the Ki decreases, the equilibrium shifts to the right, favouring the inhibitor complex – 
indicating increased binding affinity. The average Ki of marketed pharmaceuticals are in the 
order of 20 nM.28 Alternatively, an inhibitor’s potency can be quantified by an IC50 – the 
concentration where 50% of maximal inhibition is observed. Graphically, this may be 
visualised by setting up a dose response curve (see Figure 1-5). 
 
Figure 1-5 Dose response curves highlighting differences between efficacy and potency.  
Efficacy refers to the magnitude of the response obtained, regardless of drug concentration – in this 
case drugs A and B have similar efficacies. Potency refers to the concentration where half the maximal 
response is reached – in this case drugs B and C have similar potencies.  
Typically, IC50 is used in whole cell assays, whereas Ki is more typically used in enzymatic 
assays. Through the use of the Cheng-Prusoff equation36, the two may be interconverted.  
 
Ki  =  
IC50
(1+
[L]
KD
)
 
Eq 1 
Where [L] is the radio-ligand concentration used in the specific assay and KD is the affinity 
for the radio-ligand.  
Because Ki is the inverse of the equilibrium constant, it can be related to the change in 
Gibbs free energy by the following equation:  
 
∆G    =  − RT ln K 
          =      RT ln Ki 
Eq 2 
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Where ΔG equals the change in Gibbs free energy, R & T are the universal gas constants & 
temperature respectively, and K is the equilibrium constant.  
The change in Gibbs free energy is more commonly given by the following expression 
 ∆G  =  ∆H − T∆S Eq 3 
Where ΔH and ΔS are the changes in enthalpy and entropy, respectively. In an attempt to 
quantify how various aspects of a drug binding to the target contribute to the change in free 
energy, the respective contributions are given by the following equation.37 
 ∆G  =  ∆Gtrans+rot + ∆Gconf + ∆Gpolar + ∆Ghydrophob + ∆GvdW Eq 4 
This allows us to optimise for each term individually when designing drug candidates. 
Keeping these parameters in mind, it is important to realise that drug binding is a relatively 
complex process: 
Initially, the drug is in an entropically favoured, disorganised conformation as it tumbles 
freely in solution. The polar areas are complexed to solvent water molecules. For binding to 
be achieved, several things need to happen. Firstly, the molecule needs to adopt its 
bioactive conformation, which entails an entropic penalty. The drug then associates to the 
protein, losing its tumbling freedom – another entropic penalty. The desolvation penalty then 
comes into play: polar areas on the drug lose polar interactions as the water molecules 
around it are displaced. Even though these interactions may be replaced with chemical 
moieties from the protein, it is the net energy difference which affects the binding 
characteristics. Another favourable binding interaction then comes into play: the hydrophobic 
effect. Water molecules associated around hydrophobic areas of the drug are highly 
organised – an entropically disfavoured state. As the drug binds, these water molecules are 
then freed to resume a disorganised state. Finally, the van der Waals interactions govern the 
steric interactions as the drug complexes to the protein.38 
The interior of the receptor site may also be filled with water molecules. As the drug binds, 
these water molecules are displaced by the interactions of the protein with the drug.   
Pharmacokinetics - ADMET 
As a lead becomes further developed, it must always remain in the designer’s mind that the 
ultimate goal is to administer the drug to a person. Patient safety is of paramount 
importance. To ensure this, the interactions a drug as it travels through the body must be 
studied and optimised in a predictive manner. These concerns are addressed under 
pharmacokinetics. Pharmacokinetics entails five criteria, collectively named ADMET: 
Absorption, Distribution, Metabolism, Excretion and Toxicity. 
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Absorption 
For a drug to be effective, it needs to reach its site of action in its active form in sufficient 
quantity. But firstly, it needs to be administered. The preferred delivery method is oral, but it 
is also the most challenging route. The drug needs to be stable in the stomach acids, 
followed by the basic conditions of the gut. Following this, the drug needs to be hydrophobic 
enough to permeate the intestinal cellular membrane, yet still be hydrophilic enough to be 
transported in the blood.  To better predict which compounds would show good absorptive 
qualities, Lipinski devised his rule of five.39 This rule was obtained by studying the properties 
of numerous approved drugs which show good oral absorption. The rules state that ideally 
drugs should:  
 have a molecular weight of less than 500;  
 less than or equal 5 hydrogen bond donors;  
 less than or equal 10 hydrogen acceptors;  
 cLog P less than 5 (a measurement of hydrophobicity by the partitioning of the 
molecule between water and octanol, whereas the c refers to the computed 
estimate).  
However, it should be noted that 20% of orally dosed drugs available on the market do not 
adhere to one of these parameters.28 Supplementary to this work, Veber et al. suggested 
that the number of rotational bonds should not exceed 10 and that the total polar surface 
area should not exceed 140 Å2.40 To date the most accurate method to test in vitro whether 
lead candidates show good absorptive properties, is through the use of Caco-2 cell line 
test.41 Caco-2 is an immortalised line of intestinal cells which is able to effectively mimic in 
vivo conditions. After absorption from the intestines, the drug enters the hepatoportal vein to 
enter the liver. At this point, the drug endures the liver’s so called “first pass effect” – to be 
subjected to liver metabolism before the drug may have reached its target. (Drugs which are 
injected, inhaled or taken transmucosally may bypass this effect.) Only then is the drug free 
to reach the heart and enter systemic circulation at physiological pH. By choosing alternate 
delivery methods, some of these difficulties may be avoided. These include: direct injection, 
topical application, transmucosal delivery and inhalation.  
Should a drug be administered by direct injection, all of it would reach the blood stream and 
is, by definition, said to be 100% bioavailable. However, this may be drastically different for 
alternate administration routes. Some factors which might influence this include: the drug’s 
physical properties, excipients used, physiological state and drug-drug interactions.40 
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Distribution 
For drugs to have any effect, they need to reach the target site and in sufficient quantity. By 
studying how the drug distributes around the body, it may be required to optimise the drug to 
target it to the correct locale. Drugs which struggle to cross the membrane may either be 
transported by macromolecules or be bound to blood albumin proteins. This reduces the 
amount of drug reaching the site of action. Drugs which are freely circulated in systemic 
blood are usually quickly removed by the kidneys or metabolised by the liver. However, if the 
drug is excessively hydrophobic, it may be absorbed and retained by fatty tissues. This may 
lead to sporadic and unplanned surges in drug levels. Crossing of the blood-brain barrier 
poses an additional challenge: there is an additional fatty layer to penetrate and this requires 
increased drug lipophilicity.42, 43 Similarly, crossing the placental barrier also has its own 
complications. Drugs which are present in maternal blood are easily transported to the foetal 
blood. However, the foetus does not have the same metabolic capabilities as the mother – 
with the implication that drugs can remain active for much longer. This demands special 
dosing requirements.44, 45 
Metabolism 
Analogous to the immune system which defends the body against foreign biological entities 
(bacteria, proteins, etc.) the body is also equipped with a defence system against foreign 
small molecules, namely metabolism. Metabolism is the process by which foreign molecules, 
known as xenobiotics, are chemically altered so that they can safely be expelled from the 
body as metabolites. Even though pharmaceuticals may exhibit beneficial properties to the 
body, their metabolism is essential. Metabolic failure of a drug leads to its accumulation 
within the body and this, in turn, leads to toxicity issues. Conversely, if a drug is metabolised 
too quickly, it is expelled from the body before its beneficial function is bestowed. 
The rate at which a xenobiotic is metabolised is described by its half-life - the period after 
which half of the initial concentration remains. This indicates the pharmaceutical’s active 
duration. The fine tuning of a drug’s half-life is an important step in the development process: 
Should a drug have an extended half-life, the drug would remain active for long periods of 
time. This is a wanted attribute for certain cases – for example behavioural changing 
pharmaceuticals which interact with the central nervous system. However, pain medication, 
which impairs lucidity, requires relatively quick half-life times to be able to better control the 
duration of this unwanted side effect. 
Phase I metabolism of drugs is largely controlled by the cytochrome P450 isozymes. 
Although mainly located in the liver, they are found throughout the body. Although some 
these isozymes are involved in biosynthetic processes, they are also responsible for 
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xenobiotic metabolism.46 This is achieved by the phase I metabolism of xenobiotics 
(oxidation, reduction and hydrolysis) to increase hydrophilicity for excretion via the renal 
system. The notable isozymes for human xenobiotic metabolism include: CYP3A4, CYP1A2, 
CYP2D6, CYP2E1 and CYP2Cx.47 Even though the major pathways of metabolism can be 
predicted for these major groups, genetic polymorphism, induction & inhibition (affected by 
age,48 ethnicity,49 diet,50 and health51) vastly increases the variability of how these enzymes 
interact with various xenobiotics.52  
In conjunction with phase I metabolism, phase II metabolism entails the conjugation of 
xenobiotics to hydrophilic moieties by various transferase enzymes. Typical examples of 
these transferases include: UDP-glucuronosyltransferase, Glutathione-S-transferase, N-
acetyltransferase, Sulfotransferase (see Figure 1-6).53  
 
Figure 1-6 Examples of typical Phase II metabolism conjugation reactions 
Indeed, metabolism is an extremely complicated aspect of medicinal chemistry: it challenges 
the development team to maintain a strong target binding affinity whilst simultaneously 
balancing a favourable half-life profile, minimising toxicity issues yet still accounting for the 
polymorphisms of individuals. Data points are difficult to obtain, as typically animal studies or 
clinical trials have to be used for this optimisation. Because of this, it is one of the major 
contributory factors of the massive costs involved in drug research. 
Excretion 
In humans, there are three major routes available for a drug to leave the body: the urine, 
faeces, and breath. The most common route, via urine, occurs when chemicals have 
sufficient hydrophilicity to be removed from circulation by the kidneys. Some drugs are 
actively transported into the bile, which in turn is secreted into the gastrointestinal tract. Also, 
compounds which have very low molecular weight may be gaseous and these are 
exchanged at the lungs to leave the body.  
Stellenbosch University  http://scholar.sun.ac.za
Chapter 1 – Introduction 
 
13 
Per regulatory requirements, it is the responsibility of the drug company to show that the 
drug and all its metabolites are completely excreted from the body. Failure of this could once 
again lead to toxicity issues. This can be studied by the use of radio-labelled drugs which 
can be traced as they leave the body.  
Toxicity 
 Any compound in excess is toxic and as such, toxicity issues are essentially unavoidable. 
This is due to the unplanned, promiscuous activity of drugs (or their respective metabolites) 
on unintended substrates. As long as the drug can exert is beneficial effect before it 
becomes toxic, it is deemed safe. To quantify this safety margin, both the ED50 and TD50 
dose response curves are attained (Figure 1-7), where ED50 is the dose at which 50% of 
patients experience the beneficial aspect and TD50 is the dose at which 50% of patients 
exhibit toxic side effects.  
 
Figure 1-7 Graphical representation of the therapeutic window.  
Following this, the therapeutic index (or therapeutic window) can be calculated: 
  Therapeutic index   =  
TD50
ED50
 Eq 5 
A lower ED50 and a higher TD50, leads to an improved (larger) therapeutic index. Anything 
above 50 is considered to be a relatively safe drug.18 If the therapeutic index becomes too 
low, the drug could be withdrawn. However, depending on the availability of competing 
products and the seriousness of the ailment to be treated, active monitoring of drug levels in 
the body can allow certain drugs to remain on the market even though they have a very 
small therapeutic window.  
Stellenbosch University  http://scholar.sun.ac.za
Chapter 1 – Introduction 
 
14 
There are a several ways to increase this window: Firstly, the drug’s ED50 can be improved 
by increasing the affinity for the target. The drug may also be administered in an inactive 
form as prodrug. The prodrug may then have reduced toxicity issues, and is then converted 
in the body to its active form. For example, aspirin is sometimes administered as a prodrug. 
The carboxylic acid is known to cause gastric problems. By masking it as an ester, this 
unwanted issue is avoided (see Scheme 1-1).54, 55 Prodrugs are relatively common: 16% of 
drugs on the market are prodrugs.28 
Scheme 1-1 Ester prodrug of aspirin hydrolysing to the bioactive pharmaceutical – 
acetylsalicylic acid 
 
Another way is to localise the active drug to the site of action, thereby reducing the systemic 
concentration of the drug. Targeting can be exploited by using the selectivity offered by 
antibodies. Antibodies have strong affinities for larger chemical structures which may 
otherwise be difficult to target. By covalently linking the drug to an antibody, the drug 
becomes localised in the vicinity of the antigen (target of the antibody).56 This strategy is 
particularly prominent in cancer chemotherapy.57 If it is known that the drug’s metabolites are 
the reason of concern, the drug can be engineered to yield only non-toxic metabolites. The 
drug is then termed a “soft drug”.58, 59 
In the initial phases of development, there are two critical tests which drug candidates simply 
must not fail. The first concerns mutagenicity. To check for this property, the Ames test has 
been developed.60 Also, compounds which may interfere with hERG potassium ion 
channels, involved in the regulation of heartbeat, are also quickly redesigned or discarded. 61  
Bioisosterism 
Bioisosteres are replacement moieties which are used in the fine tuning of molecules to 
produce more favourable pharmacodynamic or pharmacokinetic results. They are chosen to 
occupy similar spatial and electronic arrangements of important functional groups, yet impart 
subtle differences on the molecule. Amongst other things, these alterations can lead to 
improved permeability, increased or decreased metabolic stability, conformational entropy 
gains, lowered toxicity. Examples include substituting hydrogen for fluorine to decrease 
metabolic susceptibility; carbon for silicon to allow geminal diols; carboxylic acid for tetrazole 
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or squaric acid to avoid formal charges. A comprehensive review on this topic has been 
published.62 
Clinical trials and moving from bench to bedside 
Testing compounds in vitro can only be done up to a point and human testing is then 
required. Clinical trials do this in a systematic fashion, always keeping patient safety at the 
forefront. Drugs which enter the trials undergo rigorous testing and clearing each of the 3 
phases in the trials signifies a major a milestone in drug development. It is important to note 
that only 11% of drug candidates which enter the trials succeed, so the financial risks are 
significant in this extremely expensive process (see Figure 1-8).10 However, for each phase 
cleared, the value of the drug also increases vastly. This allows earlier investors exit 
strategies (a point at which invested resources can be recuperated).  
 
Figure 1-8 Histogram indicating how common it is for drugs to fail in the clinical trials. 
10
  
In the special pre-phase I of the trials, patients are administered mere pin pricks of the 
samples to check for any severe interactions the drug may have. Following this are the 
phase I tests. During this phase, healthy patients are administered the drug. Properties 
which are tested in this phase include: establishment of toxicity profiles, drug half-lives, how 
the drug is metabolised and excreted. Should this succeed, phase II commences. 
In phase II, the drug candidate is administered to sick patients and monitored to see how 
well they respond to treatment. Following this, dosing requirements are established. The 
number of patients is also increased.  
In phase III, the same protocols are followed as in the phase II although significantly more 
patients are tested for rare side effects. This also increases statistical confidence in the 
findings.  
0%
20%
40%
60%
80%
100%
Phase I Phase II Phase III Approval
Attrition rate of drugs through the clinical trials 
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Should phase III succeed, huge celebrations are in order: The drug is registered at relevant 
regulatory bodies and is placed on the market. During this time, the so called phase IV trials 
maintain a watch on how the drug performs. This includes how patients react who use the 
drug long term and for very rare side effects. Should serious consequences arise, the drug 
may be withdrawn from the market with little notice.  
As a result of the large costs involved in the development of diseases, pharmaceutical 
companies have learned that it is financially less viable to treat diseases of the Third World 
as patients who can ill-afford food are less likely to afford medication. This has given rise to 
the presence of the so-called “neglected diseases”. These include AIDS, tuberculosis and 
malaria. For the most part, non-profit organisations and academia attempt to combat these 
diseases.  
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2. Malaria 
Introduction and life cycle 
The latest World Health Organisation Malaria Report estimates the number of malaria 
deaths to be below 1 million, with the figure quoted as 660 000 in 2010. 90% of the cases 
occur within poverty stricken of sub-Saharan Africa, a region which also accounts for 75% of 
the fatalaties. Even more disconcerting, malaria is the cause of 20 – 25% of child deaths in 
the region.63, 64 There is also a complex relationship between the spread of malaria and the 
socioeconomic burden associated with it, as the one sustains the other.65, 66 
The malaria disease is an infection of the protozoan parasite of the Plasmodium genus, 
vectored by the female Anopheles mosquito. In the Plasmodium genus, four subgenuses are 
mainly responsible for 90% of malaria infections: P. vivax, P. ovale, P. malariae and P. 
falciparum. The latter is the agent of the most rampant and treatment resistant form of 
malaria.63 After a carrier mosquito infects a person, the sporozoites localise to the liver, 
where they infect hepatocytes. In P. vivax and P. ovale, some of the sporozoites become 
dormant hypnozoites, raising the chance of a relapsing infection. However, for all four 
genera, these sporozoites become actively growing schizonts. When these schizonts are 
grown, they lyase the host cell and release merozoites. These infect host erythrocytes, 
dividing into macro and micro gametocytes, to begin the sexual stage of the lifecycle. It is 
during this stage that, once ingested by another mosquito, the male and female gametocytes 
fuse to form diploid ookinetes in the gut of the mosquito. These ookinetes are then able to 
form oocysts by entrenching themselves in the gut cells. From here, meiotic division forms 
fresh sporozoites to begin the cycle anew (see Figure 2-1).67  
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Figure 2-1 Lifecycle of Plasmodia species.
67
 
 
Current antimalarials and their mechanisms of action 
As of 2012, no vaccine has successfully been developed against the parasite. Therefore, the 
primary method of fighting the disease entails the use of small molecules, of which there are 
seven major classes. 
4-Aminoquinolines  
As the protozoa metabolise hemoglobin from host cells, a toxic by-product, known as 
ferriprotoporphyrin IX (FPPIX), is released within the parasitic food vacuole. To remove the 
toxic FPPIX from solution, the parasite crystallises FPPIX to non-toxic crystals, known as 
hemazoin, by a pi-stacking mechanism. The 4-aminoquinolines inhibit this detoxification 
process of crystallisation by an unknown mechanism. However, it is believed that the 
4-aminoquinolines, which are concentrated within the food vacuole by an unknown 
mechanism, inhibit the crystallisation process by complexing to hemazoin.68, 69 This class of 
compounds, championed by chloroquine (CQ), were introduced at the end of World War 2. 
Initially, they were extremely effective and were believed to send malaria “well on its way 
towards oblivion”.70 Unfortunately, as with most other antimalarials, resistance has become 
very common in the early 21st century, with resistance reported in 80 – 100% of cases 
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worldwide.71, 72 Several genes have been identified to be involved in 4-aminoquinoline 
resistance. The gene pfmdr encodes the protein for the drug efflux pump.73, 74 The protein 
product of pfcrt is involved in the removal of CQ from the food vacuole.73, 75 Although pfcg2 
had been considered to be involved in resistance, this notion has been discredited.76  Drugs 
falling under this class include:  Chloroquine and Amodiaquine (see Figure 2-2). 
 
Figure 2-2 4-Aminoquinolines 
8-Aminoquinolines 
This class of antimalarials are only used for radical cure (removal of hypnozoites) of P. vivax 
infections. Suspected to interfere with the Golgi apparatus’ activity by inhibition of vesicle 
formation.77 Resistance mechanisms are currently not characterised. The only 
8-aminoquiloline used clinically is Primaquine (see Figure 2-3). 
 
Figure 2-3 8-Aminoquinolines 
Arylaminoalcohols 
This class of compounds is suspected to interfere with the heme ingestion mechanism 78, 79 
The mechanism of resistance is once again the protein efflux pump protein, pfMDR1 protein, 
which is encoded by the pfmdr1 gene. Resistance is found in Southeast Asia and Western 
Oceania.80-83 Drugs falling under this class include: Quinine, Mefloquine, Halofantrine, 
Lumefantrine (see Figure 2-4). 
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Figure 2-4 Arylaminoalcohols 
Artemisinin 
The artemisinin derivatives are the current gold standard in antimalarials, characterised by 
rapid parasitic clearance times from the body. Unfortunately they have very short half lives in 
the body which limits their effective duration. The artemisinin’s (see Figure 2-5) exact 
mechanism of action is currently uncertain, although it likely entails the disruption redox 
homestasis within the cell. Furthermore, the endo-peroxide is essential for activity and that it 
is affected by a radical-type mechanism.84-87 Similarly to other classes of antimalarials, this 
class is exclusively used in combination therapy to limit the potential for resistant strains to 
develop, typically with drugs of longer duration.88 Should the parasite develop resistance to 
artemisinin, the second antimalarial would kill the parasite. In this case, artemisinin is 
“protected”. Unfortunately, the reverse does not hold true if the artemisinin has already been 
cleared from the body. There have been several alarming reports of reduced sensitivity in 
some parts of the world.89-91 Resistance is once again bestowed by the pfmdr1 gene, 80-82 as 
well as a mutation in the pfatp6 gene.92, 93 Drugs falling under this class include:  Artemether, 
Artesunate. 
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Figure 2-5 Artemisinin and derivatives 
Antifolates 
The antifolates act as competitive inhibitors towards two enzymes which are both in involved 
in the folate biosynthetic pathway: Sulfadoxine and Pyrimethamine (see Figure 2-6) are 
administered as combination therapy due to their synergistic effects in that they target 
enzymes in the same pathway: dihydropteroate synthase and dihydrofolate reductase, 
respectively.94 The advantage of having multiple targets is that both targets need to mutate 
at the same time for resistance to develop, which is significantly less likely. As with all other 
anti-malarials, resistant strains have been reported. Resistance is conferred by point 
mutations in the genes encoding for the two enzymes, pfdhps95 and pfdhfr.96  
 
Figure 2-6 Antifolates 
Respiratory chain inhibitors 
By binding to the cytochrome bc1 complex97 the drug inhibits the mitochondrial electron 
transport chain, leading to a loss in the membrane potential.98  The Y268S mutation reduces 
affinity for the drug for the binding site.99, 100 Drugs falling under this class include: 
Atovaquone, Proguanil (see Figure 2-7). 
 
Figure 2-7 Respiratory chain inhibitors 
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Antibiotics 
The tetracyclines are primarily antibiotics, but also exhibit anti-malarial activity. They 
interfere with translation by binding to the ribosomal subunits which are involved in 
translation.101 Tetracycline resistance in malaria is currently uncharacterised. Other drugs 
falling under this class include: Doxycyclin, Clindamycin (see Figure 2-8). 
 
Figure 2-8 Antibiotics 
 
The biology of Plasmodium parasites has been well studied and numerous pathways have 
been identified to be essential for the parasite’s growth – all of which contain putative drug 
targets. Among many others, these include: glycolysis, biological methylation, Coenzyme-A 
biosynthesis, and purine metabolism.102 In our efforts to combat the disease, we have 
identified two different enzymatic targets for inhibition: spermidine synthase from the 
polyamine biosynthetic pathway and protein farnesyltransferase, which is involved in post-
translational protein modification.  
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Inhibition targets for this dissertation 
Polyamine biosynthesis - Spermidine synthase 
The polyamines (putrescine, spermidine, spermine and cadaverine) seen in Scheme 2-1, are 
small molecules which are involved in a number of important cellular processes. Being highly 
flexible and cationic at pH 7.4, they have numerous interactions with anionic moieties within 
the cell.103 These interactions include DNA, RNA, ATP, certain membrane bound proteins 104-
107 and phospholipids.108 Furthermore, the polyamines are also known to be involved in 
transcriptional regulation via eukaryotic initiation factor 5 (eIF5).109 Due to this ubiquity, the 
polyamine biosynthetic pathway is an essential part of cellular metabolism and is therefore a 
viable target for inhibition.109  
In mammals, the first half of the polyamine biosynthetic pathway (see Scheme 2-1) initiates 
with the decarboxylation of L-ornithine by ornithine decarboxylase (ODC) to produce 1,4-
diaminobutane (putrescine).110 The other half of the pathway is catalysed by 
S-adenosylmethionine decarboxylase (AdoMetDC). This enzyme decarboxylates 
S-adenosylmethionine (AdoMet) to produce decarboxylated S-adenosylmethionine 
(dcAdoMet).111 However, in P. falciparum these two enzymes are fused as a unique, hinge 
joined bifunctional protein, ODC/AdoMetDC.112 Next, the pathway converges by the action of 
spermidine synthase (SpdSyn). SpdSyn transfers the aminopropyl moiety from dcAdoMet to 
putrescine to produce spermidine and the by-product, 5ʹ-methylthioadenosine (MTA). 
Additionally, spermine synthase (SpmSyn) is able to transfer a second aminopropyl from 
another dcAdoMet to produce spermine and MTA.113 However, in P. falciparum this enzyme 
is not present and spermine production is also catalysed by SpdSyn.114 Inhibitors for all of 
these enzymes have been developed.115-117 For the purposes of this dissertation, we have 
focussed our efforts on the inhibition of pfSpdSyn.  
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Scheme 2-1  Polyamine biosynthetic pathway in P. falciparum 
 
The validity of SpdSyn inhibition has been demonstrated in several species, through the use 
of SpdSyn null mutants: Dictyostelium discoideum,118 Leishmania donovani 119, 120 and 
Aspergillus nidulans.121 Although a similar null mutant has not been obtained for P. 
falciparum, the use of SpdSyn inhibitors has been shown to inhibit the parasite’s growth. 
Moreover, the use of the same inhibitors did not show notable effect on the growth in 
mammalian cells.114  
The enzyme SpdSyn consists of two homodimers, each sized 36.6 kDa with a surface 
contact area of 1460 Å2. The Km values for its two substrates, dcAdoMet and putrescine, are 
35 and 25 uM respectively.114 A number of crystal structures of this enzyme, co-crystallised 
with inhibitors, have been published and the notable excerpts are tabulated in Table 2-1. 
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Table 2-1 Important crystal structures of SpdSyn 
Ligand PDB ID Resolution (A2) Ki IC50 Reference 
Natural ligands      
Apo 2PSS 2.2 - - 122 
MTA 2HTE 2.0 - - 123 
Spermidine 2PWP 2.1 - - Unpublished 
Spermine 3B7P 2.0 - - Unpublished 
Inhibitors      
4MCHA 2PT9122 2.2 0.18 µM 35 µM 114, 124, 125 
AdoDATO 2I7C122 1.7  8.5 uM 126-128 
The active site (see Figure 2-9) of SpdSyn has four notable interaction regions: 1) 
Nucleoside binding region; 2) Proximal cation binding region where the amino propyl moiety 
from MTA is located; 3) Hydrophobic region around the alkyl chain of putrescine; and 4) 
Distal cation binding region where the far amine of putrescine is held in place. 
 
Figure 2-9 Active site of SpdSyn.  
Shown here is the superimposition of dcAdoMet (left) and spermidine (right). The red dot to the upper 
right indicates the position of the proximal cation pocket and the red dot to the lower right indicates the 
position of the distal cation pocket. Hydrogen bond interactions are displayed in green. 
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For our efforts to combat malaria, we plan to target the polyamine pathway by designing and 
synthesising small molecules which would have similar interaction points as the molecules 
which are depicted here. Additionally, our anti-malarial plan will also target a second enzyme 
which is involved in another essential pathway in malarial metabolism. 
Protein prenylation - Farnesyltransferase 
The second target for inhibition involves the enzyme which is responsible for prenylation – 
protein farnesyltransferase. Prenylation entails the post-translational conjugation of an 
isoprenoid lipid (prenyl) to a protein. These prenyl groups are postulated to serve two major 
functions: Anchorage of a protein to the cellular membrane, (proteins for these function 
include the Ras family and the GPCR’s129-133) and the mediation of protein-protein 
interactions.134, 135 It is estimated that 0.5% of proteins are prenylated, demonstrating that 
disruption of this ubiquitous protein modification could have significant repercussions 
throughout the cell.136 
There are two types of isoprenoid lipids: farnesyl and geranylgeranyl, the latter having an 
additional 5 carbon monomer (see Scheme 2-2). The isoprenoid lipids are sourced from the 
mevalonic acid pathway and are found as their corresponding diphosphates 
(farnesylpyrophosphate and geranylgeranylpyrophosphate).137 These isoprenoids are 
conjugated to proteins through the action of the enzymes Protein Farnesyltransferase (PFT) 
or by the two geranylgeranyltransferases (GGT1 & GGT2).138-142 In contrast to mammalian 
cells which also have these latter two enzymes, P. falciparum relies solely on PFT to exert 
this critical prenylation.139 For this reason, the parasite is significantly more susceptible to 
prenylation inhibition when compared to mammalian cells - this forms the basis of 
selectivity.139 For this reason, PFT can be defined as a target for inhibition and is the focus of 
the second part of this dissertation. 
PFT recognises (with some promiscuity) the amino acid sequence CA1A2X as substrate 
(where C = Cysteine, A1 & A2 are aliphatic residues and X is any C-terminal amino acid). 
Farnesylation occurs at the thiol group from the cysteine residue and in the process the 
pyrophosphate acts as a leaving group.143 
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Scheme 2-2 Reaction mechanism of protein farnesylation 
 
PFT is a heterodimeric metalloenzyme, consisting of an α and β subunit, sized 48 and 46 
kDa, respectively. It has a very large active site to accommodate both the amino acid 
sequence and the farnesyl moiety. At the time of writing, there were 55 PFT structure 
deposits in the PDB. 41 of these are from Rattus norvegicus and 14 from Homo sapiens. 
Presented in Table 2-2 are the notable crystal structures of relevance to this dissertation.  
Table 2-2 Notable crystal structures of mammalian PFT 
Ligand PDB ID Resolution (A2) IC50 Reference 
Apo 1FT1 2.3 - 
144 
PB-93 2R2L 2.2 1 nM 
145 
     
Aims 
For both these enzymatic targets, we shall design novel potential antimalarial agents. These 
designs will be inspired by currently known inhibitors which will be optimised further by the 
use of published crystal structure data and modelling techniques.  
Once these designs have been made, they are to be synthesised and tested for activity 
against the causative agent of malaria, P. falciparum. 
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3. Molecular modelling – General 
Over the years, the advancement of computer technology has changed our lives in 
significant ways. From predicting the weather, calculating satellite orbits to our simple day to 
day email requirements, it has revolutionised society. Recently, computational power has 
reached the point where we can feasibly simulate the interface between chemistry and 
biology to have a direct impact in the drug development pipeline.  
Molecular mechanics 
To model a chemical system without compromise, the Schrödinger equation offers 
unparalleled accuracy using quantum mechanics (QM). Sadly, this high degree of accuracy 
requires an extreme degree of computational power which is simply not available for 
molecules much larger than ethanol. Biological systems typically contain thousands of atoms 
and applying first principles to these cases is completely unfeasible in the early 21st century. 
Efforts to reduce this high computational cost, whilst maintaining acceptable accuracy, have 
given rise to molecular mechanics (MM). Comparatively, MM has the advantage of 
significantly reduced computational requirements to QM, albeit at the sacrifice of accuracy. 
This is implemented through the use forcefields which make approximations on the way 
molecules twist, move, and otherwise interact with one another.  
Forcefields and CHARMm 
A range of forcefields are available, each with their own special niches which may overlap 
with another. For example the UFF forcefield (Universal forcefield)146 is able to 
accommodate almost all element types, albeit at reduced accuracy as compared to a more 
specialised forcefield such as MMFF (Merck molecular forcefield).147, 148 Although MMFF 
does not support nearly as many elements, it offers superior accuracy when simulating 
organic molecules. This includes accurate portrayal of conformational energetics and non-
bonded interactions. Another forcefield, CFF (consistent force field), offers better 
incorporation of explicit solvent models and specialises in the modelling of molecules that 
are in the gas phase.149, 150  
The CHARMm forcefield, (Chemistry at HARvard Molecular Mechanics) is the preferred 
forcefield in DS (Accelrys Discovery Studio). It is a general purpose forcefield that is aimed 
to be suitable for most systems relevant in the drug discovery process.151, 152   
Generally, CHARMm works as such: Firstly, the molecule is “typed”. To do this, each 
individual atom is examined and characterised by several properties, which include the 
element type, oxidation state, hybridization state, neighbouring atom type and its general 
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“chemical environment” (see Figure 3-1). Each atom is then assigned parameters based on 
these properties, to be used in the energy equation. Amongst other parameters, these 
include equilibrium bond length, equilibrium torsion angles, van der Waals contact radii and 
partial charges. Like other forcefields, CHARMm’s parameters are obtained from large 
tables, themselves derived from training sets of X-ray diffraction data and/or ab initio 
calculations.151 
 
Figure 3-1 Simple depiction of how various atoms are assigned parameters
151
 
To reduce the computational cost in CHARMm, atoms and bonds are modelled analogous to 
simple balls on springs which are influenced by Coulombic forces. In CHARMm, the total 
energy of a system is calculated by the sum of the individual energy functions and is given 
by: 151 
 
EPot  =  Ebond + Eangle + Etorsion + Eout of plane 
+ Eelec + EvdW + Econstraint 
Eq 6 
Expanded, these energetic terms are described by the following approximative equations: 151 
 
EPot  =  ∑ kb(r − r0)
2 + ∑ Kθ(θ − θ0)
2 + ∑|k∅| − k∅cos(nθ) + ∑ kχ(χ − χ0)
2 
+ ∑
qiqj
ε4πε0rij
+ ∑ [εij
min (
Rij
min
rij
)
12
−  2 (
Rij
min
rij
)
6
] +Econstraint 
Eq 7 
Bonded interactions 
The first four terms describe the interactions between two covalently bonded atoms. These 
terms describe the bond length and angles between said atoms. These terms are deviations 
from Hooke’s law which describes two objects connected by a spring: the further away from 
equilibrium, the higher the energy state. The equilibrium distances and force constants (ie. r0 
& kb for the first term, respectively) are obtained from the CHARMm parameter table files.151 
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Non-bonded interactions 
The next two terms describe the non-bonded interactions between atoms in close proximity. 
These include the electrostatic and van der Waals interactions. Noteworthy, for reversibly 
binding inhibitors, these are the only interactions between a drug candidate and its target.  
These non-bonded interactions make up the bulk of the computational load when modelling 
biological systems using MM. In an attempt to decrease the computational cost of these 
important interactions, parameters are included that ignore interactions above a defined cut-
off distance, usually about 14 Å. However, introducing a discontinuous function (a value 
suddenly changing to 0) as we move beyond the cut-off distance may lead to discrepancies 
which could become prominent during minimisation (see below). To minimise this, an 
intermediate region is defined where a smoothing function is applied, approaching 0 at the 
outer boundary.151 
Electrostatic term 
The electrostatic interaction term, which is derived from the law of Coulomb, quantifies the 
energy between two point charges. It is given by: 
 Eelec  =  ∑
qiqj
ε4πε0rij
 Eq 8 
Where qi and qj are the charges (defined as the partial charges by the force field), ε is the 
dielectric constant (polarizability) of the medium, ε0 is the dielectric reference within vacuum 
and r is the distance between the charges.  
Van der Waals term 
Van der Waals contacts are estimated by the Lennard Jones 6-12 potential equation.153 A 
limitation is that there is no directionality in this estimation, as the potential is spherically 
symmetric.153 
 EvdW  =  ∑ [εij
min (
Rij
min
rij
)
12
−   2 (
Rij
min
rij
)
6
] Eq 9 
Where Rij is the optimum distance and εij is the well depth of the Lennard Jones potential 
(see Figure 3-2). 
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Figure 3-2 Graphical plot illustrating the Lennard Jones potential. 
153
 
At small r, the first term dominates and a strong repulsion is experienced by the atoms. As r approaches 
R, the second, stabilising term dominates and the bottom of the well is reached (given by ε). Finally, as r 
is increased, the force experienced between the atoms become negligible. 
Constraint 
This term is only used when the user specifies custom constraints on the system. 
Solvent models 
To model a molecule accurately, its environment needs to be taken into account as it can 
have significant effects on the molecule. Firstly, the phase needs to be decided upon. The 
simplest way to model a molecule is in a vacuum. This is a gross over simplification for the 
SBDD context. The solvated state is of primary importance as the solvent significantly 
influences electrostatic interactions by shielding effects. Significant computational time is 
dedicated to compensate the shielding phenomenon accurately and the choice of the 
solvation model should be carefully weighed. For ease of reference, the electrostatic term is 
again given.151 
 ∑
qiqj
4επε0rij
 Eq 10 
No solvation model 
The dielectric constant is set to 1 (that of a vacuum).154 Although by far the fastest to 
process, the use of this option will greatly overestimate the electrostatic energies and should 
generally only be used when an explicit solvent model is employed (please see below).  
Implicit solvent models 
Implicit solvent models allow for an efficient compromise between computational expense 
and an accurate depiction of the molecule in a solvated state. These approximations are 
particularly useful when large sets of chemical space have to be explored (large proteins, 
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conformational searching of molecules with many rotatable bonds, etc.) in order to estimate 
electrostatic energies. Of the various types that exist, three are briefly discussed here. 
Distance dependent dielectrics 
This is the crudest implicit solvent model in DS. It is essentially as fast as using no solvent 
model, yet significantly more accurate. Its main applications are for occasions when very 
rough estimations suffice, usually when subsequent calculations are followed up with more 
rigorous methods. Only a single variable is introduced by varying the dielectric constant over 
distance and is given by: 154 
 ε(r)  =  ε0r Eq 11 
Generalised Born 
The Generalised Born (GB) implicit solvent model estimates the electrostatic term by 
replacing the traditional sum of Coulombic charges with the Born equation.155  
 𝐺 = −166(1 −
1
𝜀
) ∑ ∑
𝑞𝑖𝑞𝑗
𝑓𝐺𝐵
𝑛
𝑗=1
𝑛
𝑖=1
 Eq 12 
Essentially, this means that the protein is covered in spheres where ε = 2 and in the 
remainder areas ε = 80 (dielectric of water). This implicit solvent model is suitable for 
simulating biological systems with a high degree of confidence, albeit at a markedly 
increased computational expense. 
Poisson-Boltzmann 
This implicit solvent model is most accurate implicit solvent model available in DS.156 Due to 
the high computational cost, this method is only available for single point energy calculations 
(not minimisation or dynamics). 
Explicit solvent model 
The most accurate, yet computationally most expensive, method to model a solvent. In this 
way, the molecule is surrounded by a host of solvent molecules (solvated) and electrostatic 
energies are applied to each atom individually. A dielectric constant of 1 is used for these 
calculations.151 
On a side note, when using an explicit solvent model, Particle Mesh Ewald electrostatics 
may be used. This technique is then able to effectively model long range electrostatic 
interactions without a cut-off distance in a computationally efficient manner using Fourier 
space. 
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Minimisation 
Minimisation can be divided into two main categories i.e. the search for local and global 
energy minima. Figure 3-3 depicts a typical energy landscape in a biomolecular system 
where multiple energy minima and maxima exist which varies on the conformational space. 
Searching for a local minimum is relatively easy and a variety of methods are available in DS 
to traverse directly down an energy gradient to find the corresponding local energy minimum. 
These methods include Adopted Basis Newton-Raphson, 157 Powell,158 Steepest Descent,159  
Conjugate gradient,160 and Smart minimiser.151 
 
Figure 3-3 Simplified depiction of the energy landscape as function of a single variable. 
This is typically an oversimplification of a typical biomolecular system where there may be thousands of 
variables.  
Searching for the global minimum of a particular system is compounded by the fact that 
minimisation algorithms can only proceed directly “downhill” from a given point on the energy 
landscape. This means that, if minimising from a random point on the energy landscape, the 
resultant minimum would likely only be a local minimum. In the event that the starting point 
was chosen directly upward from the global minimum, then the global minimum would have 
been found. However, given the vast number of variables in even moderately sized 
pharmaceuticals, this is extremely unlikely. The only way to guarantee finding the global 
energy minimum would be to perform a full systematic search of the entire system by doing 
step-wise bond rotation. This exhaustive strategy is unfeasible for anything other than the 
most constrained of systems due to computational expense. Although other prominent 
methodologies exist to aid in the search for global minima,161, 162 two methods are available 
in DS .  
Maximum 
Minimum 
Minimum 
Maximum 
Global minimum 
Minimum 
Maximum 
0
2
4
6
8
10
0 5 10 15 20 25 30
To
ta
l E
n
e
rg
y 
Conformational space 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 3 – Molecular modelling (General) 
 
34 
High temperature molecular dynamics 
The temperature can be simulated by assigning random velocities to the atoms at time 
intervals. However, between each step of increased temperature, an equilibration step is 
required. This disperses the increased energy evenly throughout the molecule, according to 
the laws of thermodynamics. Finally, the production step allows the molecule to move for a 
defined time at the reached temperature. These poses can then be used by the required 
application.163, 164 
Monte Carlo simulated annealing 
This method combines Monte Carlo searching with simulated annealing (otherwise known as 
the Metropolis method). Monte Carlo methodology involves using multiple starting points 
over numerous iterations to find an answer. Simulated annealing then minimises those 
iterations (akin to metal being cooled or annealed) to search for the corresponding local 
minima, where after energy is inserted into the system to get the system out of the energy 
well. The simulation is once again minimised (annealed) and the cycle restarts. After each 
successive iteration, the amount of energy introduced into the system is decreased. After 
numerous iterations, the global energy minimum is likely to be closely approached, although 
this can never be confirmed.165 
Docking  
Docking entails taking proposed candidate small molecules, which could have active site 
complementarity, and placing them within the active site of a target protein/enzyme.  
Throughout this dissertation, docking was extensively used to determine the validity of all 
molecules that were synthesised or planned to be synthesised.  
The CDOCKER (CHARMm-based DOCKER) protocol uses a combination of high 
temperature molecular dynamics and simulated annealing to dock molecules within a 
defined active site (Figure 3-4).166, 167 Firstly, ligand conformations are generated using high 
temperature molecular dynamics. Then one of two methods is used to dock the ligands: 
Either the full potential or a grid based method. In the grid-based method, the active site is 
prepared by setting up a grid (points spaced typically 0.5 Å apart). Each grid point stores the 
two non-bonding parameters that are notable in guest-host interactions: electrostatic 
potential and van der Waals clashes. This is followed by translating the generated 
conformers around the active site. Rigid body rotations on the bonds are performed to 
search for complementarity. Then, MD-based simulated annealing is performed within the 
active site. Finally, the placed ligand is minimised within the protein active site. Between 
each of these steps, internal scoring functions are applied to only progress the more 
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successful candidates to the next step. As the grid-based method is markedly quicker with 
minimal reduction in successful docking, only the grid based method was used in this 
dissertation. 
 
Figure 3-4 CDOCKER protocol workflow
166
 
Virtual high throughput screening and scoring 
Virtual high throughput screening (vHTS) is one of the methods available in modern hit 
discovery efforts. It allows many millions of compounds to be screened in silico for 
complementarity to a target site at a fraction of the cost. The idea of vHTS is to start with as 
large a compound list as is feasible and then successively eliminate as many negatives 
(compounds which would have no notable interaction) as quickly as possible while gradually 
increasing the computational complexity with each step.  
Databases 
Before a vHTS can be performed, a suitable database of the molecules to be screened must 
be selected and prepared appropriately. This includes, amongst other things, protonation 
state at relevant pH, removal of molecules which are not synthetically feasible or that do not 
satisfy the Lipinski’s rule.39  Examples of some databases are listed in Table 3-1. 
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Table 3-1 Molecular databases 
Database Name Approximate size Reference 
Pubchem 31 million compounds 
168 
ChemDB 7.1 million compounds 
169 
Sigma-Aldrich 14 000 compounds 
170 
Zinc database  21 million compounds 
33 
  
An essential aspect of vHTS includes the generation of the conformations of the various 
molecules, known as conformers. Each single conformer is treated like an entirely different 
molecule during the screening process. These conformers can either be calculated on-the-fly 
during the screening process or be pre-generated. The latter strategy requires significant 
amounts of storage and CPU time to generate the conformers, but once performed this 
method significantly reduces screening time. This method is especially useful if the same 
database will be used more than once.  
Docking Algorithms 
Firstly, the target site of the structure is modelled and typed using a method that is specific to 
the vHTS algorithm. The algorithm translates and rotates each conformer through the 
generated pharmacophore until pre-determined satisfaction criteria are met (these criteria 
are dependent on the algorithm). This conformer is then saved in that position and saved as 
a pose for later review. Should satisfying criteria not be met, the conformer is discarded. Two 
of the methods available in DS are LibDock171 and traditional pharmacophore based 
screening.  
Using LibDock, the active site cavity is filled with hotspots (see Figure 3-5) which are either 
classified as polar or non-polar. The protein is then removed and this map of hotspots is then 
used as a simple pharmacophore. Candidate conformers are then matched to the hotspots 
with satisfying criteria based on the number of hotspots in close proximity. 
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Figure 3-5 Example of hotspots as generated and used by LibDock
171
 
The hotspots (seen in red and grey for polar and non-polar regions, respectively) are superimposed onto 
the protein structure of SpdSyn. Notice that the hotspots fall inside the cavity areas of the protein. 
Candidate conformers are required to align with 1 or more of these hotspots to not be discarded in a 
LibDock screen. 
Traditional pharmacophore screening entails screening conformers through features which 
include, amongst other things, steric exclusions, hydrogen bond acceptor and donor 
features, pi-stacking interactions and hydrophobic regions.172  Satisfying criteria may include 
matching any combination of these things. 
Scoring 
Following a successful screen, many millions of potential compounds may be reduced to a 
few thousand. More rigorous calculations may now be performed on this smaller subset. At 
this stage, scoring functions are applied to vHTS results. There are many scoring functions 
available, each using different methods to quantify resulting poses (see Table 3-2). Because 
the field of scoring is still relatively new, the results from these functions may differ wildly and 
it is difficult to know which scoring function is the most suitable to the particular task at hand. 
To ascertain this, a training set of known inhibitors is used as positive control. Scoring 
functions that rank the positive controls high are then also used to score the potential new 
hits. In the unpreferred event where positive controls are unavailable, consensus scoring 
may be used. In this case, multiple scoring functions are applied and only poses that 
consistently rank top scores in these scoring functions are retained.173 
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Table 3-2 Scoring functions available in DS 
Scoring function Parameters taken into account for scoring Reference 
JAIN 
Lipophilic interactions  
Polar attractive interactions  
Polar repulsive interactions  
Solvation of the protein and ligand  
Entropy term for the ligand 
174 
LIGSCORE 
Van der Waals interactions (Lennard-Jones) 
Buried polar surface area 
Total polar surface area 
175 
LUDI 
Hydrogen bond interactions. 
Lipophilic interactions. 
Ionic interactions 
Entropy term for the ligand 
176, 177 
PLP Hydrogen bond interactions 
178, 179 
PMF 
Pairwise interatomic interactions 
Includes metal and halogen potentials 
180, 181 
   
It is important to note that in most instances, all the algorithms mentioned in this chapter will 
produce results. However, it is the task of the modeller to inspect these results for viability 
and to rerun the protocols with altered parameters or even discard the results if deemed 
unreliable. An ideal algorithm should be sufficiently robust to be able to accurately mimic any 
system. Sadly, this is not the available. The best way to check whether a simulation is valid 
or not, would be to test it with a positive control and applying a healthy dose of common 
sense.  
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4. Molecular Modelling - Spermidine synthase 
Our antimalarial developments commenced by using molecular modelling techniques to 
guide us in our search for inhibitors for the enzyme spermidine synthase (SpdSyn), which 
was described in Chapter 2 to be a valid drug target. Among the many SpdSyn structures in 
the PDB, we chose to work from two structures. These two were co-crystallised with the 
known inhibitors 4-methyl-cyclohexylamine (4MCHA) and adenosyl-(5ʹ)-1,8-diamino-3-
thiooctane (AdoDATO), respectively (see Figure 4-1).122  
 
Figure 4-1 4MCHA and AdoDATO 
4MCHA is much smaller and only has two notable interactions: The hydrophobic region 
around the cyclohexane ring and amine. AdoDATO has numerous interactions with the 
enzyme and also occupies a significantly larger portion of the enzyme’s active site. Although 
it has fewer interaction points, 4MCHA is the stronger inhibitor. This is because of the 
significant desolvation energy penalty which AdoDATO must overcome to be inside the 
protein. On the other hand, 4MCHA is not penalised to the same extent.  To better 
understand these processes, we used molecular modelling techniques. 
2PT9 
Our first modelling effort stemmed from the co-crystal structure of SpdSyn and 4MCHA (PDB 
ID: 2PT9). Unfortunately, structure files straight from the PDB are not ready for modelling 
purposes. As such, one of the first steps in molecular modelling is to prepare these protein 
models appropriately.  
Protein preparation 
Protein structures which are solved by X-ray diffraction (XRD), such as 2PT9, have several 
hurdles which need to be overcome. Firstly, protein XRD resolution, typically within the 
range of 1.5 – 3.0 Å, is not sufficiently accurate to identify hydrogen atoms. The positions of 
hydrogen atoms, including those which are involved in important hydrogen bonding 
interactions around the active site, have to be determined. Secondly, in the crystallisation 
process, the molecule is in the solid state and crystal packing may contort the protein. 
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Processing of the structure needs to be performed to simulate the protein in the solvated 
state. Next, there may also be foreign molecules which are added to aid the crystallisation 
process. These have to be removed manually. Finally, some protein crystal structures may 
have disorder in some parts of the residues. Should alternate conformations be found, the 
most suitable one is to be selected. Should residues be absent due to disorder, the residues 
(up to 20) may then be calculated back into the protein using the tool named “Looper”, 
provided that the primary sequence of the protein is known.182 In our efforts to find novel 
inhibitors for SpdSyn, we have prepared the two mentioned crystal structures to use in our 
drug discovery efforts. 
The PDB file (ID: 2PT9) was retrieved from the PDB. In the crystal structure, three protein 
chains have been co-crystallised in the asymmetric unit of 2PT9. Using the protein report 
tool for guidance, Chain A was selected for preparation as it had the least amount of missing 
and/or incomplete residues and the ethylene glycol crystallisation factor was removed. 
Firstly, the entire complex was typed with the CHARMm forcefield, with partial charges 
estimated by Momany-Rone. Following this, all basic amines were set with a +1 formal 
charge. (Subsequently, the tool which is able to calculate residue titration curves was found. 
The pH can then be set at a pH of 7.4 to automatically ionize the protein.) During the typing 
process, hydrogen atoms are added into the structure. Although most of these hydrogens 
are correctly placed on-the-fly by DS, in some instances additional calculation is required. As 
seen in Figure 4-2, hydrogens may be trapped in local energy minima while a more 
energetically favourable conformation may exist. To traverse the energy gradient, a standard 
dynamics cascade may be used.  
 
Figure 4-2 Optimisation required for hydrogen atoms.  
Hydrogens may exist in various positions based on the parent heavy atoms. Often, simply performing 
minimisation would not lead to the desired state. Here, the hydroxyl’s lowest energy state is when 
making a hydrogen bond to the adjacent water molecule. However, the two methyls (above and below) 
prevent this and requires additional energy to be entered into the system before the global minimum may 
be reached.  
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For the standard dynamics cascade, all atoms except hydrogens were placed under fixed 
atom constraints. This would keep all the heavy atoms (non-hydrogens) that where obtained 
from the PDB fixed in place, while only the hydrogen atoms go through the rigorous heating 
and equilibration cycles. Seen in Figure 4-3 is a graph of the total energy of the system as it 
progresses through the heating steps. The row indexes correspond to each heating step 
which, in turn, correlates to an alternative conformation set of the hydrogen atoms. 
 
Figure 4-3 Increasing the total energy of the system by the increase of the temperature.  
This is accomplished by increasing the kinetic energy of the atoms. 
After the heating phase, the simulation is allowed to equilibrate during which the kinetic 
energy becomes evenly dispersed throughout the system. This allows the potential energy 
wells to be searched. During this cascade, 10 000 data points where collected, as seen in 
Figure 4-4. 
 
Figure 4-4 Kinetic equilibration of the introduced energy.  
This allows an effective simulation of the atoms as they move around. During this period, snap shots are 
taken of their relative position and the potential energy components can be determined. This effectively 
allows the potential energy wells to be explored. Indicated in red, is the lowest potential energy point in 
this data set. 
The conformation with the lowest potential energy was picked, but unfortunately was found 
to contain a hydrogen atom steric clash near the active site. To once again expel this steric 
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clash which is trapped in a local minimum, this protein conformation was then resubjected to 
another standard dynamics cascade (see figure Figure 4-5) , which then further reduced the 
potential energy from -3226.09 kJ/mol to -3255.05 kJ/mol without any steric clashes.  
 
Figure 4-5 Graph of the potential energy as the production run of the standard dynamics 
cascade proceeds.  
The red data point represents the point of lowest energy which was carried through to the next steps. 
Next, histidine tautomeric states were adjusted manually and, if required, nearby water 
molecules were rotated to optimise hydrogen bonding networks. Seen in Figure 4-6 is a 
typical example of such an occurrence where manual manipulation is still required for 
optimisation. In this case, three alterations needed to be made, which included: histidine 
tautomeric state selection, rotation of the phenolic hydrogen and rotation of the adjacent 
water molecule. 
    
Figure 4-6 Example of histidine charge / tautomeric optimisation.  
After a cascade, even though most minima have been obtained, manual intervention may be required in 
some cases. Here, it was evident that the automatic pKa calculation placed a charge on this Histidine 
residue. This was corrected by the removal of the charge, choosing the correct tautomeric state, rotation 
the adjacent hydroxyl bond and rotation of the entire adjacent water molecule yielded the correct state. 
Although the water molecule was rotated from its original position, this will be corrected for in the final 
minimisation step. 
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Following this, the protein was minimised for a final time using much more rigorous 
parameters. Only the peptide backbone was constrained and an explicit solvent model was 
used to increase the accuracy of the simulation. This step would alleviate most of the crystal 
packing energy and attempt to simulate the protein in the solvated state. The final 
minimisation criteria for this minimisation was RMS = 0.1 Å. To test whether the prepared 
protein is adequate for modelling purpose, the co-crystallised ligand was then re-docked 
back into the active site. In this case, 4MCHA was successfully redocked, back into the 
structure with an RMSD of 0.508 Å compared to the original crystal pose (seen in Figure 
4-7). The prepared protein structure was now ready for use. 
 
Figure 4-7 Successful redock of 4MCHA (in orange) back into 2PT9.  
This gave indication that the prepared protein was ready to use for further modelling purposes. For 
reference, the original crystal ligands are also shown (grey carbons).  
One of the first applications for this newly prepared model would be to use it to perform 
vHTS in efforts to quickly identify possible hits. 
Virtual high-throughput screens 
Virtual high-throughput screens (vHTS) require significant computational time to scan large 
databases of candidate molecules. To reduce this cost, vHTSs are performed so as to 
eliminate unsuitable candidates as soon as possible while using minimal computational 
resources. After each step, increased computational resources are applied to examine 
candidate molecules in greater detail, to culminate in the most rigorous simulation only at the 
final stage of the vHTS. Using this strategy, expensive computational time is not wasted on 
candidate molecules which could be have been eliminated using simple analyses. 
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For this dissertation, two types of vHTS were performed: a pharmacophore based screen 
and a hotspot based screen. 
Pharmacophore based screen  
Our first vHTS was performed on our newly prepared model of pfSpdSyn (PDB ID: 2PT9). 
To ensure that the hits were easily obtainable, we used the Sigma Aldrich catalogue as a 
database of compounds because any hits coming from this exercise could then easily be 
purchased. 
Database preparation 
To start our vHTS, we obtained a previously prepared SD file containing the entire Sigma-
Aldrich vendor catalogue. We decided to generate conformations before-hand, which 
increased the 13 573 compounds available in the SD file to 217 701 compounds and their 
corresponding conformations using the build 3D database tool. Following this, the 
pharmacophore had to be constructed. 
Pharmacophore construction and screening 
Construction of the pharmacophore is a critical part of the vHTS and requires careful 
consideration throughout this phase, as it directly influences how the possible hit interacts 
with the protein. Firstly, because of the significant energy penalty involved in the 
displacement of conserved, structural water molecules, they needed to be identified. This 
was done by superimposing the apo enzyme (PDB ID: 2PSS) onto the 4MCHA complex 
protein (see Figure 4-8). From this, possible hydrogen bond donating and accepting 
interaction sites were added (see Figure 4-9). Next the active site shape of 2PT9 was 
determined and defined using Q-site,183  which would impose spatial constraints on the 
search. Following this, a hydrophobe was placed in the middle of the active site and a pi-
interaction was placed coming off a tyrosine residue. 
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Figure 4-8 Development of the pharmacophore inspired by 4MCHA (carbons in orange).  
The co-crystallised water molecules are shown in red and in green are the water molecules from the apo 
enzyme. Although there are discrepancies, it is still apparent which molecules are conserved and should 
be retained in the active site. The yellow region defines the shape of the active site. 
 
Figure 4-9 Completed pharmacophore inspired by 4MCHA (carbons in orange).  
Shaded area indicates the shape of the active site; purple arrows indicate hydrogen bond donors; 
turquoise dot in the middle indicates hydrophobe; orange arrow indicates a pi-interaction; blue dot 
indicates a negatively charged aminoacid.  
Stellenbosch University  http://scholar.sun.ac.za
Chapter 4 – Molecular modelling (Spermidine Synthase) 
 
46 
The SD file containing the Sigma compounds and their various conformations was then 
screened against our pharmacophore. This resulted in 273 hits and after removing 
duplicates, 25 unique molecules were obtained. Having eliminated compounds from the 
database which would not fit the requirements of our pharmacophore, we were now in a 
position to apply far more rigorous and computationally expensive techniques to the 
remaining 25 compounds. For this, we turned to CDOCKER for docking. The results with the 
5 highest CDOCKER scores were selected for purchase and were subsequently tested at a 
concentration of 100 µM in an enzymatic assay. The results of this vHTS are presented in 
Table 4-1.  
Table 4-1 Results of the Sigma-Aldrich catalogue screen by pharmacophoric features. 
 
Control 
  
 
 
 
 
 
 
1 2 3 4 5 
CDOCKER 
interaction 
energy 
47 30 28 8.2 -24 -31 
CDOCKER 
score 
40 14 12 -4.2 -82 -131 
Enzymatic 
assay 
(100 µM 
inhibition) 
52% 7% Negligible Negligible Negligible Negligible 
       
The difference between the CDOCKER interaction energy and the CDOCKER score is that 
the former only accounts for interactions that the ligand has with the protein. The score 
includes the interaction energy, but also accounts for the conformational strain which the 
ligand is subjected to in that proposed bioactive conformation.  
Unfortunately, only one compound showed activity in the enzymatic assay. Also, barring the 
limited data points available, we can also see that there may be a trend of activity which 
correlate the CDOCKER score and the enzymatic activity. 
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2I7C 
Although the inhibitor 4MCHA is potent, it only has interaction with a small region of the 
active site of SpdSyn. To expand the number of possible interactions available for new 
inhibitors, we prepared the structure with PDB ID: 2I7C. This structure is co-crystallised with 
the other mentioned potent inhibitor, AdoDATO. Compared to 4MCHA, AdoDATO is 
approximately four times larger and has interaction with the entire putative binding site. This 
means that the protein is in a conformation which is slightly more accommodative towards 
both AdoDATO and other molecules of similar sizes. For this reason, we used this protein 
structure for the remainder of this dissertation. This included a second vHTS (later in this 
chapter) and the design and docking of novel antimalarials (Chapters 5 and 6). 
Protein preparation 
Similarly to PDB ID: 2PT9,122 three proteins were crystallised in the asymmetric unit of PDB 
ID: 2I7C and also similarly to PDB ID: 2PT9, chains B & C made up the homodimer. 
Although in these two chains, several residues had either incomplete or alternate 
conformations, in this case we deemed it to be more appropriate to use the entire 
homodimer to prepare the protein structure. Again using the “Clean protein” tool, these 
residues were corrected and the protein was then typed with the CHARMm forcefield. Ligand 
ionisation states were manually assigned while for the rest of the protein the residue states 
were calculated using the “Calculate Protein Ionization and Residue pKa” tool. The histidine 
tautomeric states were again manually adjusted. Following this, the standard dynamics 
cascade was performed with all non-hydrogen atoms fixed in place. Once again, the lowest 
potential energy conformation was selected and monitored for bumps.   
The final minimisation was performed with the explicit solvent model, incorporating Particle 
Mesh Ewald electrostatics. The crystal waters were kept in place. To test the model, 
CDOCKER was successfully used to dock the co-crystallised ligand, AdoDATO with an 
RMSD of 0.5369 Å, although this included a slight conformation mismatch in the region of 
the sulphur atom (see Figure 4-10).  
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Figure 4-10 Prepared crystal structure of 2I7C.  
The co-crystallised ligand, AdoDATO, has successfully been redocked (orange carbons). Superimposed 
for reference is the ligand from the actual crystal structure (carbons in grey). Only mild deviation is 
evident in the linker sulphur.  
Hotspot guided screen - LibDock 
In another attempt of vHTS, a significantly larger database was used in combination with the 
LibDock184 algorithm.  
Database preparation tool 
DS includes numerous tools to prepare a chemical database for vHTS and this process can 
be streamlined using Pipeline Pilot (PP). For this dissertation, a custom database 
preparation protocol was written to automate the preparation of chemical databases and was 
subsequently used to prepare such a database from the ChemDB database.169 This reduces 
user input requirement, reducing the chance of user error while also providing better 
overview of the entire process. Seen in Figure 4-11 is a representative flow diagram of the 
workflow. Subroutines that are clustered together are expanded below the grouped 
protocols. 
In the first block the protocol starts by reading the input file(s) which store the molecule 
entries (typically in SD format). The user needs to specify how many entries are read at a 
time. This has two purposes: If too many files are passed into the pipeline at a single time, 
the system RAM could be overloaded and a crash would result. Also, the output files are 
written as multiple smaller files which are more manageable rather than a single huge file.  
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Figure 4-11 Schematic of Pipeline Pilot workflow to prepare large databases for screening. 
In the second block, the entries which are now in the pipeline are passed along to the 
various stages of preparation. Starting with the computationally least expensive processes, 
compounds which fail the criteria are removed in the filters section: blocks 3 and 4. Firstly, 
some databases come with hydrogens attached to the compounds, whereas others do not. 
By resetting this state manually, the protocol ensures that hydrogens are added. Next, if 
metal salts are present, these are stripped from the molecules. Then, the organic filter 
removes any molecule which does not entirely consist of C, H, O, N, S, P, F, Cl, Br and I. 
The protocol then calculates two properties of each molecule: the number of chiral centres 
as well as the number of rotational bonds so that the user can specify the removal of them if 
need be. Molecules with chiral centres are difficult to synthesise and molecules with ≥ 10 
rotational bonds are difficult to handle in silico. The user may then specify whether 
molecules which exceed criteria in this regard should be discarded. Following this, Lipinski 
(described earlier) and SMARTS filters are applied as specified by the user. SMARTS filters 
are a variety of chemical signatures which may describe a variety of structural features of 
molecules which may be discarded. These range from chemically reactive moieties, known 
toxicophores to synthetically challenging moieties. The complete list is provided below. 
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Table 4-2 SMARTS filters 
Filters applied in database preparation  
Sulfonyl halide  
Acid anhydrides  
Acid halides  
HOBt esters  
Phosphoramides 
Di or Triphosphates 
Crown ethers 
 
Epoxides or Thioepoxides or Aziridines 
Nitros 
Quaternary C-Cl-I-P-S 
Peroxides 
Lawesson reagent and derivatives 
Triflates 
Aromatic azides 
Filters not applied in database preparation  
Disulfides 
Thiols 
Fluorines  
Cl-Br-I 
Cyanohydrines 
Sulfate esters 
Pentafluorophenyl esters  
Paranitrophenyl esters 
Beta carbonyl quaternary N 
Acyl cyanides 
Sulfonyl cyanides 
Thioesters  
Cyanamides  
Cyano 
Isocyanates or Isothiocyanates 
Paranitrophenyl esters 
Isocyanates and Isothiocyanates 
Polyenes  
Carbazides 
Squalestatin derivatives 
Sulfonate ester 
Phosphonate ester 
Isonitriles  
P or S Halides 
Carbodiimide 
Aliphatic alcohols  
2-4-5 trihydroxyphenyl 
2-3-4 trihydroxyphenyl 
Hydrazothiourea 
Sulfonates 
Thiocyanates 
Carbodiimides 
Sulfonates 
Cyanidin derivatives  
Thiocyanate 
Benzylic quaternary Nitrogen 
Phosphoramides 
Beta carbonyl quaternary Nitrogen  
Acylhydrazide 
Phosphoranes  
Nitroso 
Isonitrile 
Triacyloximes  
Cyanohydrins  
Acyl cyanides  
Sulfonyl cyanides  
Cyanophosphonates  
Azocyanamides  
Azoalkanals  
Aliphatic methylene chains 7 or more long  
Compounds with 4 or more acidic groups  
Four numbered Lactones  
Di and Triphosphates  
Betalactams  
Quinones  
Cytochalasin derivatives  
Saponin derivatives  
Cycloheximide derivatives  
Monensin derivatives  
Alkyl halides 
 
Once the filtration steps have been completed in blocks 3 and 4, the pipeline is followed in 
block 2. This leads to the manipulation step, which is expanded in block 5. The molecules 
are then ionised at physiological pH of 7.4, followed by the enumeration of the 
stereoisomers. After each of these two steps, duplicate molecules are prone to occur and 
are then filtered out. Finally, conformations are generated from the entries by Catalyst. 
Conformation generation is a computationally expensive process and will drastically increase 
the time required to process the protocol. Also, the storage space required for the output file 
is also increased significantly. It is up to the user to decide whether to generate 
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conformations beforehand or calculate them on-the-fly during the database screening phase. 
Finally, the output entries are saved as SD files for storage as a prepared database. The 
ChemDB database was prepared using this protocol, with the parameters listed in Table 4-3. 
This reduced the 7.1 million unique compounds to 3.2 million compounds, which included 
pre-generated conformers.  
Table 4-3 Database preparation parameters 
Process Parameter Justification 
Chiral filter ≤ 2 Synthetically challenging 
Rotatable bonds filter ≤ 10 Difficulty during docking 
SMARTS filters Underlined in list Various 
   
Scoring functions 
To determine which scoring functions would be best suited towards a particular system, a 
positive control is required. This entails using poses of known inhibitors in the active site and 
applying scoring functions to those poses. Functions which score known inhibitors high can 
then be used to score potential new inhibitors. To find appropriate scoring functions for our 
system, we used results from Jacobsson et al as positive control.185 In their study, they 
identified 28 compounds in a vHTS, of which 4 showed notable enzymatic activity. These 28 
compounds were docked into the active site of the protein using CDOCKER. All available 
scoring functions were applied to the resultant poses and the scores were normalised 
according to the maximum score obtained for each scoring system. This data was then 
plotted and visually examined to compare the scores (see Figure 4-12). LigScore1 returned 
very good (>85) results for 3/4 inhibitors. PLP2 also scored 2/4 inhibitors well. LigScore2 
rates almost all the inhibitors very high and would therefore not be appropriate. LigScore1 
and PLP2 would be used in our vHTS scoring step. The magnitudes of these two scores 
were also recorded to be able to directly compare these scores with the results which we 
may obtain (see Table 4-4). 
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Figure 4-12 Different scoring functions applied to the various potential inhibitors reported by 
Jacobsson et al. 
185
 
The 4 compounds highlighted in yellow are known to be good binders to SpdSyn and were used as 
positive controls. 
 
Table 4-4 Range of magnitudes of the scores which delivered potent results. 
Compound LigScore1 range -PLP2 range 
1 5.1 - 6.4 50 – 60 
10 4.2 120 
11 6.1 - 6.4 117 – 121 
26 4.9 - 6.7 78 – 111 
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Libdock sequence 
The LibDock sequence was then used to screen this prepared ChemDB database of 
3,277,039 possible ligands. Of these, 2,636,460, either failed to align to the hotspots or had 
mismatching polar/non-polar regions. The remainder resulted in 3,945,513 successful poses. 
Appropriate scoring functions were then needed to filter down the results.  
After applying consensus scoring on the top 10%, 4 million poses were reduced to 13 967 
poses. After removing duplicates, aqueous solubility and intestinal absorption criteria, 2470 
unique compounds remained.43, 186 Using TOPKAT AMES 3.1 mutagenicity prediction, all 
compounds which had more than 10% chance to have toxicity were removed, resulting in 
1 661 unique compounds. Of these compounds, 943 were successfully docked in the protein 
structure using CDOCKER. These poses were then visually examined, of which 7 were 
deemed to be possible hit compounds. Furthermore, the poses returned from CDOCKER 
were compared to those from LibDock to assess whether the same pose was returned. Also, 
the LigScore1 and PLP2 scores were reapplied for these new poses. The results are 
presented in Table 4-5.  
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Table 4-5 Possible hits of the vHTS using LibDock from 3.2 million compounds from 
ChemDB database 
# ID Structure 
-CDOCKER 
Score 
LigScore1 
Score 
-PLP2 
Score 
1 3842842 
 
44 5.2 100 
2 5716589 
 
43 4.5 101 
3 4144030 
 
40 5.6 103 
4 7499777 
 
35 4.5 91 
5 4409360 
 
32 3.9 85 
6 3637839 
 
25 5.4 95 
7 3638125 
 
21 5.4 94 
      
Given that CDOCKER returned the same pose as LibDock for 5 of the 7 compounds, 
relatively high –CDOCKER scores and that both LigScore1 and –PLP2 scores are within the 
same range as the positive controls used from Jacobsson et al,185 it is very likely that at least 
1 or more of these compounds could have very notable inhibition towards SpdSyn activity. 
Unfortunately, we were unable to test these compounds for activity to classify them as “hits”. 
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However, should one of them prove to be effective, there is a good likelihood that those 
compounds would advance several more steps during the hit to lead phase, bearing in mind 
that these 9 compounds have already passed through numerous filters (Lipinski, toxicity, 
solubility, etc.) to reach this stage.  
To the laboratory… 
This point also highlights the limitations of computational methods, which are based on 
theory. These methods would almost always deliver results, but they remain just that: 
theoretical. Only once actual, physical compounds are tested, can the results of these 
methods be proven. Then, if these compounds show activity, comprehensive and systematic 
structure activity relationship studies (SAR), with frequent testing, have to be performed on 
these molecules to thoroughly explore the chemical space of the active site. These SAR 
studies involve installing various groups on various points on the molecule to determine what 
affects these may have on the activity. Some of these groups include: electron withdrawing 
groups, electron donating groups and spacers.  
Although modelling may guide the drug discovery process at this point, the bulk of this work 
still resides within the synthetic organic chemistry laboratory. Only with real molecules that 
are actually tested can reliable data points be sourced to monitor the development of a 
possible hit or lead. However, the only way how the proposed inhibitors can be obtained, is 
using synthetic techniques.  
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5. Spermidine Synthase – Electrophilic adenosine 
Design 
Our synthetic efforts would stem from the transition state analogue AdoDATO (refer to 
Figure 5-1). AdoDATO is a conjunction of the two natural substrates of SpdSyn: dcAdoMet & 
putrescine. It has hydrogen bonding interactions to SpdSyn via the nucleoside and the two 
primary amines, including a pi-stacking interaction (refer to Figure 5-2). 
  
Figure 5-1 Natural substrates of SpdSyn 
AdoDATO is a transition state analogue of the two natural substrates of SpdSyn; dcAdoMet & putrescine. 
 
 
Figure 5-2 AdoDATO interactions areas with SpdSyn. 
Including the nucleoside, dcAdoMet has interactions with the two cationic pockets (to the upper and 
lower left) and the hydrophobic region between them. 
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To begin our library (refer to Scheme 5-1), we chose adenosine 1 to act as a starting 
scaffold. It is readily available and has a natural affinity for our target. Importantly, from a 
synthetic point of view, the primary hydroxyl offers a versatile handle for functionalisation. 
After the nucleoside has been prepared, we envisaged to create a library of compounds 
which may act as nucleophilic right hand side (RHS) moieties, similar to the alkyl/amino 
functionality found in AdoDATO and putrescine to allow linking to the adenosyl on the left 
hand side (LHS).  
Scheme 5-1 Synthetic strategy to prepare SpdSyn inhibitors 
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Synthesis – Chloroadenosine 
Scheme 5-2 Attempted synthesis of 2 
  
To prepare the LHS as an electrophile, the synthesis began by the conversion of the primary 
hydroxyl into a chloride using thionyl chloride in hexamethylphosphoramide (HMPA).187 To 
neutralise the HCl by-product, pyridine was added. Although the secondary hydroxyls would 
also be susceptible to conversion, their reduced reactivity would offer the required 
chemoselectivity.  
Unfortunately, no new products were evident by TLC after an extended period. After this 
failure, the use of HMPA as solvent was abandoned for three major reasons: it is both 
carcinogenic and toxic; it is difficult to remove from the organics and also requires vacuum 
distillation prior to use.  
Scheme 5-3 Alternative attempted synthesis of 2 
 
The chlorination was re-attempted in acetonitrile using a procedure developed by Robins et 
al.188, 189 The reaction proceeded as expected, up to the point that the excess thionyl chloride 
was neutralised with a mixture of MeOH and aqueous NH4OH. As this was performed, the 
neutralisation was monitored by TLC and it was observed that the newly formed product 
reverted back to starting material. We suspected that the basic aqueous solution was 
nucleophilic enough to displace the newly created chloride.  
Stellenbosch University  http://scholar.sun.ac.za
Chapter 5 – Spermidine Synthase (Electrophilic adenosine) 
 
59 
Scheme 5-4 Attempted synthesis of 3 
 
On the suspicion that it might be easier to handle the compound if the polarity was reduced 
and to avoid potential future chemoselectivity issues, it was decided to protect the vicinal diol 
as a ketal. Using a catalytic amount of para-toluene sulfonic acid (PTSA), the ketalation was 
attempted in acetone. Owing to Le Chatelier's principle, the large excess of acetone would 
drive the reaction forward, mitigating any water present in the technical grade acetone. 
Unfortunately, these conditions did not produce any new products.  
Scheme 5-5 Synthesis of 3 
 
Having been unsuccessful in our first attempt to install the ketal protecting group, we now 
reattempted the reaction with modifications.190 Firstly, strict anhydrous conditions were used 
to remove the water by-product which would push the reaction equilibrium backwards. This 
included the addition of molecular sieves to the reaction vessel, thorough purging of the 
atmosphere in the vessel with anhydrous nitrogen, hot assembly of the glassware from the 
oven pre-drying of all reagents and solvents. Also, even though only a catalytic amount of H+ 
is required theoretically, 10 equivalents of PTSA catalyst were used to expedite the reaction. 
The successful synthesis of the ketal was confirmed using 1H NMR spectroscopy by the 
presence of two upfield singlets which both integrated for 3 protons. These signals 
corresponded to the two methyls from the acetone molecule. It is noteworthy that these two 
methyls appear as two distinct signals, as they are not chemically equivalent when 
considering the three dimensional structure of the chiral molecule.  
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Scheme 5-6 Alternative synthesis 3 
 
In an alternative method to produce the ketal, the irreversible reaction using dimethoxy 
propane was investigated.191 Four equivalents of DMP were added and the reaction was 
performed in acetone solvent. Using 12 equivalents of PTSA, the reaction went to 
completion in 48 hours. Again, the successful synthesis was confirmed using 1H NMR 
spectroscopy. The obtained spectrum matches the molecule obtained by the synthetic 
procedure using only acetone.  
Scheme 5-7 Synthesis of 4 
 
Once the protected adenosine was isolated and purified, the chlorination was performed 
again using the same conditions as in Scheme 5-3.189  
In tandem with a change in the chromatographic retention factor, 1H NMR spectroscopy 
confirmed that the chloro-adenosine was obtained by the disappearance of the hydroxyl 
signal, a slight change in the chemical shift signals and the complete assignment of all 
signals (refer to Table 5-1).  
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Table 5-1 
1
H NMR spectroscopic signals of 3 and 4 
Atom 3 4 
1 and 2 
8.34 (s, 1H) 8.33 (s, 1H) 
8.15 (s, 1H) 8.18 (s, 1H) 
14 7.34 (s, 2H) 7.37 (s, 2H) 
6 6.12 (d, J = 3.1 Hz, 1H) 6.23 (d, J = 2.4 Hz, 1H) 
8 5.34 (dd, J = 6.2, 3.1 Hz, 1H) 5.48 (dd, J = 6.3, 2.4 Hz, 1H) 
15 5.24 (t, J = 5.6 Hz, 1H) N/A 
9 4.96 (dd, J = 6.2, 2.5 Hz, 1H) 5.07 (dd, J = 6.3, 2.9 Hz, 1H) 
7 4.21 (td, J = 4.8, 2.5 Hz, 1H) 4.34 (td, J = 6.6, 2.9 Hz, 1H) 
13a 
3.63 – 3.45 (m, 2H) 
3.86 (dd, J = 11.2, 7.0 Hz, 1H) 
13b 3.75 (dd, J = 11.2, 6.2 Hz, 1H) 
11 and 12 
1.54 (s, 3H) 1.54 (s, 3H) 
1.32 (s, 3H) 1.34 (s, 3H) 
   
It was interesting to note that the methylene protons, situated at position 13, presented as 2 
unique signals owing to the adjacent chiral centre (position 7). These two protons coupled 
very strongly to each other (11.2 Hz) and also to 7 (7.0 and 6.2 Hz). Furthermore, the 
coupling experienced at 7 is an average of the couplings from 13a and 13b.  
Adenosine 1 was successfully made electrophilic at the required position using thionyl 
chloride. The task was now to expand the library to include a complementing suite of 
nucleophiles. These would comprise of easily deprotonated heteroatoms: hydroxyls, amines 
and thiols. 
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Synthesis – RHS moieties 
Reduction 
Scheme 5-8 Synthesis of 6 
 
NaBH4 is a mild reducing agent, typically used for the reduction of more reactive moieties 
like aldehydes or ketones. In this instance, it was used to synthesise the alcohol 6 from 
4-chlorobenzaldehyde 5 in excellent yield.  
1H NMR spectroscopy confirmed that the reduction occurred by the disappearance of the 
aldehyde singlet and appearance of a broad singlet, integrating for 1 and another singlet, 
integrating for 2 protons. Additional Note however that it was not expected for the hydroxyl 
proton to couple to the methylene carbon protons. Additional characterisation was not 
performed as the compound has been synthesised previously.192 
This alcohol was planned to be the first molecule to be bonded to the chloro-adenosine 4.  
Chemoselective protection 
Scheme 5-9 Synthesis of 8 and 9 
 
Two more substrates to the chloro-adenosine could be made from ethanolamine 7. As both 
ends of the molecule have nucleophilic sites, selective protection of one moiety would allow 
the other to be joined to the chloro-adenosine.  
For the protection of the amine, the base stable protecting group, Boc-anhydride (Boc2O), 
was used.193 Although the hydroxyl is also potentially able to act as a nucleophile to the 
carbamate, the amine’s much stronger nucleophilicity at the pH of the reaction would afford 
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the required chemoselectivity. To accelerate the reaction, a catalytic amount of the acyl 
carrier dimethylamino pyridine (DMAP) was added to the reaction.  
1H NMR spectroscopy confirmed that the carbamate 8 was synthesised by the appearance 
of an identifying upfield singlet, integrating for 9 protons, which corresponded to the tert-butyl 
group.  
In contrast to the N-selective protection offered by Boc2O, tert-butyldimethyl silyl chloride 
(TBDMSCl) was used to protect the hydroxyl.194 The chemoselectivity of the silyl towards the 
oxygen is facilitated by the hard-hard interaction between the two atoms.  
As hydrochloric acid is released in this reaction and would remove this acid labile protecting 
group, imidazole was added. During the work-up of the reaction, excess imidazole could not 
be removed using the conventional method of protonation as this would also have 
protonated the amine on the product. Instead, column chromatography was used for 
purification. After the isolation of the product 9, 1H NMR spectroscopy confirmed the 
successful synthesis of the silyl protected ethanolamine by the appearance of two upfield 
singlets, integrating for 6 and 9 protons.  
Both the N- and O-protected groups were ready for attachment to the chloro-adenosine 4.  
Aldehyde to thiol conversion  
For the natural substrate of SpdSyn, dcAdoMet, the linking hetero atom between the 
adenosine and the aminopropyl moiety is a sulphur atom. In an effort to introduce this 
functionality, we developed a reaction sequence to convert an aldehyde into a thiol which 
could be joined to the chloro-adenosine 4. This entailed the reduction of 
4-hydroxybenzaldehyde 10 to the respective hydroxyl. Using a Mitsonobu reaction, a 
reaction which turns an acidic heteroatom into a leaving group, the hydroxyl was to be 
replaced with a thioester. Finally, the reduction of that thioester would then yield the 
respective thiol. The phenolic hydroxyl, however, had to be protected throughout the entire 
sequence.   
Scheme 5-10  Synthesis of 11 
 
Firstly, using TBDMSCl, the protection of the alcohol 10 was successfully performed in good 
yield.195 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 5 – Spermidine Synthase (Electrophilic adenosine) 
 
64 
Analysis by 1H NMR spectroscopy indicated the presence of the characteristic two upfield 
singlets that integrate for 6 and 9 protons.  
Scheme 5-11  Synthesis of 12 
 
The reactive aldehyde 11 was then reduced using the mild reducing agent NaBH4.
196 The 
successful reduction to the alcohol 12 was confirmed by the disappearance of the downfield 
aldehyde singlet and the appearance of both a triplet corresponding to the hydroxylic proton 
and a doublet to correspond to the two benzylic protons.  
Scheme 5-12  Synthesis of 13 
 
To convert the alcohol into a leaving group, a Mitsunobu reaction was used in conjunction 
with thioacetic acid to afford a thioester.197 The reaction mechanism is presented in Scheme 
5-13. Although it wasn’t relevant in this case, it is interesting to note that the step where the 
alcohol carbon is attacked by the nucleophilic thioate, proceeds via an SN2 mechanism.  
1H NMR spectroscopy of the crude material confirmed that the thioester 13 was synthesised 
due to the disappearance of the upfield signal corresponding to the hydroxyl and the 
appearance of a singlet which integrated for 3 protons.  
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Scheme 5-13 Mitsunobu reaction mechanism198 
  
Scheme 5-14  Synthesis of 14 
 
To reduce the thioester, a functionality that is far less susceptible to reduction than 
aldehydes or ketones, NaBH4 was unsuitable. The much stronger reducing agent, lithium 
aluminum hydride, was chosen owing to its higher reactivity.197 The reaction mechanism 
involves the formation of a complex with the carbonyl to facilitate hydride insertion. After an 
acidic work-up with a saturated solution of ammonium chloride, the thiol 14 was isolated in 
modest yield over two steps. 
The product was characterised by 1H NMR spectroscopy which observed that the methyl 
protons of the thioester have disappeared and that a triplet appeared, corresponding to the 
thiol, which integrated for one proton. Further, a doublet was observed which corresponded 
to the methylene protons with a coupling constant that matched the triplet corresponding to 
the thiol.  
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Synthesis – Linking attempts1 
After the completion of these five potential RHS molecules, the task at hand was to establish 
a protocol to link the molecules to the chloro-nucleoside 4. To confer nucleophilicity the 
acidic heteroatoms, they would be deprotonated with a suitable strong base.  
Scheme 5-15  Attempted synthesis of 15 
 
The first target compound for the nucleophilic addition would be 15. This was to be 
accomplished using a method analogous to Robins et al who synthesised a thioether using a 
thiol and chloroadenosine.199  
The thiol was added to an ice cold solution of DMF and treated with a 10% molar excess of 
NaH. After the anion was allowed to generate, the chloro-adenosine was introduced and the 
temperature increased. The reaction was monitored by TLC for an extended period, but no 
new UV-active compounds were evident and the reaction was abandoned.  
Scheme 5-16 Attempted synthesis of 16 
 
The reaction was setup again using similar conditions, this time using 12 to have oxygen as 
the nucleophile. Again, after monitoring the reaction for an extended time via TLC, no new 
products formed and the reaction was discarded.  
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Scheme 5-17  Attempted synthesis of 17 
 
After the two failures, the NaH base was substituted for potassium tert-butoxide. To adhere 
to the conditions used by Kung et al as closely as possible,200 chloroadenosine without the 
ketal protection group was used. The reaction was monitored with TLC but once again, no 
products formed.  
Scheme 5-18  Attempted synthesis of 18 
 
In a final attempt to create an ether linkage, potassium tert-butoxide was added to the 
benzylic alcohol 06. Unfortunately, in this last attempt, no possible products were detected 
for this reaction either. A possible explanation for these results could possibly include the 
presence of water in the reaction or inactive reagents. The latter explanation is unlikely as 
the addition of sodium hydride to the solution evolved hydrogen gas and the potassium tert-
butoxide was freshly prepared by sublimation.  
At this point, the attempts to synthesise thioether bonds were abandoned via the chloro-
adenosine. Instead, we would now reverse the strategy and introduce nucleophilicity to the 
adenosine 3.  
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Conclusion 
After optimisation, an electrophilic adenosine was successfully synthesised using thionyl 
chloride and pyridine in acetonitrile in moderate yield. Additionally, five functionalities were 
also prepared that were planned to be coupled to the chloro-adenosine. Numerous attempts 
were made to this aim, but were unfortunately unsuccessful for unknown reasons.  
It would have been worthwhile to try alternative functionalities to introduce electrophilicity to 
the adenosine. For example, introduction of a mesylate or a triflate would have kept the 
primary alcohol oxygen in place without the harsh acidic conditions associated with the 
introduction of the chloride. Although there is a primary nitrogen present, its nucleophilicity is 
reduced compared to the hydroxyl oxygen, owing to its participation to the adjacent aromatic 
system. Furthermore, these alternative functionalities would also confer much stronger 
electrophilicity at the terminal carbon.190  
 
 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 6 – Spermidine Synthase (Nucleophilic adenosine) 
 
69 
6. Spermidine Synthase – Nucleophilic adenosine 
Synthesis – Thioester adenosine 
Turning the strategy around, the left hand side of the molecule can also be turned into the 
nucleophile. Pignot et al successfully used adenosine derivatised with a thio-ester as a 
masked nucleophile to create thio-ether linkages to electrophilic molecules.201 This 
nucleophilic thiolate anion 19 was prepared in situ by the addition of sodium methoxide to 
the thionucleoside 20 (refer to Scheme 6-1). 
Scheme 6-1 Mechanism of nucleophilic conversion of thionucleoside via sodium 
methoxide201 
 
Scheme 6-2 Synthesis of the thionucleoside 20 201 
 
The thionucleoside was synthesised by a Mitsunobu reaction from the ketal-protected 
adenosine using the procedure from Pignot et al. 201 As an alteration for this reaction, 
instead of using the conventional Mitsonobu reagent, di-ethyl azodicarboxylate (DEAD), we 
used the di-tert-butyl azodicarboxylate (DtBAD) variant. This tert-butyl derivative is easily 
removed from the reaction by decomposing to volatile products in the presence of an acidic 
medium.198 Using thioacetic acid, the corresponding thio-ester was synthesised by 
converting the primary hydroxy into a leaving group. 
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Mass spectrometry and NMR spectroscopy confirmed that the synthesis of the thioester was 
successful with a yield of 98%. All signals in the 1H NMR spectrum were assigned, which 
also allowed all the signals in the 13C NMR spectrum to be assigned, in conjunction with 
GHSQC (refer to Table 6-1). Once again the two protons at position 13, adjacent to the 
chiral centre, each presented unique signals. 
Table 6-1  Assignment of 20 
1
H & 
13
C NMR spectroscopy signals 
Atom position 1H 13C 
15 − 194.5 
3, 4 or 5 − 155.8 
1 or 2 8.34 (s, 1H) 53.2 
3, 4 or 5 − 149.2 
1 or 2 7.89 (s, 1H) 139.9 
3, 4 or 5 − 120.3 
14 6.12 (s, 2H) − 
10 − 114.5 
6 6.06 (d, J = 2.1 Hz, 1H) 90.9 
8 5.50 (dd, J = 6.4, 2.1 Hz, 1H) 84.2 
9 4.96 (dd, J = 6.4, 3.1 Hz, 1H) 83.7 
7 4.33 (td, J = 6.9, 3.1 Hz, 1H) 86.1 
13a 3.28 (dd, J = 13.8, 7.2 Hz, 1H) 
31.3 
13b 3.17 (dd, J = 13.8, 6.7 Hz, 1H) 
16 2.33 (s, 3H) 30.6 
11 or 12 1.58 (s, 3H) 27.0 
11 or 12 1.37 (s, 3H) 25.4 
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Synthesis – RHS moieties 
Method development using alkyl chains 
With the thionucleoside 20 in hand, we established the critical coupling reaction protocol as 
developed by Pignot et al.201 To avoid complications, we used readily accessible 
monofunctionalised alkyl electrophiles.  
Scheme 6-3 Synthesis of 21 
 
For our first reaction to join an alkyl group to the thionucleoside 20, we used 
1-bromo-octane. The simple alkyl chain was chosen due to its uncomplicated nature and 
was expected to be free from compounding side reactions  
In our first attempt, we added the sodium methoxide to the stirred solution of the 
thionucleoside 20 at 0°C (refer to Table 6-2). After an hour of stirring, no change in the 
retention factor was observed by TLC. Nevertheless, we proceeded to add a large excess 
(10x) of the alkyl bromide, as the limiting reagent for this reaction was the thionucleoside. 
After leaving the reaction overnight, TLC analysis showed no evidence of the formation of a 
new compound. Fearing the possibility of an interfering elimination reaction, we halved the 
large excess of alkyl bromide to 5 equivalents for the subsequent attempt. 
Table 6-2 Development of thioetherification procedure  
Equivalents of 
alkyl bromide 
Base (equivalents) Solvent Temperature Yield 
10 NaOMe (2.2) MeOH 0°C Unsuccessful 
5 KOH (1.0) DMF 0 to 55°C Unsuccessful 
5 
NaOMe made in situ 
from Na metal (1.1) 
MeOH -15°C Unsuccessful 
5 NaOMe (1.0) MeOH -15°C 30.2% 
 
On this second attempt, we changed four parameters. Firstly, a smaller excess of the alkyl 
bromide was used and the solvent was exchanged for DMF, as it could help to stabilise the 
anion. Also, KOH was substituted as the base. To see whether it could help, the temperature 
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was also increased after sufficient time was allowed for the anion to generate. TLC analysis 
showed that this combination of parameters did not produce any new compounds either.  
On the third attempt, we reverted back to the conditions in the original procedure by Pignot 
et al. 201 The reaction was started from -15°C in methanol and a stoichiometric amount of 
sodium metal was added to generate sodium methoxide in situ. Once again, no new 
compounds were observed by TLC.  
Fearing that there could be water contamination in this particularly water sensitive reaction, 
all precautions possible were taken to remove all traces of water from the system for our 
next attempt. This included using solvent that was freshly distilled from CaH2.
202  Also, 
commercially produced NaOMe in methanol was also sourced for this reaction. After adding 
the methoxide base and allowing 15 minutes for the anion to generate, 5 equivalents of the 
alkyl bromide was added. The reaction was left to stir overnight and after TLC analysis, we 
discovered the presence of a new compound. After purification by column chromatography 
and lyophilisation, a yield of 30% was obtained for the compound 21. 1H, 13C NMR 
spectroscopy and mass spectrometry then confirmed that the thioether bond was formed.  
Scheme 6-4 Synthesis of 22 
 
With the thioether 21 in hand, only the deprotection of the ketal was required to offer the first 
final product in this series. This was easily achieved through the use of formic acid and 
purified water.  
After monitoring the reaction using TLC, the starting material was consumed after two days. 
As planned, all by-products and reagents of this reaction are volatile: formic acid, water and 
acetone. These were removed by a combination of rotary evaporation and high vacuum. 
1H NMR spectroscopy then confirmed that the two methyl peaks correlating to the ketal 
methyl protons disappeared. Further, 13C NMR spectroscopy and mass-spectrometry 
confirmed that the isolated product was pure and agreed with expected results. After the 
deprotection of the hydroxides, the highly polar nature of this compound dictated that 
deuterated methanol was required for the NMR experiment as solvent. Due to this, the 
hydroxyls and the amines were subject to deuterium exchange and no proton signals for 
these moieties were observed. Also, owing to the extreme hygroscopic nature of methanol, 
water contamination of the solvent is unavoidable. To circumvent this, a signal is introduced 
into the NMR pulse sequence to saturate the water signal. Performing this water 
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suppression drastically reduced the size of the peaks in representing water and was applied 
whenever deuterated methanol was used.  
We had our first final compound in hand with a yield of 11.75 mg. Armed with the sound 
confidence that our method works, we set to work to join the remaining three alkyl bromides 
to the thionucleoside.   
Scheme 6-5 Synthesis of 23 
 
Similar conditions for the synthesis of octyl 21 were used to prepare the hexyl derivative 23. 
Again using strict anaerobic conditions, the alkylation of the thionucleoside was performed.  
After quenching the reaction with water, purification using chromatography and lyophilisation 
afforded the pure product. 1H and 13C NMR spectroscopy and mass-spectrometry confirmed 
that the hexane derivatised thionucleoside 23 was formed.  
Scheme 6-6 Synthesis of 24 
 
After the acid catalysed deprotection of the vicinal hydroxides, the second pure product 24 in 
the series created. 
1H NMR and 13C NMR spectroscopy in conjunction with mass spectrometry confirmed the 
successful synthesis of the second compound in the series.  
Scheme 6-7 Synthesis of 25 
 
We then proceeded to derivatise secondary halogenated alkanes. Although the secondary 
halogenated carbon would be slightly less electrophilic, the reaction went without difficulty.  
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Mass-spectrometry and NMR spectroscopy confirmed that that synthesis proceeded as 
planned. However, a racemic mixture of 2-bromo-octanol was used and this was 
incorporated into the thioether 20 to create diastereomers. Therefore, atoms that are in close 
proximity to the racemic chiral centre are in slightly different chemical environments as the 
corresponding atoms in the opposite diastereomer and these differences are observed by 
NMR spectroscopy. These differences are most evident on the atoms adjacent to the chiral 
centre and become gradually less pronounced farther away. For this reason, 1H NMR signal 
multiplicities could not be resolved in all instances and assignments could not be performed 
by deduction from the coupling constants. Therefore, most signals were reported as 
multiplets and assignments were based on the knowledge of the previously obtained 
spectra. Additionally, 13C NMR spectra presented similar complications. As a result, spectral 
signals could not be unambiguously assigned to the structure. This complication persisted 
for the remaining diastereomeric compounds in this sequence. As these diastereomers did 
not separate using conventional chromatographical techniques, further separation attempts 
would only be attempted should there be significant biological activity. 
Scheme 6-8 Synthesis of 26 
 
From here, the ketal was removed using formic acid and water to afford the two free 
hydroxyls. 
1H and 13C NMR spectroscopy and mass-spectrometry confirmed that the third compound, 
26, in the series was successfully formed. This pair of diastereomers was submitted for 
testing.  
Scheme 6-9 Synthesis of 27 
 
Our final alkylation was performed with 2-bromo-heptane to yield 27.  
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Again, due to the incorporation of the racemate, two diastereomers of the thioether were 
created and were visible in both the 1H and 13C NMR spectra. Mass-spectrometry was also 
in agreement with the expected products.  
Scheme 6-10 Synthesis of 28 
 
Once again, the final deprotection of the ketal 27 was performed over 2 days using formic 
acid and water.  
After purification, 1H and 13C NMR spectroscopy and mass-spectrometry confirmed the 
successful deprotection of the ketal and the successful formation of the final alkylation 
product 28.  
AdoDATO and 4MCHA hybrid 
Armed with a working method to derivatise the thionucleoside and with several inhibitors in 
hand, we would now design and synthesise inhibitors with additional functionality to interact 
with the binding pocket. Looking to the two known inhibitors for inspiration, we attempted to 
use characteristics of both molecules in a single hybrid molecule. 
To do this, we superimposed the two known inhibitors into the same co-ordinate space (refer 
to Figure 6-1). We observed that the far amine of AdoDATO and the amine from 4MCHA 
both interact with the protein in same region, which we shall refer to as the distal binding 
pocket. We would also refer to the interaction zone of the second amine of AdoDATO as the 
proximal binding pocket. Because there was a region of overlap between the two known 
inhibitors, we would combine them into our first iteration of a hybrid molecule. This resultant 
molecule 29 contained synthetically challenging chiral centres but fitted very well within the 
binding site with a CDOCKER score of 47, compared to the potent inhibitor AdoDATO with a 
score of 82. 4MCHA could not be used as reference due to the difference of the inhibitor’s 
size and interaction regions.  
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Figure 6-1 First iteration of a hybrid molecule 
To negate the one chiral centre, the cyclohexane ring was aromatised to an aniline 
derivative 30 (Figure 6-2). After docking this structure into the protein, it was evident that 
there could be a pi-stacking interaction with a tyrosine residue located directly above the 
aniline (Figure 6-3). This improved the CDOCKER score to 65 for aniline derivative 30. 
 
Figure 6-2 Ideal hybrid 30 
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Figure 6-3 Proposed hybrid of AdoDATO and 4MCHA docked into the active site of SpdSyn. 
The two strong inhibitors, AdoDATO and 4MCHA, are presented here in the active site of SpdSyn. The 
aniline derivative 30 (carbons in orange) incorporates interactions of both of the known inhibitors. 
Even though this molecule looked like a promising inhibitor, the incorporation of both 
segments which interact with the two binding pockets was synthetically unfeasible at the 
time. To quicken our development, the propylamine segment was removed from the design 
which yielded a molecule, 31, which would be easily accessible, yet still contain the main 
interaction criteria (see Scheme 6-11). This molecule would be made by joining the 
nucleophilic thionucleoside to an aniline derivative with a suitable electrophilic centre. 
Because the amine could potentially cause unwanted effects during the linking reaction, it 
would be masked as a nitro group before being reduced to the amine (using the Pd/C) as 
shown in the disconnection to 32. 
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Scheme 6-11 Disconnection of 30 
 
 
Scheme 6-12 Synthesis of 34 
 
An efficient way to turn a hydroxyl into a leaving group is by its conversion to a mesylate and 
this reaction was used for the derivatisation of 4-(4-nitrophenyl)butan-1-ol 34 in excellent 
yield.203  
After purification, 1H NMR spectroscopy indicated the presence of an upfield singlet which 
integrated for 3 protons, which confirmed that the mesylate was obtained in good yield.  
Scheme 6-13 Synthesis of 32 
The mesylate was then ready for coupling to the thionucleoside using the previously 
established method (refer to Scheme 6-5). Although only a poor yield was obtained, 1H and 
13C NMR spectroscopy, and mass spectrometry confirmed that the nitrobenzene nucleoside 
was obtained.  
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Scheme 6-14 Synthesis of 35 
To reduce the nitro group to the respective amine, palladium on carbon and hydrogen gas 
was used. After 3 days, a new product was observed by TLC analysis, which also tested 
positive for ninhydrin, which suggested that the amine had formed.  
Unfortunately, the completion of this promising compound 35 was never realised due to time 
constraints.  
Tyrosine derivative 
In an alternative attempt to produce a hybrid with a phenyl moiety, we would incorporate 
tyrosine into the thionucleoside to yield the tyrosine derivative 36 (Figure 6-4).  
 
Figure 6-4 Proposed tyrosine hybrid derivative 36 and tyrosine  
Although tyrosine has a hydroxyl at the para- position (as opposed to an amine), the 
hydroxyl can also act as a hydrogen bond donor if rotated to the correct position. Modelling 
suggested the possibility of a new hydrogen bond interaction that could be made to the 
protein via the tyrosine amine (Figure 6-5). This tyrosine derivative 36 obtained a CDOCKER 
score of 49 (for ease of reference AdoDATO has a CDOCKER score of 83). 
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Figure 6-5 Proposed hybrid of 4MCHA, 36, docked into the active site of SpdSyn.  
Hydrogen bonding interactions are shown in green, whilst the orange line indicates a possible 
pi−interaction. For reference, AdoDATO is also shown (grey carbons). 
To incorporate tyrosine into the thionucleoside, a disconnection was planned that would use 
esterified tyrosine 37 as the starting material (see Scheme 6-15). Both the amine and 
phenolic oxygen would be protected with the base stable protecting groups, Boc and tBDMS 
for the amine and hydroxyl, respectively. An appropriate leaving group for the thiolation can 
then be installed on the ester carbon by reducing it to the hydroxyl using LAH and which will 
then be mesylated. Ultimately, the protecting groups would have to be removed.  
Scheme 6-15 Disconnection of 36 
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Scheme 6-16 Synthesis of 37 
 
The synthesis commenced with the Boc protection of the amine using Boc2O in acetonitrile 
in combination with the acyl transfer catalyst DMAP.204 Unfortunately, no new analytes were 
observed using TLC. After the misfortune, a literature search found that this reaction may 
also be performed in THF to excellent yield using the same catalyst.205 Again, the expected 
product was not formed. Substituting the DMAP for TEA, another group synthesised the 
carbamate using DCM as solvent.206 Unfortunately, the final attempt in ethanol using 
NaHCO3 also did not work.
207 For a tabulation of these reaction conditions attempted, refer 
to Table 6-3. 
Table 6-3 Conditions attempted for the synthesis of 38 
Catalyst / Base Solvent 
DMAP MeCN 
DMAP THF 
TEA DCM 
NaHCO3 EtOH 
 
Scheme 6-17 Synthesis of 39 
 
In an effort to circumvent the problematic reaction, the protection of the hydroxyl was first 
attempted by means of tert-butyl-dimethyl-silyl chloride (TBDMSCl).208 
The synthesis of the silyl ether was confirmed with the appearance of two singlet signals 
which integrated for 9 and 6 protons in the 1H NMR spectrum.  
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Scheme 6-18 Synthesis of 40 
 
This allowed us to re-attempt the amine protection in a slightly altered environment. The 
reaction was performed in THF, which resulted in a number of side reactions, the products of 
which were not isolated. The solvent was then changed to acetonitrile, which reduced the 
by-products to only 3. After purification, one of these products was confirmed by 1H NMR 
spectroscopy to be the desired carbamate with the appearance of an upfield singlet which 
integrated for 9 protons.  Unfortunately, only a trace amount of desired product 40 was 
obtained from this reaction. At this point, this synthetic route was abandoned for more 
promising compounds.  
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Triazole derivatives 
Design 
Another molecule was designed to incorporate an aromatic ring, this time a triazole. 
Triazoles are both synthetically easily accessible and have good drug-likeness. The triazole 
moiety would be well accommodated in the same region as 4MCHA, also possibly with a 
pi-interaction with the above-lying tyrosine residue. The triazole would be substituted with an 
amino-methyl group to be able to interact with the distal cation binding pocket (see Figure 
6-6). The triazole derivative 41 that was planned for synthesis was docked into the prepared 
protein structure with a CDOCKER score of 43 (for ease of reference AdoDATO has a 
CDOCKER score of 83). 
 
Figure 6-6 The 3 carbon linked triazole derivative, docked into the active site.  
The red dots designate the cation binding sites. 
Planning 
The disconnection was planned as follows (Scheme 6-19). The triazole could be formed 
using a Huisgen 1,3-dipolar cycloaddition from an azide. Using copper as catalyst would 
ensure that only the desired 1,4 regioisomer 41 would be formed with propargylamine 42 
after deprotection.209 The azide would be linked to the nucleophilic adenosine via an 
electrophilic centre, easily accessed from a hydroxyl. The azide functionality would be 
accessed by the reaction of sodium azide and a hydroxyl. This concluded the disconnection 
sequence with propane-1,3-diol 43 as starting material.  
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Scheme 6-19 Synthesis pathway to the proposed triazole derivative 41 
 
 
Scheme 6-20 Mechanism of the copper catalysed Huisgen 1,3-dipolar cycloaddition 
The exact mechanism of the reaction is still unknown. However, it is known that copper is 
able to co-ordinate to the alkyne after the acidic proton has been abstracted with a suitable 
base.210 
 
Synthesis 
Scheme 6-21 Synthesis of 44 
 
The construction of the three carbon linked triazole was started with the bis-mesylation of 
1,3-dipropanol by the use of mesylchloride.211 
After the reaction was left to stir overnight, the salt was removed by filtration and the volatiles 
were removed using flash distillation. The crude product was then used to create the azide 
without further purification.  
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Scheme 6-22 Synthesis of 45 
 
To make the azide, a stoichiometric amount of NaN3 was added to the crude dimesylate and 
heated at reflux overnight. After the reaction was completed, TLC was used to examine the 
products formed. To visualise the azide, we used two stains. One, reliant on a mini Click-
chemistry reaction, proved to be very ineffective.212 Another, reliant on a mini Staudinger 
reaction, proved to be very sensitive.213 The latter entailed dipping the TLC plate in a PPh3 
solution to reduce the azide to the amine and then dipping the plate in ninhydrin to visualise 
the amine. After column chromatography, the yield was 42% over the two steps. We were 
now ready to join this molecule to the thionucleoside. The 1H NMR spectrum was used to 
confirm that the molecule was expected by the disappeared of one mesyl group and change 
in chemical shifts of the signals. Additional characterisation was not performed as the 
compound is not novel.214 
Scheme 6-23 Synthesis of 46 
 
With our established method (refer to Scheme 6-5), a slight excess of NaOMe was used to 
generate the anion 19 at -15°C for 1 hour. After this, the azide 45 was added to stir 
overnight.  
The reaction was quenched with a small amount of water. After purification using column 
chromatography, the compound was analysed by 1H NMR, 13C NMR and mass 
spectrometry. Two triplet signals, both of which integrated for two protons, were present in 
the 1H NMR spectrum which correlated to the two atom positions indicated (1 and 3). Due to 
the increased electronegativity of nitrogen over sulphur, the more downfield signal was 
assigned to the protons of the carbon neighbouring the azide (3).  
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Scheme 6-24 Synthesis of 47 
 
With the thioadenosine 20 suitably derivatised with the azide, we were ready for the copper 
catalysed Click reaction. To ensure that the 1,4 regioisomer would form, CuI was used as 
catalyst for the reaction. A slight excess of propargylamine 42 was added to ensure that the 
reaction went to completion.215  
The reaction was monitored by TLC. After an hour, starting material was still evident in the 
reaction mixture, so additional propargyl amine was added. After another hour, no azide was 
observed. The reaction was then quenched with a saturated solution of NH4Cl and purified 
using column chromatography to give a good yield. 1H NMR spectroscopy analysis 
presented the opportunity for several observations: 
1. The presence of an additional singlet signal in the aromatic region was observed. This 
was the primary indication of the successful formation of the triazole.  
2. The signal that was assigned to the protons on the carbon adjacent to the sulphur for the 
preceding reaction (1), had very small difference in the chemical shift (2.5 vs 2.4 ppm). In 
contrast, the protons present on the carbon adjacent to the azide (3), shifted much more as 
these were now adjacent to the much more strongly electron withdrawing triazole (3.3 vs 4.3 
ppm). This observation provided additional confidence that the preceding assignment was 
correct.   
3. Using copper to catalyse the Huisgen 1,3-dipolar cycloadditions, only the 1,4-disubstituted 
triazole was expected to form.209 In an effort to confirm that the 1,4-regioisomer had indeed 
formed, a NOESY NMR experiment was performed even though we were not too hopeful of 
conclusive results. The experiment was based on the principle that if the 1,4-isomer had 
formed as expected, that the protons adjacent to the triazole could be in close enough 
proximity to the aromatic proton at the 5ʹ position to allow cross-coupling to be observed 
(drawn explicitly, see Figure 6-7). Unfortunately, no definitive “through space coupling” was 
observed for either of the two possible regioisomers.  
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Figure 6-7 Two possible triazole regioisomers 
If the 1,4-regiomer had formed, through space coupling could have been observed between the triazole 
neighbouring protons and the aromatic proton. Alternatively, through space coupling could have been 
observed to either the amine or neighbouring carbons protons. 
All 19 of the carbon atoms were accounted for in the 13C NMR spectroscopy experiment. 
LCMS confirmed that the mass was as expected and UV absorbance indicated that the 
product was 97.8% pure. The final deprotection step could now be performed to remove the 
ketal.  
Scheme 6-25 Synthesis of 48 
 
The triazole 47 was dissolved in formic acid and purified water to remove the ketal protecting 
group. After two days, no starting material could be detected by TLC. All the volatiles were 
then removed by a combination of vacuum distillation and high vacuum to yield the 
di-hydroxy nucleoside 48. LCMS indicated that the resultant product was 89.7% pure by UV, 
which also confirmed that the mass was as expected. 
1H NMR spectroscopy confirmed the disappearance of the two singlets in the upfield region, 
which correlated to the methyl peaks of the ketal. 13C NMR spectroscopy indicated the 
presence of 16 carbons, which also correlated with the structure. This compound was then 
submitted for enzymatic assay testing.  
In an analogous sequence, these steps were repeated on a 2 carbon diol 49 to explore the 
number of linker atoms to the thiazole and amine.  
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Scheme 6-26 Synthesis of 50 
 
Once again, the sequence was started by the bis-mesylation of ethane-1,2-diol 49.211 After 
the reaction was left to proceed overnight, the triethylamine salts were removed by filtration 
and the volatiles were removed by vacuum distillation. The compound was used in the 
following azidification reaction without purification. 
Scheme 6-27 Synthesis of 51 
 
The azidification was performed under reflux conditions overnight.211 Because the di-azide 
could potentially be explosive, exactly one stoichiometric equivalent of sodium azide was 
added to the reaction, based on the mass of the diol.  
After purification using column chromatography, 1H NMR spectroscopy confirmed that one 
mesyl group was present with the presence of an upfield singlet signal which integrated for 3 
protons with no hydroxyl peak evident.  
Scheme 6-28 Synthesis of 52 
 
Again, a modest yield was obtained over the two steps to use in the reaction to couple the 
azide 51 to the thionucleoside 20.201 The reaction was performed in freshly distilled 
methanol, in which the nucleophile was prepared using sodium methoxide. After 3 days, the 
reaction was deemed to be complete, as all of the thionucleoside was consumed. After the 
product was isolated and purified, the obtained 1H and 13C NMR spectra and the mass 
spectrum was consistent with the structure 52.  
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Scheme 6-29 Synthesis of 53 
 
The azide 52 would again be converted to a 1,4-triazole using Click chemistry. The reagents 
were added together with a final addition of a catalytic amount of copper iodide. The reaction 
was monitored by TLC and an additional portion of propargyl amine was added after an hour 
to facilitate the reaction. 13C NMR spectroscopy data was consistent with the number of 
carbons and 1H NMR spectroscopy indicated the appearance of a singlet in the aromatic 
region which would indicate the successful formation the triazole and the disappearance of 
the singlet in the upfield which would indicate the loss of the thionucleoside methyl group. All 
other signals in the 1H NMR spectrum were assigned to the expected molecule 53.  
Scheme 6-30 Synthesis of 54 
 
Only the ketal deprotection remained using a combination of formic acid and water. The 
reaction was left to stir for 2 days and monitored by TLC. When no more ketal 53 could be 
detected, the product was collected by removing all the volatiles. 1H NMR spectroscopy 
confirmed the disappearance of two singlets in the upfield region, which would correspond to 
the ketal protons. Signals which would correspond to the hydroxyls would not be seen due to 
proton exchange with the deuterated methanol solvent used for the experiment. 13C NMR 
and mass spectrometry data were also concordant with the structure and confirmed that the 
second triazole compound was complete. 
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Results 
After the completion of the syntheses, the compounds were sent for enzymatic analysis.216 
The results of the tests are presented in Figure 6-8. The 4 alkyl derivatives, which are 
intended to occupy the hydrophobic region of the active site presented no inhibition. This can 
either be ascribed to experimental error or an unknown, possibly agonistic, mechanism.  
Of the 5 compounds, the triazole derivative 48 presented the strongest inhibition activity, 
albeit marginal.  
 
Figure 6-8 SpdSyn inhibition results 
The enzymatic activity was conducted at 100 µM for each compound. The triazole derivative is 
highlighted in red. For reference, the potent inhibitor 4-MCHA is included. 
 
  
100 104 
112 117 112 
95 
14 
E
n
z
y
m
a
ti
c
 a
c
ti
v
it
y
 (
%
) SpdSyn inhibition results 
Blank 4-MCHA 22 26 24 28 48
Stellenbosch University  http://scholar.sun.ac.za
Chapter 6 – Spermidine Synthase (Nucleophilic adenosine) 
 
91 
Conclusion 
Nucleophilicity was successfully conferred to adenosine by the incorporation of a thioester 
onto the molecule using a high yield Mitsunobu reaction. 
By releasing the masked thiolate using sodium methoxide, 4 alkyl chains were also 
introduced to the adenosine. This set the stage to incorporate additional functionality (such 
as an azide) via nucleophilic displacement of a mesyl group. Ultimately, this led to the 
incorporation of a triazole of which two analogues were made.  
Two additional functionalities were also planned to be introduced, also via the nucleophilic 
displacement of a mesylate. This included an aniline and a tyrosine derivative. Unfortunately, 
the former could not be completed due to time constraints and the latter was compounded 
with synthetic problems. 
Unfortunately, none of the compounds synthesised obtained notable activity against 
Spermidine Synthase. 
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7. Protein Farnesyltransferase inhibition 
For our PFT inhibitor development efforts, we took inspiration from the work of van Voorhis 
et al. 145 This group successfully synthesised and assayed a wide series of inhibitors with low 
nanomolar potencies in vivo. Because of the superior nature of these inhibitors, we based 
our own designs on this series and expanded the subset.   
Derivatisation of indole Nʹ position − Proof of concept 
The inhibitors developed by Voorhis et al. were based on a tetrahydroquinoline (THQ) 
scaffold.145 The most potent inhibitor in the series, PB-93 (see Figure 7-1), was co-
crystallised with PFT to better understand its mode of action (PDB ID: 2R2L). After analysing 
the crystal structure, we found several key interactions: 
1) The THQ scaffold has a pi-pi interaction with a tyrosine residue which is located 
directly underneath it.  
2) An imidazole, which extends from the THQ scaffold, forms a chelating interaction 
with a zinc ion located within the active site. 
3) A nitrile, which also extends directly from the THQ scaffold, occupies a hydrophobic 
cavity within the active site.  
To develop our own variation of this inhibitor, we substituted the THQ scaffold with an indole. 
An indole, similar to quinoline, is also a biologically privileged structure meaning that the 
structure exhibits good pharmacodynamic and pharmacokinetic properties. This novel 
scaffold allowed us to retain interactions (Figure 7-1). By superimposing this new molecule, 
our proof of concept, onto PB-93 within the crystal structure, we could see this how this new 
molecule would be well accommodated within the active site (Figure 7-2). Once we have 
successfully synthesised this proof of concept compound 58 and demonstrated activity, we 
would expand the indole at positions 2ʹ and 3ʹ to increase the site occupancy to refine the 
selectivity and potency. 
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Figure 7-1 Tetrahydroquinoline based inhibitor developed by van Voorhis et al. and our 
indole derivative.
145
  
The scaffold of the molecules have been bolded to highlight the similarity between them. The indole 
3ʹposition would be expanded further to develop the compound series.  
 
 
Figure 7-2 Wide entrance to the active site of protein farnesyltransferase (PDB code: 2R2L). 
Our proof concept indole derivative 55 with a CDOCKER score of 25 is superimposed on the crystallised 
tetrahydroquinoline scaffold (carbons in orange, CDOCKER score 55). Note the imidazole chelating to the 
zinc (green) and the nitrile filling the hydrophobic cavity to the left. The groove along the right is the 
binding site for the farnesyl moiety.  
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Synthetic planning 
To make this proposed proof of concept compound (Figure 7-1), the main step would involve 
attaching the indole to the imidazole derivative. To achieve this key step (see Scheme 7-1), 
we would exploit the indole nitrogen’s nucleophilicity to attach the imidazole functionality. 
The imidazole residue, would then be derivatised with a suitable leaving group at the 
appropriate position to make it electrophilic. To this aim, we sourced an imidazole 59 which 
was substituted with a hydroxyl group. The hydroxyl would then be converted to a chloride to 
impart electrophilicity at the appropriate position. Moreover, this imidazole was not 
methylated like PB-93. In order to avoid the imidazole acting as a nucleophile, it would be 
first need to be protected with a base stable protecting group.  
Scheme 7-1 Proposed disconnection of the proof of concept 58 
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Synthesis 
Imidazole derivative 
The synthesis of the imidazole zinc chelating moiety half of the proof of concept compound 
was commenced.  
Scheme 7-2 Synthesis of 58 
 
We envisaged that from (1H-imidazol-4-yl)methanol 59, which is commercially available, the 
primary alcohol could be converted into a convenient leaving group, facilitating the 
substitution of this moiety onto the indole. To negate the possibility that the imidazole 
nitrogen could act as pofssible competing nucleophile, we used a base stable protecting 
group on it. Boc anhydride (Boc2O) fulfilled this criterion. The Boc group was introduced in 
good yield using a catalytic amount of dimethoxy-aminopyridine (DMAP) as acyl carrier. 
After following the reaction with TLC, the product 58 was purified using column 
chromatography. This removed most impurities, including the characteristic Boc protection 
by-product - tert-butanol. The reaction was deemed to be successful with the appearance of 
the characteristic NMR signal which integrates for 9 protons in the upfield region. It was 
interesting to note that this signal was divided into two separate peaks: imidazole has two 
tautomeric states, both being susceptible to Boc protection. Therefore, we concluded that 
two regioisomers had formed. Judging by the relative ratio of these two peaks, roughly 83% 
of the Boc attached to the nitrogen at the 3ʹ position, while the 1ʹ nitrogen accepted the 
remainder (see Figure 7-3). Taking the sterics of the primary alcohol into account, it can be 
presumed that the more significant amount of the Boc group went on to the 3ʹ amine, whilst 
the remainder went on the more sterically hindered 1ʹ amine. This presumption could be 
confirmed by an NOE experiment, but was deemed unnecessary as the Boc would soon be 
removed without impacting the end result.  
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Figure 7-3 NMR segment of the tert-butyl group 
The signal split is proportional to the locale of the Boc protection group (Integration indicated below). 
Scheme 7-3 Synthesis of 57 
 
After the successful protection of the amine, the hydroxyl needed to be converted into an 
appropriate leaving group. For our purposes, we used thionyl chloride for the conversion to 
the respective chloride 57. 217 
In this reaction, HCl would be released as a by-product. This posed a potential problem: If 
the medium turned acidic, the Boc group could inadvertently be lost. To minimise this, the 
reaction was performed at 0°C to limit the possibilty of this unwanted deprotection reaction 
and was closely followed by TLC. As soon as the starting material had been consumed, the 
reaction was quenched and the product was isolated. Finally, the product was purified by 
column chromatography. 1H NMR spectroscopy confirmed that the chloride was formed 
owing to the change in chemical shifts and the disappearance of the broad hydroxyl signal. 
Key step 
Scheme 7-4 Attempted synthesis of 60 
 
With the Boc-protected electrophile in hand, we were ready to attach it to the indole. The 
indole nitrogen was deprotonated with sodium hydride to generate the desired nucleophile. 
After 10 minutes, the evolution of hydrogen ceased and the electrophilic imidazole was 
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added. The reaction was then left to proceed overnight. After purifying with column 
chromatography, we discovered an unexpected result: Instead of the nucleophile displacing 
the chloride, it turned out that the carbamate was the more electronegative functional group 
and instead resulted in the N-Boc-indole 61 (see Scheme 7-5). With this unexpected result, 
we were back to the drawing board to consider an alternative strategy to this problem. 
Scheme 7-5 Mechanism of how the unexpected product, 61, had formed. 
 
An alternative strategy 
Close examination of the imidazole functionality in PB-93 observed that the one nitrogen, 
opposite to the zinc chelating nitrogen, was methylated. 145, 218 If we were to revise the proof 
of concept compound to incorporate this methylated functionality 62, the previously 
experienced issues would be resolved. Furthermore, we did not expect that the binding 
efficacy would be adversely affected as this methyl group faces directly away from the zinc 
atom (refer to Figure 7-4).  
 
Figure 7-4  Alternative proof of concept compound 
The atom highlighted in yellow was to be substituted from a proton to a methyl give 62, similar to PB-93.  
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Scheme 7-6 Synthesis of 64 
 
We were able to purchase a suitably methylated imidazole derivative as the aldehyde 69, 
which we promptly reduced using LiAlH4.
218 Due to the amphoteric nature of this molecule, 
excess LiAlH4 was quenched using Na2SO4•10H2O. 
1H NMR spectrum confirmed the 
aldehyde was successfully reduced owing to the disappearance of the upfield aldehyde 
singlet and the appearance of a broad hydroxyl signal.  
Scheme 7-7 Synthesis of 65 
 
To make the hydroxy-substituted carbon electrophilic once again, the alcohol was converted 
to the chloride.218 In contrast to the previous chlorination where we added a stoichiometric 
amount of thionyl chloride, a vast excess of SOCl2 was now added. Under these conditions, 
the chloride was now isolated as the hydrochloric salt. Trituration with diethyl ether afforded 
the purified chloride salt. The 1H NMR spectrum obtained agreed with what we expected, 
with no evident broad hydroxyl signal. Because the solvent for the NMR experiment was 
different, we could not make a direct comparison to the chemical shifts of the signals. In 
retrospect, mass-spectrometry would have given more confidence that that reaction was 
chloride was obtained, but this was not performed at the time.  
Scheme 7-8 Synthesis of 62 
 
With the required precursor now in hand, we were ready for a second attempt to link the 
major two components together. Once again, sodium hydride was used to deprotonate the 
indole 59 to produce the nucleophile, using an additional equivalent of sodium hydride to 
neutralise the hydrochloric acid salt of the imidazolic chloride. Once bubbling ceased, the 
chloride 71 was added. Because the generated indole anion would act as a base to the 
acidic crystal salts, we used an extra equivalent sodium hydride to neutralise the salt. The 
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reaction was left to stir overnight. After workup, the product was purified by chromatography. 
1H NMR spectroscopy indicated that all expected signals were present, all of which 
integrated appropriately. Unfortunately, not all peaks could be unambiguously assigned due 
to overlapping signals. It was however enough to confirm that we successfully synthesised 
the desired proof of concept compound. As the crystal structure was solved, 13C NMR 
characterisation was not performed. Although only a modest yield was attained, it was 
sufficient for testing purposes.  
The IC50 in whole cell assay was measured to be 139 μM according to the procedures by 
Makler et al.219 Although this is only modest activity we could now incorporate functional 
groups to optimise hydrophobicity to pass the cell wall and provide additional reversible 
binding interaction within the large active site of PFT. To characterise this important 
intermediate further, we determined and published the crystal structure using X-ray 
crystallography (refer to Figure 7-5).i  
 
Figure 7-5 Crystal structure of the proof of concept compound, 62.  
 
It is interesting to note that this crystallised form of the ligand is not in the minimum energy 
conformation. Using (simulated heating) annealing and a subsequent minimisation, the 
conformation with the lowest potential energy was searched for and compared to the 
obtained crystal structure.  (This method is not suited for entire protein/ligand complexes, but 
this ligand only has 3 notable rotatable bonds.) When the energies between these two states 
are compared, a significant difference is observed (~7x).  
                                               
i
 Acta Cryst. (2012). E68, o3486 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 7 – Protein Farnesyltransferase inhibition 
 
100 
Table 7-1 Energy differences in crystal structure and the global minimum. 
Solvent model 
Solid State Energy 
(kcal/mol) 
Global minimum 
(kcal/mol) 
None 147.064 22.5184 
DDDE 144.838 20.1710 
GBMV 145.643 19.5651 
PBSA 145.917 20.7626 
   
This difference is exemplary of how different crystal packing may affect the conformation of 
even a small molecule. It also highlights the requirement of a minimisation step when 
preparing protein crystal structures for modelling application, especially if the structure is of 
low resolution ( > 2 Å). However, it should be noted that these energy values are dependent 
on the equilibrium values given in the CHARMm forcefield.  
Derivatisation indole 3ʹ position − (Xylene) 
Familiarisation of the biochemical environment 
As a significant amount of work has already been done in this area, we needed to harness 
this knowledge to better understand the biochemical environment of the target site.143, 145, 220-
223 Previous work included the publication of numerous PFT crystal structures of various 
classes of ligands, including ethylenediamine, tetrahydroquinoline and piperidine based 
structures. We would attempt to combine some of the best features of these compounds. 
To do this, we downloaded all Rattus norvegicus PFT crystal structures from the PDB with a 
resolution of ≤ 2.3 Å and superimposed them to the 2R2L crystal structure. In DS, this is 
done by examining the primary sequence of the proteins and aligning the backbone of the 
proteins into the same co-ordinate frame. The residues in or near the active site where then 
examined one by one. The result is shown in Figure 7-6. From this, we expected to see 
three things: A) the degree of conformational change that could be as a result of the induced 
fit from the various ligands;224 B) the key interaction sites of the known inhibitors; and C) the 
conserved moieties of known inhibitors and their respective locations.  
Stellenbosch University  http://scholar.sun.ac.za
Chapter 7 – Protein Farnesyltransferase inhibition 
 
101 
       
Figure 7-6 Superimposition of the active site of 18 PFT structures, co-crystallised with 
various ligands.  
By referring to the RMSD’s of the protein structures relative to 2R2L, we can see that there is minimal 
deviation in the various crystal structures. Indeed, it is the apo-enzyme crystal structure with the largest 
deviation. For reference, the active site Zn is shown in green.  
It was quickly evident that there was minimal alteration as result of induced fit apart from the 
phenol rings of two tyrosine residues. The first tyrosine veers slightly left, away from the 
active site (seen in the upper left in Figure 7-6). The other tyrosine veers strongly away from 
the active site (seen to the right). None of the three crystal structures with these three 
induced fit alterations contained ligands which resembled inhibitors which we would design. 
Therefore, we could safely assume that the structure with PDB ID: 2R2L would be a good 
choice to use for inhibitor design.  
Following this, we examined the ligands to see which interaction sites were significant and 
whether there were any apparent trends. We quickly noted that several inhibitors contained 
aromatic rings in similar regions. The enzyme’s affinity for aromatic rings is reinforced with 
the knowledge that the enzyme has strong affinity for certain aromatic amino acid containing 
protein sequences (the natural substrates). Moreover, the locale of these aromatic amino 
acids was also easily accessible from the indole 3ʹ position. To exploit this, we would to 
PDB ID RMSD (Å) 
2R2L --- 
1FT1 
(Apo) 
0.81 
1D8D 0.43 
1N95 0.49 
1NI1 0.48 
1O1R 0.22 
1O1S 0.21 
1O1T 0.18 
1O5M 0.20 
1TN7 0.43 
1TN8 0.42 
1JCR 0.43 
1JCS 0.42 
1KZO 0.42 
1KZP 0.43 
3E33 0.41 
3E34 0.42 
3KSL 0.19 
3KSQ 0.21 
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attach a benzene ring to this location. Further, in order to reduce the conformational entropy 
penalty, we would include methyl groups to help keep the molecule in the bioactive shape. 
Although a single methyl would suffice, the resulting molecule, 63, would then have the 
added complexity of being in either of two rotamers (see Figure 7-7). 63 was docked into the 
prepared 2R2L structure (see Figure 7-8). Although a CDOCKER score of 25 was obtained 
(which is equal to the indole proof of concept compound), we believed that the xylene would 
increase the affinity for the active site.  
 
Figure 7-7 Demonstration of possible rotamer creation 
Possible steric clash (indicated in purple) of a mono-methylated benzyl group which would result in two 
rotamers, depending whether the benzylic group is attached with the methyl coordinated to the top or 
bottom of the indole plane.  
 
Figure 7-8 Active site surface of 2R2L docked with the planned indole-xylene derivative 63.  
The position of the aromatic groups of other inhibitors are also shown in orange while the active site Zn 
ion is shown in green. 
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Planning 
Albeit with a CDOCKER score of 25, similar to the proof of concept compound 62, the 
xylene-coupled indole 63 looked to be a promising compound. A strategy was soon 
developed to access this molecule efficiently.  
Functionalisation at the 3ʹ position in the indole is relatively easily accomplished as it is the 
most nucleophilic position on the molecule: the indole nitrogen’s lone pair can delocalise to 
conjugate through to the 3ʹ position (Figure 7-9).  
 
Figure 7-9 Mechanism of indole 3ʹ position's nucleophilicity 
To attach the indole directly on to the xylene, we would have to use palladium chemistry, as 
a conventional substitution reaction would break the xylene ring’s aromaticity. To do this, we 
would employ a Suzuki reaction, which involves oxidative addition and reductive elimination 
instead.225 Typically, the conventional method to functionalise the indole 3ʹ position would be 
to install a halogen (for example, using N-bromosuccinimide) and then perform lithium 
halogen exchange to be able to access a borate ester. From that point, a base work-up 
would yield the boronic acid from which a Suzuki coupling would be performed to link the 
xylene to the indole. Unfortunately, we could not use this route because our indole was 
already substituted with bromide at the 5ʹ position, which would give chemoselectivity issues 
at the lithium halogen exchange step. We therefore needed an alternative method to access 
the boronic acid for the palladium coupling reaction.  
Xiong et al were able to do just this, based on a mercuration reaction first published by 
Dimrith in 1898 (refer to Scheme 7-9).226, 227 Starting from an N-protected-5-bromo-indole 64, 
the group derivatised the 3ʹ position with mercuric acetate in glacial acetic acid to yield a 
mercurial compound 65. This was then converted to the boronic acid 66 using borane. The 
Suzuki coupling’s reagents would then be ready and installation of the nitrile and imidazole 
moiety would then allow access to target compound 67.  
For this synthetic sequence, the group protected the indole nitrogen with a tosylate.226 
Because we had easy access to Boc2O we used it instead of the tosyl-protection group.  
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Scheme 7-9 Retrosynthesis of xylene-derivative indole, 63 
 
Synthesis 
Scheme 7-10 Synthesis of 64 
 
The Boc protected indole was obtained by using Boc anhydride and a catalytic amount of 
DMAP on 5-bromo-indole 70.228 After the reaction was purified by column chromatography in 
excellent yield, 1H NMR spectroscopy confirmed the characteristic tert-butyl upfield signal 
which integrates for 9 protons.  
Scheme 7-11 Synthesis of 65 
 
The mercuration was started by dissolving mercuric acetate in glacial acetic acid.226 To this 
was added the Boc-protected indole 64. After the mixture was stirred overnight, a white 
precipitate was collected by filtration and used without further purification. 1H NMR 
spectroscopy then confirmed that the desired mercurial 65 formed due to the disappearance 
of an aromatic signal and the appearance of an upfield singlet which integrates for 3 protons. 
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Scheme 7-12 Synthesis of 66 
 
After the isolation of the mercurial 65, borane was used in dimethyl sulfide to make the 
boronic acid 66.226 Insoluble impurities were removed via filtration and 1H NMR spectroscopy 
confirmed the product to be free of significant impurities was then used without further 
purification. Further, 1H NMR showed the disappearance of the upfield methyl singlet and 
the appearance of a broad singlet which integrated for 2 protons. Together with the change 
in retention factor, this led us to believe that the boronic acid was successfully isolated and 
our reagent was ready for Suzuki cross-coupling.  
Scheme 7-13 Synthesis of 71 
 
To synthesise the palladium catalyst, we started with a solution of dibenzylideneacetone and 
sodium acetate in hot methanol.229 We then added the PdCl2 and allowed the reaction to stir. 
After a while, the product started to precipitate, which was furthered by cooling the solution. 
After filtration with water and acetone, we had pure Pd(DBA)2 71. Although air stable, the 
reagent was stored shielded away from light in a desiccator. From this reagent, we would 
prepare tetrakis(triphenylphosphine)palladium(0) (tetrakis) (Pd(PPh3)4) in situ.  
Scheme 7-14 Attempted synthesis of 68 
 
Finally, with all the reagents in hand, we attempted our Suzuki reaction. Although we were 
aware that the bromine present on the indole could potentially also be susceptible to 
derivatisation, we were hopeful that the iodo would be more labile and afford the required 
chemoselectivity.  
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As this reaction is very oxygen sensitive, all solutions used were degassed with nitrogen. In 
a three neck flask, we added Pd(DBA)2 71 to dimethoxyethane (DME). This was followed by 
the addition of PPh3. The solution soon turned bright yellow which confirmed the successful 
formation of tetrakis (Pd(PPh3)4) in situ. This was followed by the addition of the iodo-xylene 
69, boronic acid 66 and Na2CO3. The reaction was left to stir overnight, after which it turned 
green. Upon examination with TLC, numerous by-products formed which we deemed 
fruitless to purify. Alterations which could be made to make the reaction work would include: 
the use of a different base (example Cs2CO3); preparation of the tetrakis beforehand; 
employment of freeze thaw techniques to remove all traces of oxygen; variation of the Pd 
catalyst and the concentration thereof. However, our first action was to eliminate the 
possibility that it could be the protecting group used. So we changed the indole nitrogen 
protection from the Boc group to a tosyl, which was used by Xiong et al. 
Scheme 7-15 Synthesis of 72 
 
Sodium hydride was used to deprotonate the indole nitrogen and afford the nucleophile. To 
this we added the tosyl chloride.230 After purification, 1H NMR spectroscopy confirmed that 
that the tosylation was successful by the appearance of two aromatic doublet signals (both 
of which integrated for 2 protons) and the appearance of an upfield singlet which integrated 
for 3 protons. 
Unfortunately, this project’s allocated time expired at this point and was halted. 
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Derivatisation indole 3ʹ position − (Maleimide) 
In another effort to expand deeper into the binding cavity, we would synthesise an indole 73 
that is derivatised with a maleimide at the 3ʹ position (refer to Figure 7-10).  
 
Figure 7-10 Maleimide-indole 73 docked in the active site of PFT.  
The moiety extends from the indole 3ʹ position. Again, the green sphere indicates the catalytic zinc ion. 
Planning 
Once again, the first disconnection points would be between the imidazole and nitrile 
functionalities to the indole. From here, the maleimide disconnection begins. The maleimide 
74 can be accessed from the addition of furan-2,5-dione 75 to the amine 76. This amine can 
be obtained from the reduction of the nitro 77, using a suitable reducing agent like Raney 
Nickel which is preceded by the reduction of the alkene 78. The nitro, in turn, could be 
prepared by the use of a Henry reaction from the aldehyde 79. Finally, the aldehyde can be 
constructed by exploiting the nucleophilicity of the 3ʹ position in the indole 70 using a 
Vilsmeier-Haack reaction.231  
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Scheme 7-16 Disconnection of indole-maleimide 73 
 
 
Synthesis 
Scheme 7-17 Synthesis of 80232 
 
We started our synthesis of the aldehyde 79 using a Vilsmeier-Haack formylation based on 
precedence set by Schumacher et al.232 This started with the dropwise addition of 
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phosphoryl chloride to DMF. Once the electrophilic Vilsmeier salt was formed, the 
nucleophilic indole was added to form the iminium ion. Finally, aqueous base was added to 
hydrolyse the iminium ion to the aldehyde. Filtration was sufficient to yield pure product in 
very good yield.   
Together with an increased polarity (determined by TLC), 1H NMR spectroscopy confirmed 
that the correct product had formed: The spectrum indicated the presence of a far downfield 
singlet which integrated for 1, consistent with the presence of an aldehyde proton. Also, the 
remainder of the signals were unambiguously assigned.  
Scheme 7-18 Synthesis of 78233 
 
The installation of the required nitro group by a Henry reaction was performed according to 
the procedure of Muratore et al.233 Under reflux conditions, nucleophilic nitromethane 
attacked the aldehyde to form a hydroxyl intermediate. The alcohol is then eliminated in an 
E1cB mechanism to produce the double bond. 233 With the aid of TLC, it was evident that 
product formation occurred, but during the work-up water wash step, the product degraded. 
Subsequent attempts at this reaction skipped this step to directly purify the product with 
column chromatography. Unfortunately, poor solubility compounded these efforts and only a 
modest yield was attained.  
The bright orange product was analysed by 1H NMR spectroscopy which led us to believe 
that we had obtained the expected nitro 78 owing to the disappearance of the aldehyde 
singlet and the appearance of two signals which integrate for 1 proton each. 
Scheme 7-19 Synthesis of 80 
 
The next step in the sequence was to reduce the double bond of the nitro-indole derivative 
78, but this was compounded by solubility issues. In an attempt to alleviate the solubility 
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problem, we would increase the molecule’s hydrophobic character by introducing Boc 
protection on the indole nitrogen.  
In a standard Boc protection method, Boc-anhydride was added to the indole in THF and a 
catalytic amount of the acyl transfer agent, DMAP, was added.  After overnight stirring, the 
reaction was worked up and purified. 1H NMR spectroscopy indicated the tell-tale upfield 
singlet which integrated for 9 protons. All other signals present were accounted for, which 
convinced us that the carbamate 80 had indeed formed in excellent yield.  
Unfortunately, due to the fact that the project focus required a shift in the direction of the 
SpdSyn inhibitors (the required assay would only be available for a limited period of time), 
further work on this synthetic route was halted.  
 
Conclusion 
Synthesis of the proof of concept compound 62 was successfully completed and was 
demonstrated to inhibit parasitic growth in whole cell assay. However, it still remains to be 
demonstrated, using an enzymatic assay method, that the target is indeed the enzyme 
Protein Farnesyltransferase. 
Future work in this project should include functionalising the indole at the 3ʹ position to allow 
for increased occupancy of the enzymatic cavity. This should include additional attempts to 
introduce an aromatic moiety, using modified methods of palladium chemistry. 
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8. Experimental 
Synthetic Procedures - General 
Solvent purification  
Reaction solvents were purified by distillation under nitrogen atmosphere using the following 
drying agents: 202 
THF  Sodium flakes and benzophenone as indicator 
Diethyl ether Sodium wire 
Toluene Sodium chunks 
DCM CaH2 
Methanol CaH2 with a catalytic amount of iodine  
DME Used straight from anhydrous container 
Pyridine Potassium hydroxide 
Chromatography 
Thin layer chromatography used Alugram XTRA Silica G/UV254 plates. Visualisation of the 
analytes was achieved by: UV fluorescence, iodine, vanillin, KMnO4 or ninhydrin staining.  
Column chromatography was employed for sample purification. Gravity chromatography 
used 400 mesh silica, whilst flash silica used 60 mesh size whilst under pressure from 
compressed air using generally accepted procedures.234 
Spectroscopy 
NMR: Spectra were performed on Varian INOVA spectrometers (300 and 400 MHz) from the 
Central Analytical Facility from University Stellenbosch. In all cases, residual solvent signals 
were used as reference for chemical shifts, reported in ppm (CDCl3 = 7.260, DMSO-d6 = 
2.500, MeOD-d4 = 3.310). 
X-ray diffraction: Bruker APEXII CCD diffractometer 
Spectrometry 
MS: Waters API Q-TOF Ultima spectrometer, using electron spray ionisation. 
General 
Reactions were performed under inert atmospheres (N2), unless otherwise stated. 
Glassware was oven or flame dried. Reaction containers were purged with nitrogen which 
had been passed through a column of 4 Å molecular sieves. 
In vacuo solvent removal entails the use of a rotary evaporator to remove solvent. When 
required, a high vacuum pump was used to remove the remaining traces of solvent under ~ 
0.1 mm Hg.  
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Synthetic Procedures (Chapter 5) 
3 ((3aR,4R,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methanol 
   
To an anhydrous solution of adenosine 1 (500 mg, 1.87 mmol) in acetone (100 mℓ) was 
added PTSA (3.20 g, 18.7 mmol) and molecular sieves. The reaction mixture was allowed to 
stir for 24 hours under an anhydrous nitrogen atmosphere. The solution was made basic by 
the addition of ice cold, saturated NaHCO3 solution. The product was extracted with DCM 
(3x 150 mℓ), washed with brine and dried with MgSO4. After removal of the solvent in vacuo, 
the solid was purified by chromatography (1:9 MeOH:DCM) to afford a white product (63 mg, 
11%). Rf = 0.47 (1:9 MeOH:DCM). 
1H NMR (400 MHz, DMSO) δ 8.34 (s, 1H, 1 or 2), 8.15 
(s, 1H, 1 or 2), 7.34 (s, 2H, 14), 6.12 (d, J = 3.1 Hz, 1H, 6), 5.34 (dd, J = 6.2, 3.1 Hz, 1H, 8), 
5.24 (t, J = 5.6 Hz, 1H, 15), 4.96 (dd, J = 6.2, 2.5 Hz, 1H, 9), 4.21 (td, J = 4.8, 2.5 Hz, 1H, 7), 
3.63 – 3.45 (m, 2H, 13), 1.54 (s, 3H, 11 or 12), 1.32 (s, 3H, 11 or 12). 
3  (Alternative synthesis) 
To an anhydrous solution of adenosine 1 (2500 mg, 9.355 mmol) in acetone (60 mℓ) was 
added PTSA (19.33 g, 112.3 mmol), dimethoxypropane (3897 mg, 37.42 mmol) and 
molecular sieves. The reaction mixture was allowed to stir for 48 hours under an anhydrous 
nitrogen atmosphere. The solution was made basic by the addition of ice cold, saturated 
NaHCO3 solution. The product was extracted with DCM (5x 50 mℓ), washed with brine and 
dried with MgSO4. After removal of the solvent in vacuo, the solid was purified by 
chromatography (1:9 MeOH:DCM) to afford a white powder (2.386 g, 83%). Rf = 0.47 (1:9 
MeOH:DCM). 1H NMR (300 MHz, DMSO) δ 8.34 (s, 1H, 1 or 2), 8.15 (s, 1H, 1 or 2), 7.35 (s, 
2H, 14), 6.12 (d, J = 3.1 Hz, 1H, 6), 5.34 (dd, J = 6.2, 3.1 Hz, 1H, 8), 5.23 (t, J = 5.5 Hz, 1H, 
15), 4.96 (dd, J = 6.2, 2.5 Hz, 1H, 9), 4.21 (td, J = 4.8, 2.5 Hz, 1H, 7), 3.63 – 3.44 (m, 2H, 
13), 1.54 (s, 3H, 11 or 12), 1.32 (s, 3H, 11 or 12). 
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4 9-((3aR,4R,6S,6aS)-6-(Chloromethyl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine 
 
To an ice cold stirring solution of 3 (300 mg, 0.978 mmol) in MeCN (10 mℓ) was added SOCl2 
(232 mg, 1.95 mmol) and pyridine (255 mg, 3.2 mmol). The reaction mixture was allowed to 
stir for 16 hours under anhydrous nitrogen atmosphere. The volatiles were then removed in 
vacuo and the crude was dissolved in EtOAc (5 x 50 mℓ), washed with brine and dried with 
MgSO4. Purification with flash chromatography (97.5:2.5 EtOAc:MeOH) yielded a darkish 
yellow powder (200 mg, 60%). Rf = 0.10 (98:2 EtOAc : MeOH). 
1H NMR (400 MHz, D2O) δ 
8.33 (s, 1H, 1 or 2), 8.18 (s, 1H, 1 or 2), 7.37 (s, 2H, 14), 6.23 (d, J = 2.4 Hz, 1H, 6), 5.48 
(dd, J = 6.3, 2.4 Hz, 1H, 8), 5.07 (dd, J = 6.3, 2.9 Hz, 1H, 9), 4.34 (td, J = 6.6, 2.9 Hz, 1H, 7), 
3.86 (dd, J = 11.2, 7.0 Hz, 1H, 13a), 3.75 (dd, J = 11.2, 6.2 Hz, 1H, 13b), 1.54 (s, 3H, 11 or 
12), 1.34 (s, 3H, 11 or 12). 
6 (4-Chlorophenyl)methanol 
 
To an ice cold solution of 4-chlorobenzaldehyde 5 (300 mg, 2.13 mmol) in DCM (5 mℓ) was 
added NaBH4 (96 mg, 2.56 mmol) and EtOH (10 mℓ). After 15 minutes, the reaction was 
quenched with saturated aqueous NH4Cl. The DCM and EtOH were removed in vacuo 
whereafter the aqueous phase was extracted with EtOAc (3x 50 mℓ). The combined organic 
layers were washed with brine and dried with MgSO4. After filtration, the solvent was 
removed in vacuo and the crude purified using column chromatography (1:9 
EtOAc:Hexanes) to yield an off-white solid (298 mg, 98%). Rf = 0.25 (1:9 EtOAc:Hexanes). 
1H NMR (300 MHz, CDCl3) δ 7.28 – 7.17 (m, 4H, 1 - 4), 4.59 (s, 2H, 5), 1.76 (s, 1H, 6).   
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8 Tert-butyl (2-hydroxyethyl)carbamate 
 
To a stirred solution of ethanolamine 7 (500 mg, 8.19 mmol) in THF (10 mℓ) was added di-
tert-butyl dicarbonate (1956 mg, 9.00 mmol). After the addition of a catalytic amount of 
DMAP, the reaction was left to stir for 16 hours. Solvent was removed in vacuo and the 
remainder was partitioned against EtOAc (3 x 50 mℓ) and saturated NaHCO3. The 
recombined organic layers were then washed with brine and dried with MgSO4. After 
filtration, the solvent was removed in vacuo and flash chromatography (25:75 
EtOAc:Hexanes to 1:1 EtOAc:Hexanes) yielded a colourless oil (553 mg, 84%). Rf = 0.35 
(1:1 EtOAc:Hexanes). 1H NMR (300 MHz, CDCl3) δ 5.02 (s, 1H, 1 or 4), 3.74 – 3.62 (m, 2H, 
2 or 3), 3.33 – 3.20 (m, 2H, 2 or 3), 2.49 (s, 1H, 1 or 4), 1.43 (s, 9H, 5). 
9 2-((Tert-butyldimethylsilyl)oxy)ethanamine 
 
To a stirred solution of ethanolamine 7 (500 mg, 8.19 mmol) and imidazole (669 mg, 9.82 
mmol) in DCM (8 mℓ) was added TBDMSCl (1480 mg, 9.82 mmol). After 1 hour, the reaction 
was quenched by the addition of water. The solution was extracted with EtOAc (3 x 100 mℓ) 
and washed briskly with ice cold 0.1 M HCl. The aqueous phase was extracted with EtOAc 
(3 x 100 mℓ). The recombined organic layers were washed with saturated NaHCO3 and 
again the aqueous layer was extracted with EtOAc (3 x 100 mℓ). The recombined organic 
layers were washed with brine and dried with MgSO4. After removal of the solvent in vacuo, 
the crude was purified by flash chromatography (2:2:96 MeOH:TEA:EtOAc) to yield a 
colourless oil (452 mg, 31%). Rf = 0.32 (2:2:96 MeOH:TEA:EtOAc) which was visualised 
with ninhydrin and KMnO4. 
1H NMR (300 MHz, CDCl3) δ 3.60 (t, J = 5.3 Hz, 2H, 3 or 4), 2.75 
(t, J = 5.3 Hz, 2H, 3 or 4), 1.47 (s, 2H, 5), 0.88 (s, 9H, 1), 0.04 (s, 6H, 2).  
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11 4-((Tert-butyldimethylsilyl)oxy)benzaldehyde 
 
To a stirred solution of 4-hydroxybenzaldehyde 10 (200 mg, 1.64 mmol) in THF (5 mℓ) was 
added TBDMSCl (296 mg, 1.97 mmol) and imidazole (167 mg, 2.46 mmol). After 16 hours, 
the solvent was removed in vacuo and partitioned against water and EtOAc (3 x 50 mℓ). The 
recombined organic layers were washed with brine, dried with MgSO4 and filtered. The 
crude was purified by column chromatography (3:97 EtOAc:Hexanes) to yield a clear oil 
(304 mg, 80 %). Rf = 0.5 (1:9 EtOAc:Hexanes). 
1H NMR (400 MHz, D2O) δ 9.88 (s, 1H, 1), 
7.86 – 7.81 (m, 2H, 2 or 3), 7.06 – 7.02 (m, 2H, 3 or 2), 0.96 (s, 9H, 5), 0.24 (s, 6H, 4).  
12 (4-((Tert-butyldimethylsilyl)oxy)phenyl)methanol 
 
To an ice cold solution of 11 (294 mg, 1.24 mmol) in DCM (5 mℓ) was added NaBH4 (57 mg, 
1.51 mmol). After 4 hours, the reaction was quenched with a saturated solution of NH4Cl. 
The solution was extracted with DCM (3 x 50 mℓ). The recombined organic layers were 
washed with brine, dried with MgSO4, and filtered. Purification with column chromatography 
(13:87 EtOAc:Hexanes) yielded a clear oil (264 mg, 89%). Rf = 0.2 (1:9 EtOAc:Hexanes). 
1H 
NMR (400 MHz, DMSO) δ 7.21 – 7.16 (m, 2H, 3 or 4), 6.81 – 6.76 (m, 2H, 3 or 4), 5.04 (t, J 
= 5.7 Hz, 1H, 1), 4.41 (d, J = 5.7 Hz, 2H, 2), 0.94 (s, 9H, 6), 0.17 (s, 6H, 5). 
13 S-4-(Tert-butyldimethylsilyl)benzyl ethanethioate 
 
To an ice cold solution of PPh3 (265 mg, 1.01 mmol) in THF (5 mℓ) was added DtBAD (232 
mg, 1.01 mmol). After 30 minutes, 12 (150 mg, 0.674 mmol) and thioacetic acid (77.0 mg, 
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1.011 mmol), dissolved in THF (2 mℓ), were added dropwise to stir for 2 hours at 0 °C. After 
the solvent was removed in vacuo, the crude was purified by column chromatography (5:95 
EtOAc:Hexanes) to yield a colourless oil. 1H NMR (300 MHz, CDCl3) δ 7.17 – 7.10 (m, 2H, 3 
or 4), 6.78 – 6.72 (m, 2H, 3 or 4), 4.07 (s, 2H, 2), 2.34 (s, 3H, 1), 0.98 (s, 9H, 6), 0.19 (s, 6H, 
5). 
14 (4-((Tert-butyldimethylsilyl)oxy)phenyl)methanethiol 
 
To an ice cold solution of 13 (100 mg, 0.357 mmol) in THF (30 mℓ) was added LiAlH4 
(17.9 mg, 0.499 mmol). The reaction was closely monitored by TLC and quenched with 
water. Volatile solvent was removed in vacuo and the aqueous layer was extracted with 
EtOAc (50 mℓ). The organic layer was washed with brine and dried using MgSO4. After the 
solvent was removed in vacuo, the crude was purified by column chromatography (5:95 
EtOAc:Hexanes) to yield a colourless oil (57 mg, 20% over 2 steps). Rf = 0.8 (1:9 
EtOAc:Hexanes).1H NMR (300 MHz, CDCl3) δ 7.17 (d, J = 8.7 Hz, 2H, 3 or 4), 6.77 (d, J = 
8.7 Hz, 2H, 3 or 4), 3.70 (d, J = 7.3 Hz, 2H, 2), 1.73 (t, J = 7.3 Hz, 1H, 1), 1.01 – 0.95 (m, J = 
1.6 Hz, 9H, 6), 0.22 – 0.15 (s, 6H, 5). 
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Synthetic Procedures (Chapter 6) 
20 S-(((3aS,4S,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methyl) ethanethioate 
 
To an ice cold, stirred solution of PPh3 (950 mg, 5.00 mmol) in THF (5 mℓ) was added 
DtBAD (828.9 mg, 5.00 mmol). After the creamy white suspension was stirred for 30 
minutes, 3 (500 mg, 1.627 mmol) was added and allowed to stir for an additional 10 minutes 
at 0°C. Following this, thioacetic acid (266 µℓ, 3.6 mmol) was added dropwise to turn solution 
completely miscible and black. The reaction proceeded for 16 hours, after which the solvent 
was removed in vacuo. The precipitate was purified by flash chromatography (8:2 
CHCl3/THF to 9:10 CHCl3:MeOH) to yield a yellow foam (590 mg, 98%). Rf = 0.56 (1:9 
MeOH:DCM). MS Elemental: C15H20N5O4S. [H
+]: Calc 366.1231; Found 366.1236. 1H NMR 
(300 MHz, CDCl3) δ 8.34 (s, 1H, 1 or 2), 7.89 (s, 1H, 1 or 2), 6.12 (s, 2H, 14), 6.06 (d, J = 
2.1 Hz, 1H, 6), 5.50 (dd, J = 6.4, 2.1 Hz, 1H, 8), 4.96 (dd, J = 6.4, 3.1 Hz, 1H, 9), 4.33 (td, J 
= 6.9, 3.1 Hz, 1H, 7), 3.28 (dd, J = 13.8, 7.2 Hz, 1H, 13a), 3.17 (dd, J = 13.8, 6.7 Hz, 1H, 
13b), 2.33 (s, 3H, 16), 1.58 (s, 3H, 11 or 12), 1.37 (s, 3H, 11 or 12). 13C NMR (75 MHz, 
CDCl3) δ 194.5 (s, 15), 155.8 (s, 3, 4 or 5), 153.2 (s, 1 or 2), 149.2 (s, 3, 4 or 5), 139.9 (s, 1 
or 2), 120.3 (s, 3, 4 or 5), 114.5 (s, 10), 90.9 (s, 6), 86.1 (s, 7), 84.2 (s, 8), 83.7 (s, 9), 31.3 
(s, 13), 30.6 (s, 16), 27.1 (s, 11 or 12), 25.4 (s, 11 or 12). 
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21 9-((3aR,4R,6S,6aS)-2,2-Dimethyl-6-((octylthio)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine 
 
To a solution, cooled to -15 °C, of 20 (50 mg, 0.137 mmol) in freshly distilled MeOH (5 mℓ) 
was added NaOMe in MeOH 25% m/v (30 µℓ, 0.137 mmol). After 45 minutes, 
2-bromooctane (132 mg, 0.685 mmol) was added and allowed to stir for 24 hours. The 
reaction was quenched with water and the solvent removed. After the crude was lyophilised 
overnight, flash chromatography (1:99 MeOH:DCM to 4:96 MeOH:DCM) afforded an oil (18  
mg, 30.2%). Rf = 0.56 (1:9 MeOH:DCM). MS Elemental: C21H34N5O3S. [H
+]: Calc 436.2377; 
Found 436.2382. 1H NMR (300 MHz, CDCl3) δ 8.34 (s, 1H, 1 or 2), 7.92 (s, 1H, 1 or 2), 6.08 
(d, J = 2.2 Hz, 1H, 6), 5.91 (s, 2H, 14), 5.51 (dd, J = 6.4, 2.2 Hz, 1H, 8), 5.05 (dd, J = 6.4, 3.1 
Hz, 1H, 9), 4.39 (ddd, J = 7.5, 6.3, 3.1 Hz, 1H, 7), 2.83 (dd, J = 13.6, 7.5 Hz, 1H, 13a), 2.75 
(dd, J = 13.6, 6.3 Hz, 1H, 13b), 2.52 – 2.45 (m, 2H, 15), 1.64 – 1.13 (m, 18H, 11, 12 and 
16), 0.89 – 0.81 (m, 3H, 17). 13C NMR (101 MHz, CDCl3) δ 155.6 (s), 153.1 (s, 1 or 2), 149.3 
(s), 140.0 (s), 120.3 (s), 114.4 (s), 90.9 (s, 6), 86.8 (s, 7), 84.1 (s, 8), 83.8 (s, 9), 34.4 (s, 13), 
32.7 (s, 15), 31.8 (s, 16), 29.6 (s, 16), 29.2 (s, 16), 29.1 (s, 16), 28.8 (s, 16), 27.1 (s, 11 or 
12), 25.4 (s, 11 or 12), 22.6 (s, 16), 14.1 (s, 17). 
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22 (2R,3R,4S,5S)-2-(6-Amino-9H-purin-9-yl)-5-((octylthio)methyl)tetrahydrofuran-3,4-
diol 
 
To a solution of 21 (12.94 mg, 0.0297 mmol) in water (7 mℓ) was added formic acid (2 mℓ). 
The reaction was left to stir for 4 days. Volatiles were removed in vacuo to yield pure white 
powder (11.75 mg 100%). Rf = 0.63 (1:9 MeOH:DCM). MS [H
+]: Calc 396.2064; Found 
396.2065. 1H NMR (300 MHz, CD3OD) δ 8.32 (s, 1H, 1 or 2), 8.21 (s, 1H, 1 or 2), 6.00 (d, J 
= 4.8 Hz, 1H, 6), 4.81 – 4.75 (m, 1H, 8), 4.37 – 4.30 (m, 1H, 9), 4.23 – 4.16 (m, 1H, 7), 2.96 
– 2.89 (m, 1H, 13a), 2.60 – 2.48 (m, 1H, 13b), 1.63 – 1.15 (m, 14H, 10), 0.88 (t, J = 6.1 Hz, 
3H, 15). 13C NMR (75 MHz, CD3OD) δ 155.9 (s), 152.5 (s), 149.3 (s), 140.0 (s), 119.1 (s), 
88.7 (s), 84.5 (s), 73.5 (s), 72.6 (s), 33.8 (s), 32.5 (s), 31.6 (s), 29.6 (s), 28.9 (s), 28.8 (s), 
28.5 (s), 22.3 (s), 13.0 (s). 
23 9-((3aR,4R,6S,6aS)-6-((Hexylthio)methyl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine 
 
To a solution, cooled to -15 °C, of 20 (100 mg, 0.274 mmol) in freshly distilled MeOH was 
added a solution of NaOMe in MeOH 25% m/v (64 µℓ, 0.301 mmol). The reaction was 
allowed to proceed for 45 minutes, after which 1-bromohexane (90.3 mg, 0.547 mmol) was 
added. The reaction was allowed to proceed for 24 hours, after it was quenched by the 
addition of water (5 mℓ). The MeOH was removed in vacuo and the remainder was extracted 
with DCM (3 x 150 mℓ). The recombined organic layers were washed with brine and dried 
with MgSO4. The solvent was removed in vacuo and the crude was lyophilised overnight. 
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Flash chromatography (DCM to 4:96 MeOH:DCM) afforded the pure oil (55 mg, 63%).  Rf = 
0.56 (1:9 MeOH:DCM). MS Elemental: C19H30N5O3S [H
+]: Calc 408.2064; Found 408.2069. 
1H NMR (300 MHz, CDCl3) δ 8.34 (s, 1H, 1 or 2), 7.92 (s, 1H, 1 or 2), 6.08 (d, J = 2.2 Hz, 
1H, 6), 5.84 (s, 2H, 14), 5.51 (dd, J = 6.4, 2.2 Hz, 1H, 8), 5.05 (dd, J = 6.4, 3.1 Hz, 1H, 9), 
4.39 (ddd, J = 7.5, 6.3, 3.1 Hz, 1H, 7), 2.83 (dd, J = 13.6, 7.5 Hz, 1H, 13a), 2.75 (dd, J = 
13.6, 6.3 Hz, 1H, 13b), 2.52 – 2.45 (m, 2H, 15), 1.61 (s, 3H, 11 or 12), 1.56 – 1.43 (m, 2H, 
16), 1.39 (s, 3H, 11 or 12), 1.38 – 1.13 (m, 6H, 16), 0.92 – 0.80 (m, 3H, 17). 13C NMR (75 
MHz, CDCl3) δ 155.7 (s), 153.3 (s), 149.4 (s), 140.1 (s), 120.4 (s), 114.57 (s), 91.1 (s), 87.0 
(s), 84.2 (s), 84.0 (s), 34.5 (s), 32.8 (s), 31.5 (s), 29.7 (s), 28.6 (s), 27.2 (s), 25.5 (s), 22.7 (s), 
14.2 (s). 
24 (2R,3R,4S,5S)-2-(6-Amino-9H-purin-9-yl)-5-((hexylthio)methyl)tetrahydrofuran-
3,4-diol 
 
To a solution of 23 (55 mg, 0.136 mmol) in water (7 mℓ) was added formic acid (2 mℓ). The 
reaction was left to stir for 4 days. Volatiles were removed in vacuo to yield pure white 
powder (50.02 mg, 100%). Rf = 0.63 (1:9 MeOH:DCM). MS Elemental: C16H26N5O3S [H
+]: 
Calc 368.1751; Found 368.1756. 1H NMR (300 MHz, CD3OD) δ 8.33 (s, 1H, 1 or 2), 8.22 (s, 
1H, 1 or 2), 6.02 (d, J = 4.9 Hz, 1H, 6), 4.82 – 4.77 (m, 1H, 8), 4.39 – 4.33 (m, 1H, 9), 4.26 – 
4.18 (m, 1H, 7), 2.98 (dd, J = 14.2, 5.4 Hz, 1H, 13a), 2.90 (dd, J = 14.2, 6.0 Hz, 1H, 13b), 
2.58 – 2.49 (m, 2H, 10), 1.60 – 1.46 (m, 2H, 16), 1.40 – 1.13 (m, 6H, 16), 0.91 – 0.83 (m, 
3H, 15). 13C NMR (75 MHz, CD3OD) δ 157.3 (s), 153.8 (s), 150.7 (s), 141.4 (s), 120.5 (s), 
90.1 (s), 85.9 (s), 74.9 (s), 74.0 (s), 35.2 (s), 33.9 (s), 32.5 (s), 30.7 (s), 29.5 (s), 23.6 (s), 
14.4 (s). 
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25 9-((3aR,4R,6S,6aS)-2,2-Dimethyl-6-((octan-2-ylthio)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine 
 
To a solution, cooled to -15 °C, of 20 (50 mg, 0.137 mmol) in freshly distilled MeOH (5 mℓ) 
was added NaOMe in MeOH 25% m/v (30 µℓ, 0.137 mmol). After 45 minutes, 2-
bromooctane (47.7 mg, 0.247 mmol) was added and allowed to stir for 24 hours. The 
reaction was quenched with water and the solvent removed. After the crude was lyophilised 
overnight, flash chromatography (1:99 MeOH:DCM to 4:96 MeOH:DCM) afforded an oil (25 
mg, 41%). Rf = 0.56 (1:9 MeOH:DCM). MS Elemental: C21H34N5O3S [H
+]: Calc 436.2377; 
Found 436.2382. 1H NMR (300 MHz, CDCl3) δ 8.35 (s, 1H, 1 or 2), 7.93 (s, 1H, 1 or 2), 6.07 
(d, J = 2.1 Hz, 1H, 6), 5.86 – 5.72 (m, 2H, 14), 5.53 – 5.48 (m, 1H, 8), 5.09 – 5.03 (m, 1H, 9), 
4.42 – 4.34 (m, 1H, 7), 2.91 – 2.81 (m, 1H, 13a), 2.81 – 2.67 (m, 1H, 13b), 1.66 – 1.14 (m, 
20H, 11, 12, 15, 16 and 17), 0.89 – 0.81 (m, 3H, 18).  
26 (2R,3R,4S,5S)-2-(6-Amino-9H-purin-9-yl)-5-((octan-2-ylthio)methyl) 
tetrahydrofuran-3,4-diol 
 
To a solution of 25 (25 mg, 0.057 mmol) in water (7 mℓ) was added formic acid (2 mℓ). The 
reaction was left to stir for 4 days. Volatiles were removed in vacuo to yield pure white 
powder (23.43 mg, 100%). Rf = 0.63 (1:9 MeOH:DCM). MS [H
+]: Calc 396.2064; Found 
396.2067. 1H NMR (300 MHz, CD3OD) δ 8.34 – 8.30 (m, 1H, 1 or 2), 8.21 (s, 1H, 1 or 2), 
6.00 (d, J = 4.9 Hz, 1H, 6), 4.83 – 4.76 (m, 1H, 8), 4.38 – 4.30 (m, 1H, 9), 4.24 – 4.16 (m, 
1H, 7), 3.04 – 2.95 (m, 1H, 13a), 2.95 – 2.85 (m, 1H, 13b), 2.85 – 2.75 (m, 1H, 15), 1.61 – 
1.12 (m, 13H, 16 and 17), 0.87 (t, J = 6.8 Hz, 3H, 10).  
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27 9-((3aR,4R,6S,6aS)-6-((Heptan-2-ylthio)methyl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine 
 
To a -15°C solution of 20 (40 mg, 0.109 mmol) in freshly distilled MeOH, was added 
dropwise NaOMe in MeOH 25% m/v (23.6 µℓ, 0.109 mmol) and allowed to stir. After 45 
minutes, 2-bromoheptane (98.0 mg, 0.547 mmol) was added and allowed to stir for 24 
hours. The reaction was quenched with water and the solvent was removed in vacuo. After 
the crude was lyophilised overnight, flash chromatography (DCM to 4:96 MeOH:DCM) 
yielded the product as a pale yellow oil (38 mg, 82%). Rf = 0.56 (1:9 MeOH:DCM). MS 
Elemental: C20H32N5O3S [H
+]: Calc 422.2220; Found 422.2226. 1H NMR (300 MHz, CDCl3) δ 
8.34 (s, 1H, 1 or 2), 7.93 (s, 1H, 1 or 2), 6.07 (d, J = 2.2 Hz, 1H, 6), 5.93 (s, 2H, 14), 5.54 – 
5.46 (m, 1H, 8), 5.10 – 5.02 (m, 1H, 9), 4.43 – 4.33 (m, 1H, 7), 2.90 – 2.66 (m, 3H, 13a, 13b 
and 15), 1.64 – 1.17 (m, 17H, 11, 12, 16 and 10 or 17), 0.90 – 0.82 (m, 3H, 10 or 17).  
28 (2R,3R,4S,5S)-2-(6-Amino-9H-purin-9-yl)-5-((heptan-2-ylthio)methyl) 
tetrahydrofuran-3,4-diol 
 
To a solution of 27 (25.9 mg, 0.061) in water (7 mℓ) was added formic acid (2 mℓ). The 
reaction was left to stir for 4 days. Volatiles were removed in vacuo to yield pure white 
powder (23.43 mg, 99%). Rf = 0.63 (1:9 MeOH:DCM). MS Elemental: C17H28N5O3S [H
+]: 
Calc 382.1907; Found 382.1913. 1H NMR (300 MHz, CD3OD) δ 8.33 – 8.28 (m, 1H, 1 or 2), 
8.20 (s, 1H, 1 or 2), 6.00 (d, J = 4.8 Hz, 1H, 6), 4.82 – 4.76 (m, 1H, 8), 4.39 – 4.30 (m, 1H, 
9), 4.24 – 4.14 (m, 1H, 7), 3.03 – 2.94 (m, 1H, 13a), 2.94 – 2.84 (m, 1H, 13b), 2.84 – 2.72 
(m, 1H, 15), 1.60 – 1.11 (m, 11H, 16 and 10 or 17), 0.89 – 0.81 (m, 3H, 10 or 17).  
Stellenbosch University  http://scholar.sun.ac.za
Chapter 8 – Experimental 
 
123 
33 4-(4-Nitrophenyl)butyl methanesulfonate 
 
To an ice cold solution of 4-(4-nitrophenyl)butan-1-ol 34 (500 mg, 2.56 mmol) and TEA 
(499 µℓ, 3.59 mmol) in DCM (15 mℓ) was added dropwise mesylchloride (237 µℓ, 3.07 mmol). 
This was allowed to stir for 3 hours. The suspension was filtered and the filtrate 
concentrated. The concentrate was purified by flash chromatography to yield the pure oil 
(635 mg, 90%). 1H NMR (300 MHz, CDCl3) δ 8.19 – 8.12 (m, 2H, 1 or 2), 7.38 – 7.30 (m, 
2H, 1 or 2), 4.29 – 4.22 (m, 2H, 3 or 6), 3.01 (s, 3H, 7), 2.82 – 2.73 (m, 2H, 3 or 6), 1.88 – 
1.71 (m, 4H, 4 and 5).  
32 9-((3aR,4R,6S,6aS)-2,2-Dimethyl-6-(((4-(4-nitrophenyl)butyl)thio)methyl) 
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-amine 
 
To a solution, cooled to -15 °C, of 20 (300 mg, 0.821 mmol) in freshly distilled MeOH (15 mℓ) 
was added dropwise addition of a solution of NaOMe in MeOH 25% m/v (203 µℓ, 0.944 
mmol) and allowed to stir for 45 minutes. This was followed by the addition of 33 (258 mg, 
0.944 mmol). The reaction was then allowed to stir for 24 hours, after which the reaction was 
quenched by the addition of water. The MeOH was removed in vacuo and the water layer 
was then extracted with DCM (4x 100 mℓ). The recombined organic layers were washed with 
brine, dried with MgSO4 and filtered. The crude was purified by flash chromatography (DCM 
to 2:98 MeOH:DCM to 4:94 MeOH:DCM) to yield product (65 mg, 15.8%). MS Elemental: 
C23H29N6O5S [H
+]: Calc 501.1914; Found 501.1920. 1H NMR (300 MHz, CDCl3) δ 8.31 (s, 
1H, 1 or 2), 8.13 – 8.06 (m, 2H, 18 or 19), 7.91 (s, 1H, 1 or 2), 7.30 – 7.24 (m, 2H, 18 or 
19), 6.10 (s, 2H, 14), 6.07 (d, J = 2.2 Hz, 1H, 6), 5.51 (dd, J = 6.4, 2.2 Hz, 1H, 8), 5.05 (dd, J 
= 6.4, 3.2 Hz, 1H, 9), 4.36 (td, J = 6.9, 3.2 Hz, 1H, 7), 2.82 (dd, J = 13.7, 7.2 Hz, 1H, 13a), 
2.74 (dd, J = 13.7, 6.6 Hz, 1H, 13b), 2.64 (m, 2H, 14, 15 or 16), 2.50 (t, J = 7.1 Hz, 2H, 17), 
1.72 – 1.44 (m, 7H, 14, 15 or 16 and 11 or 12), 1.38 (s, 3H, 11 or 12). 13C NMR (75 MHz, 
CDCl3) δ 155.8 (s), 153.2 (s), 150.0 (s), 149.3 (s), 146.4 (s), 140.2 (s), 129.2 (s), 123.7 (s), 
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120.4 (s), 114.6 (s), 91.0 (s), 87.1 (s), 84.1 (s), 84.0 (s), 35.4 (s), 34.5 (s), 32.4 (s), 29.9 (s), 
29.0 (s), 27.2 (s), 25.4 (s). 
39 (S)-Methyl 2-amino-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propanoate 
 
To a stirred solution of L-tyrosine methyl ester 37 (500 mg, 2.56 mmol) in THF (50 mℓ) was 
added imidazole (261 mg, 3.84 mmol) and (463 mg, 3.07 mmol) TBDMSCl. After 16 hours, 
the solvent was removed in vacuo and was partitioned between saturated NaHCO3 and 
DCM (3 x 100 mℓ). After washing with brine, drying with MgSO4 and filtration, the crude was 
purified by flash chromatography (1:1 EtOAc:Hexanes) to yield a colourless oil (502 mg, 
63%). Rf = 0.35 (1:1 EtOAc:Hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.09 – 6.96 (m, 2H, 2 or 
3), 6.81 – 6.71 (m, 2H, 2 or 3), 3.70 (s, 3H, 7), 3.69 – 3.66 (m, 1H, 5), 3.07 – 2.73 (m, 2H, 4), 
1.49 (s, 2H, 6), 0.97 (s, 9H, 1), 0.18 (s, 6H, 2). 
40 (S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((tert-
butyldimethylsilyl)oxy)phenyl)propanoate 
 
To a solution of 39 (145 mg, 0.469 mmol) in MeCN (40 mℓ), was added Boc2O (102 mg, 
0.469 mmol) and a catalytic amount of DMAP. The reaction was then left to proceed for 16 
hours, after which the solvent was removed in vacuo. Purification by column 
chromatography (1:9 EtOAc:Hexanes) afforded an oil (15 mg, 7%). Rf = 0.61 (2:8 
EtOAc:Hexanes). 1H NMR (300 MHz, CDCl3) δ 7.01 – 6.93 (m, 2H, 3 or 4), 6.81 – 6.71 (m, 
2H, 3 or 4), 5.00 – 4.88 (m, 1H, 6 or 7), 4.59 – 4.46 (m, 1H, 6 or 7), 3.69 (s, 3H, 9), 3.05 – 
2.93 (m, 2H, 5), 1.42 (s, 9H, 1 or 8), 0.97 (s, 9H, 1 or 8), 0.18 (s, 6H, 2).  
44 Propane-1,3-diyl dimethanesulfonate 
 
To an ice cold solution of propane-1,3-diol 43 (500 mg, 6.57 mmol) in THF (20 mℓ) was 
added (2289 µℓ TEA, 16.43 mmol). This was followed by the dropwise addition of MsCl 
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(1220 µℓ, 15.77 mmol) and was allowed to stir for 4 hours. The white precipitate was 
removed by filtration and the yellow filtrate was concentrated in vacuo. The crude was used 
without further purification.   
45 3-Azidopropyl methanesulfonate 
 
To a stirred solution of 44 (1429 mg, 6.152 mmol) in MeCN was added NaN3 (400 mg, 6.152 
mmol) and set to reflux for 16 hours.  The solvent was removed in vacuo and the crude was 
partitioned against water and EtOAc (3x 100 mℓ). Afterwards, the recombined organic layers 
were washed with brine, dried with MgSO4 and filtered. The crude was purified by flash 
chromatography (1:4 EtOAc:Hexanes) to yield a colourless oil over two steps (494 mg, 
42%). Rf = 0.42 (1:4 EtOAc:Hexanes). 
1H NMR (300 MHz, CDCl3) δ 4.38 – 4.27 (t, 2H, 2 or 
4), 3.53 – 3.41 (m, 2H, 2 or 4), 3.04 (s, 3H, 1), 2.07 – 1.94 (m, 2H, 3). 
46 9-((3aR,4R,6S,6aS)-6-(((3-Azidopropyl)thio)methyl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-amine 
 
To a solution, cooled to -15 °C, of 20 (300 mg, 0.821 mmol) in freshly distilled MeOH (10 mℓ) 
was added NaOMe in MeOH 25% m/v (185 µℓ, 0.858 mmol) and allowed to proceed for 1 
hour. This was followed by the addition of 45 (294 mg, 1.642 mmol) and allowed to stir for a 
24 hours. The reaction was quenched with water. After the MeOH was removed in vacuo, 
the solution was extracted with chloroform (5 x 100 mℓ), washed with brine and dried with 
MgSO4. The solution was concentrated in vacuo and purified by flash chromatography (DCM 
to 4:96 MeOH:DCM) to yield pure product (145 mg, 65%). Rf = 0.63 (1:9 MeOH:DCM). MS 
Elemental: C16H21N8O3S [H
+]: Calc 407.1608; Found 407.1614. 1H NMR (400 MHz, CDCl3) δ 
8.33 (s, 1H, 1 or 2), 7.91 (s, 1H, 1 or 2), 6.07 (d, J = 2.1 Hz, 1H, 6), 6.03 (s, 2H, 14), 5.51 
(dd, J = 6.4, 2.1 Hz, 1H, 8), 5.06 (dd, J = 6.4, 3.2 Hz, 1H, 9), 4.37 (td, J = 6.9, 3.2 Hz, 1H, 7), 
3.33 (t, J = 6.6 Hz, 2H, 17), 2.85 (dd, J = 13.7, 7.3 Hz, 1H, 13a), 2.78 (dd, J = 13.7, 6.5 Hz, 
1H, 13b), 2.59 – 2.53 (m, J = 7.1 Hz, 2H, 15), 1.75 (m, 2H, 16), 1.60 (s, 3H, 11 or 12), 1.39 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 8 – Experimental 
 
126 
(s, 3H, 11 or 12). 13C NMR (101 MHz, CDCl3) δ 155.8 (s), 153.4 (s), 149.4 (s), 140.3 (s), 
120.6 (s), 114.7 (s), 91.1 (s), 87.1 (s), 84.2 (s), 84.0 (s), 50.1 (s), 34.6 (s), 29.8 (s), 28.9 (s), 
27.3 (s), 25.6 (s). 
47 9-((3aR,4R,6S,6aS)-6-(((3-(4-(Aminomethyl)-1H-1,2,3-triazol-1-
yl)propyl)thio)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-
purin-6-amine 
 
To a solution of 46 (148 mg, 0.364 mmol) in MeCN (5 mℓ) was added TEA (110 µℓ, 1.09 
mmol) and propargylamine 42 (22.2 mg, 0.437 mmol). Finally, CuI (6.4 mg, 0.034 mmol) was 
added and the reaction proceeded for 1 hour. An additional portion of propargyl amine 
(9 mg, 0.161 mmol) was added and the reaction proceeded for an additional hour. Saturated 
ammonium chloride was added and the organics were extracted with chloroform (6 x 50 mℓ). 
The solvent was removed in vacuo and the distillate was purified using column 
chromatography (10:2:88 MeOH:TEA:DCM) to yield pure product (140 mg, 83%). Rf = 0.71 
(4:96 MeOH:DCM). MS Elemental: C19H28N9O3S. [H
+]: calc: 462.2030; found: 462.2044. 1H 
NMR (400 MHz, CDCl3) δ 8.27 (s, 1H, 1 or 2), 7.90 (s, 1H, 1 or 2), 7.41 (s, 1H, 18), 6.38 (s, 
2H, 14), 6.05 (d, J = 2.0 Hz, 1H, 6), 5.50 (dd, J = 6.4, 2.0 Hz, 1H, 8), 5.04 (dd, J = 6.4, 3.1 
Hz, 1H, 9), 4.36 – 4.29 (m, 3H, 7 and 17), 3.95 (s, 2H, 19), 3.05 (s, 3H, 20), 2.81 (dd, J = 
13.7, 6.9 Hz, 1H, 13a), 2.75 (dd, J = 13.7, 6.8 Hz, 1H, 13b), 2.43 (t, J = 7.0 Hz, 2H, 15), 2.06 
– 1.97 (m, 2H, 16), 1.57 (s, 3H, 11 or 12), 1.36 (s, 3H, 11 or 12). 13C NMR (101 MHz, 
CDCl3) δ 155.9 (s), 153.2 (s), 149.1 (s), 140.1 (s), 121.2 (s), 114.5 (s), 90.9 (s), 87.2 (s), 
84.0 (s), 83.9 (s), 48.5 (s), 46.0 (s), 37.5 (s), 34.4 (s), 29.7 (s), 29.3 (s), 27.1 (s), 25.4 (s), 
10.7 (s). 
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48 (2R,3R,4S,5S)-2-(6-Amino-9H-purin-9-yl)-5-(((3-(4-(aminomethyl)-1H-1,2,3-triazol-
1-yl)propyl)thio)methyl)tetrahydrofuran-3,4-diol 
 
To a solution of formic acid and water was added 47 (16 mg, 0.035 mmol) and was allowed 
to stir for 3 days. The volatiles were then removed in vacuo and the remaining solvent was 
removed by lyophilisation to yield a white powder (14 mg, 99%). Rf = 0.13 (1:4 MeOH:DCM). 
MS Elemental: C16H24N9O3 [H
+]: Calc 422.1717; Found 422.1723. 1H NMR (300 MHz, 
CD3OD) δ 8.15 (s, 1H, 1, 2 or 18), 8.05 (s, 1H, 1, 2 or 18), 7.87 (s, 1H, 1, 2 or 18), 5.85 (d, J 
= 4.8 Hz, 1H, 6), 4.70 – 4.64 (m, 1H, 8), 4.32 (t, J = 6.8 Hz, 2H, 17), 4.23 – 4.16 (m, 1H, 9), 
4.11 (s, 2H, 19), 4.06 – 3.99 (m, 1H, 7), 3.20 – 3.14 (m, 1H, 13a), 2.85 – 2.78 (m, 1H, 13b), 
2.40 (t, J = 6.9 Hz, 2H, 15), 2.05 – 1.91 (m, 2H, 16). 13C NMR (75 MHz, CD3OD) δ 165.6 (s), 
157.1 (s), 153.5 (s), 150.6 (s), 141.6 (s), 141.2 (s), 125.5 (s), 120.5 (s), 90.2 (s), 85.7 (s), 
74.8 (s), 74.1 (s), 35.4 (s), 35.1 (s), 30.9 (s), 30.2 (s). 
50 Ethane-1,2-diyl dimethanesulfonate 
 
To an ice cold solution of ethane-1,2-diol 49 (500 mg, 8.06 mmol) in THF (15 mℓ) was added 
(1933 µℓ TEA, 20.14 mmol). This was followed by the dropwise addition of MsCl (1030 µℓ, 
19.33 mmol) and was allowed to stir for 16 hours. The white precipitate was removed by 
filtration and the yellow filtrate was concentrated in vacuo. The crude was used without 
further purification.   
51 2-Azidoethyl methanesulfonate 
 
To a stirred solution of 50 (1129 mg, 8.06 mmol) in MeCN was added NaN3 (524 mg, 8.06 
mmol) and set to reflux for 16 hours.  The solvent was removed in vacuo and the crude was 
partitioned against water and EtOAc (3x 100 mℓ). Afterwards, the recombined organic layers 
were washed with brine, dried with MgSO4 and filtered. The crude was purified by flash 
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chromatography (2:8 EtOAc:Hexanes) to yield a colourless oil over two steps (628 mg, 
47%). Rf = 0.42 (2:8 EtOAc:Hexanes). 
1H NMR (300 MHz, CDCl3) δ 4.39 – 4.30 (m, 2H, 2 or 
3), 3.63 – 3.55 (m, 2H, 2 or 3), 3.11 – 3.05 (m, 3H, 1).  
52 9-((3aR,4R,6S,6aS)-6-(((2-Azidoethyl)thio)methyl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine 
 
To a solution, cooled to -15 °C, of 20 (300 mg, 0.821 mmol) in freshly distilled MeOH (10 mℓ) 
was added NaOMe in MeOH 25% m/v (185 µℓ, 0.858 mmol) and allowed to proceed for 1 
hour. This was followed by the addition of 51 (271 mg, 1.641 mmol) and allowed to stir for a 
24 hours. The reaction was quenched with water. After the MeOH was removed in vacuo, 
the solution was extracted with CHCl3 (5x 100 mℓ), washed with brine, dried with MgSO4 and 
filtered. The solution was concentrated in vacuo and purified by flash chromatography (DCM 
to 1:24  MeOH/DCM) to yield pure product (110 mg, 34%). Rf = 0.63 (1:9 MeOH:DCM). MS 
Elemental: C15H21N8O3S [H
+]: Calc 393.1451; Found 393.1457. 1H NMR (300 MHz, CDCl3) δ 
8.32 (s, 1H, 1 or 2), 7.90 (s, 1H, 1 or 2), 6.32 (s, 2H, 14), 6.07 (d, J = 2.2 Hz, 1H, 6), 5.50 
(dd, J = 6.4, 2.2 Hz, 1H, 8), 5.07 (dd, J = 6.4, 3.3 Hz, 1H, 9), 4.41 – 4.33 (m, 1H, 7), 3.35 (t, J 
= 6.8 Hz, 2H, 15 or 16), 2.95 – 2.79 (m, 2H, 13), 2.66 (t, J = 6.8 Hz, 2H, 15 or 16), 1.59 (s, 
3H, 11 or 12), 1.38 (s, 3H, 11 or 12). 13C NMR (75 MHz, CDCl3) δ 156.0 (s), 153.2 (s), 149.2 
(s), 140.1 (s), 120.4 (s), 114.7 (s), 90.9 (s), 87.2 (s), 84.1 (s), 83.8 (s), 51.1 (s), 34.6 (s), 31.8 
(s), 27.2 (s), 25.4 (s).  
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53 (1-(2-((((3aS,4S,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro 
[3,4-d][1,3]dioxol-4-yl)methyl)thio)ethyl)-1H-1,2,3-triazol-4-yl)methanaminium 
 
To a solution of 52 (110 mg, 0.280 mmol) in MeCN (5 mℓ) was added TEA (119 µℓ, 0.841 
mmol) and propargylamine 42 (18.5 mg, 0.336 mmol). Finally, CuI (5.3 mg, 0.028 mmol) was 
added and the reaction stirred for 1 hour. An additional portion of propargyl amine (9mg, 
0.161 mmol) was added and the reaction proceeded for an additional hour. Saturated 
ammonium chloride was added and the organics were extracted with chloroform (6x 50 mℓ). 
The solvent was removed in vacuo and the distillate was purified using column 
chromatography (10:2:88 MeOH:TEA:DCM), a white product was obtained (43 mg, 34%). Rf 
= 0.23 (10:1:89 MeOH:TEA:DCM). MS [H+]: calc: 434.1717; found: 434.1723. 1H NMR (300 
MHz, CDCl3) δ 8.31 (s, 1H, 1 or 2), 7.91 (s, 1H, 1 or 2), 7.35 (s, J = 7.5 Hz, 1H, 1 or 17), 
6.16 (s, 2H, 14), 6.05 (d, J = 2.1 Hz, 1H, 6), 5.49 (dd, J = 6.4, 2.1 Hz, 1H, 8), 5.04 (dd, J = 
6.4, 3.4 Hz, 1H, 9), 4.48 – 4.25 (m, 3H, 7 and -CH2-), 3.95 (s, 2H, 19), 3.17 – 3.00 (m, 3H, 
20), 2.96 – 2.86 (m, 2H, 13), 2.83 – 2.77 (m, 2H, -CH2-), 1.59 (s, 3H, 11 or 12), 1.37 (s, 3H, 
11 or 12). 13C NMR (75 MHz, CD3OD) δ 155.9 (s), 153.3 (s), 149.2 (s), 140.2 (s), 121.3 (s), 
120.4 (s), 114.7 (s), 90.9 (s), 87.4 (s), 84.0 (s), 83.8 (s), 53.2 (s), 50.6 (s), 49.9 (s), 34.6 (s), 
32.7 (s), 27.2 (s), 25.4 (s). 
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54 (2R,3R,4S,5S)-2-(6-Amino-9H-purin-9-yl)-5-(((2-(4-(aminomethyl)-1H-1,2,3-triazol-
1-yl)ethyl)thio)methyl)tetrahydrofuran-3,4-diol 
 
To a solution of formic acid and water was added 53 (10.6 mg, 0.024 mmol) to stir for 
3 days. The volatiles were removed in vacuo and the remaining solvent was removed by 
lyophilisation to yield a white powder (9.6 mg, 99%). Rf = 0.11 (1:4 MeOH:DCM). MS 
Elemental: C15H22N9O3S. [H
+]: Calc 408.1561; Found 408.1566. 1H NMR (400 MHz, CD3OD) 
δ 8.24 – 8.21 (m, 1H, 1, 2 or 16), 8.15 (d, J = 2.0 Hz, 1H, 1, 2 or 16), 7.95 (s, 1H, 1, 2 or 
16), 5.95 (d, J = 4.7 Hz, 1H, 6), 4.75 (t, J = 5.1 Hz, 1H, 8), 4.55 – 4.50 (m, 2H, -CH2-), 4.28 
(t, J = 5.2 Hz, 1H, 9), 4.19 (s, 2H, 17), 4.15 – 4.09 (m, 1H, 7), 3.09 – 3.02 (m, 1H, 13a), 3.02 
– 2.95 (m, 1H, 13b), 2.94 – 2.90 (m, 2H, -CH2-). 
13C NMR (75 MHz, CD3OD) δ 165.6 (s), 
153.8 (s), 141.6 (s), 125.7 (s), 90.3 (s), 86.0 (s), 74.7 (s), 74.0 (s), 51.0 (s), 47.8 (s), 35.4 (s), 
35.2 (s), 33.7 (s), 9.2 (s), 7.6 (s). 
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Synthetic Procedures (Chapter 7) 
58 Tert-butyl 4-(hydroxymethyl)-1H-imidazole-1-carboxylate 
 
To a solution of (1H-imidazol-4-yl)methanol 59 (500 mg, 5.10 mmol) in DMF (20 mℓ) was 
added di-tert-butyl dicarbonate (1334 mg, 6.11 mmol). To this was added a single crystal of 
DMAP and left to stir for 1 hour at RT. The solvent removed in vacuo by toluene azeotrope. 
The remainder was partitioned against brine and EtOAc (3 x 50 mℓ). After removal of the 
solvent in vacuo, the crude was purified by column chromatography (35:65 EtOAc:Hexanes 
to 70:30 EtOAc:Hexanes to EtOAc). Rf =0.35 (35:65 EtOAc:Hexanes). 
1H NMR (300 MHz, 
CDCl3) δ 8.06 – 7.98 (m, 1H, 1 or 2), 7.26 (s, 1H, 2 or 1), 4.55 (s, 2H, 3), 2.37 (s, 1H, 4), 
1.65 – 1.57 (m, 9H, 5). 
57 Tert-butyl 4-(chloromethyl)-1H-imidazole-1-carboxylate 
 
To an ice cold solution of 58 (300 mg, 1.51 mmol) in DCM (7 mℓ) and 1 drop DMF, was 
added dropwise a solution of SOCl2 (0.200 mℓ, 2.72 mmol) in DCM (0.35 mℓ) over 3 minutes. 
The reaction was left to stir for 20 minutes after which the solvent was removed in vacuo. 
The crude was dissolved in EtOAc, and rinsed with ice cold saturated NaHCO3. The 
aqueous phase was extracted with (2x 50ml) EtOAc. The recombined organic layers were 
washed with brine and dried using NaSO4. Flash chromatography (2:8 EtOAc:Hexanes) 
afforded a colourless oil (270 mg, 83%). Rf = 0.32 (2:8 EtOAc:Hexanes). 
1H NMR (400 MHz, 
CDCl3) δ 8.05 – 8.02 (m, 1H, 1 or 2), 7.37 (s, 1H, 2 or 1), 4.56 – 4.49 (m, 2H, 3), 1.61 – 1.59 
(m, 9H, 4). 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 8 – Experimental 
 
132 
61 Tert-butyl 5-cyano-1H-indene-1-carboxylate 
 
To an ice cold solution of 1H-indole-5-carbonitrile 56 (63.0 mg, 0.443 mmol) in DMF (2 mℓ) 
was added NaH in oil dispersion (15.6 mg, 0.650 mmol). After evolution of hydrogen ceased 
(5 minutes), 57 (120 mg, 0.553 mmol) dissolved in DMF (3 mℓ) was added. The reaction was 
allowed to proceed for 10 minutes. The reaction was quenched with the addition of water 
and extracted with EtOAc (3 x 50 mℓ). Afterwards the recombined organic layers were 
washed with brine, dried with MgSO4 and filtered. Flash chromatography (1:9 
EtOAc:Hexanes) afforded the pure product (52.9 mg, 49.2%). Rf = 0.28 (1:9 
EtOAc:Hexanes). 1H NMR (300 MHz, CDCl3) δ 8.25 (d, J = 8.6 Hz, 1H, 1), 7.89 (d, J = 1.6 
Hz, 1H, 3), 7.70 (d, J = 3.8 Hz, 1H, 4 or 5), 7.55 (dd, J = 8.6, 1.6 Hz, 1H, 2), 6.63 (d, J = 3.8 
Hz, 1H, 4 or 5), 1.68 (s, 9H, 6). 
64 (1-Methyl-1H-imidazol-5-yl)methanol 
 
To an ice cold solution of 1-methyl-1H-imidazole-5-carbaldehyde 63 (275 mg, 2.50 mmol) in 
10 mℓ THF was added LiAlH4 (220 mg, 5.80 mmol) and allowed to stir for 20 minutes. The 
reaction was quenched by the careful addition of NaSO4•10H2O and allowed to stir for an 
additional hour. The precipitate was removed via filtration and the solvent was removed in 
vacuo to yield product (180 mg, 88.6%). 1H NMR (300 MHz, CDCl3) δ 7.36 (s, 1H, 1 or 2), 
6.84 (s, 1H, 2 or 1), 4.60 (s, 2H, 3), 3.69 (s, 3H, 4), 3.59 – 2.10 (m, 1H, 5). 
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65 5-(Chloromethyl)-1-methyl-1H-imidazole hydrochloride 
 
To a stirred solution of 64 (171 mg, 1.52 mmol) in SOCl2 (5 mℓ) was added 1 drop of DMF. 
After 30 minutes, the solvent was removed in vacuo. The remainder was dissolved in 
ethanol and triturated with diethyl ether to yield an off white solid (179 mg, 90%). 1H NMR 
(300 MHz, DMSO) δ 9.21 – 9.18 (m, 1H, 1 or 2), 7.80 – 7.78 (m, 1H, 2 or 1), 5.04 – 5.01 (m, 
2H, 3), 3.90 – 3.88 (m, 3H, 4). 
62 1-((1-Methyl-1H-imidazol-5-yl)methyl)-1H-indole-5-carbonitrile 
 
To an ice cold, stirred solution of 1H-indole-5-carbonitrile 56 (195 mg, 1.37 mmol) in 5 mℓ 
DMF was added 60% NaH in oil dispersion (131 mg, 3.28 mmol). After hydrogen evolution 
ceased, 65 (179 mg, 1.07 mmol) was added to stir for 16 hours. After the solvent was 
removed in vacuo, the remainder was partitioned between water and EtOAc (3 x 50 mℓ). The 
recombined organic layers were then washed with brine, dried with MgSO4 and filtered. The 
product was purified by column chromatography (3:1:96 MeOH:TEA:DCM) and recrystallized 
from DCM/Hexanes/Toluene to afford pale yellow crystals (110 mg, 34%). Rf = 0.08 (1:1:98 
MeOH:TEA:DCM). 1H NMR (300 MHz, CDCl3) δ 7.98 - 7.97 (m, 1H, ArH), 7.48 - 7.43 (m, 
3H, ArH), 7.17 (s, 1H, ArH), 7.10 (d, J = 3.3 Hz, 1H, ArH), 5.30 (s, 2H, 6), 3.34 (s, 3H, 7). 
64 Tert-butyl 5-bromo-1H-indole-1-carboxylate 
 
To a stirring solution of 5-bromo-indole 70 (500 mg, 2.55 mmol) in MeCN (15 mℓ), was 
added Boc2O (612 mg, 2.81 mmol) and a catalytic amount of DMAP. After the reaction was 
allowed to stir for 16 hours at room temperature, the solvent was removed in vacuo. The 
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crude was partitioned with water and extracted with EtOAc (3 x 50 mℓ). The combined 
organic layers washed with brine, dried with MgSO4 and filtered. The crude was purified 
using gravity chromatography (1:9 EtOAc:Hexanes) to yield a clear oil (679 mg, 90%). Rf = 
0.30 (1: 9 EtOAc:Hexanes). 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 8.9 Hz, 1H, 1), 7.69 (d, 
J = 2.0 Hz, 1H, 3), 7.58 (d, J = 3.7 Hz, 1H, 4 or 5), 7.39 (dd, J = 8.9, 2.0 Hz, 1H, 2), 6.50 (d, 
J = 3.7, 1H, 5 or 4), 1.67 (s, 9H, 6). 
65 Acetoxy(5-bromo-1-(tert-butoxycarbonyl)-1H-indol-3-yl)mercury 
 
To a stirring solution of 64 (679 mg, 2.29 mmol) in glacial acetic acid (17 mℓ), was added 
mercury(II) acetate (729 mg, 2.29 mmol). After the reaction was left to stir overnight, the 
slurry was filtered to give a solid which was used without further purification (1146 mg, 90%). 
Rf = 0.50 (20% EtOAc / Hexanes). 
1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 8.7 Hz, 1H, 1), 
7.69 (d, J = 1.9 Hz, 1H, 3), 7.54 (s, 1H, 4), 7.41 (dd, J = 8.7, 1.9 Hz, 1H, 2), 2.13 (s, 3H, 6), 
1.67 (s, 9H, 5). 
66 (5-Bromo-1-(tert-butoxycarbonyl)-1H-indol-3-yl)boronic acid 
 
To a solution of 65 (1146 mg, 2.070 mmol) in THF (30 mℓ) purged with nitrogen was added a 
solution of borane (155 mg, 20.7 mmol). After the mixture was agitated for 1 hour, water was 
added (15 mℓ). The liquid portion was separated from the elemental mercury and 
concentrated. The residue was dissolved in THF/EtOAc mixture the solids removed by 
filtration. The filtrate was partitioned between water and brine and the aqueous phases 
discarded. The organic phase was concentrated in vacuo and used without further 
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purification (504 mg, 71%). Rf = 0.16 (20% EtOAc/ Hexanes). 
1H NMR (300 MHz, DMSO) δ 
8.24 – 8.22 (m, 2H, 6), 8.22 – 8.21 (m, 1H, Ar), 8.14 – 8.12 (m, 1H, Ar), 8.00 – 7.94 (m, 1H, 
Ar), 7.45 – 7.40 (m, 1H, Ar), 1.63 (s, 9H, 5). 
71 Tris(dibenzylideneacetone)dipalladium  
 
To a solution of hot 50°C MeOH (15 mℓ) that has been purged with nitrogen, containing 
dibenzylacetone (460 mg, 1.96 mmol) and sodium acetate (390 mg, 4.75 mmol) was added 
PdCl2 (105 mg, 0.592 mmol). The solution was left to stir for 4 hours at 40°C to form a 
precipitate which was removed by filtration after cooling. After washing with water and 
acetone, the product was dried in vacuo to yield a purple powder (0.365g, 71%).  
72 5-Bromo-1-tosyl-1H-indole 
 
To an ice cold solution of 5-bromoindole 70 (100 mg, 0.511 mmol) in DMF (20 mℓ) was 
added 60% NaH in oil dispersion (13.4 mg, 0.561 mmol). After the evolution of hydrogen 
ceased (15 minutes), tosylchloride (107 mg, 0.561 mmol) was added and the reaction was 
allowed to proceed for 5 hours. The reaction was quenched by the addition of water (100 mℓ) 
and extracted with EtOAc (3 x 50ml). The recombined organic layers were washed with 
brine, dried with MgSO4, and filtered. Purification with column chromatography (1:9 
EtOAc:Hexanes) yielded a white precipitate (95 mg, 53%). Rf = 0.4 (1:9 EtOAc:Hexanes).
 1H 
NMR (400 MHz, CDCl3) δ 7.88 – 7.84 (m, 1H, Ar), 7.75 – 7.74 (m, 1H, Ar), 7.74 – 7.71 (m, 
1H, Ar), 7.67 – 7.64 (m, 1H, Ar), 7.57 – 7.55 (m, 1H, Ar), 7.42 – 7.37 (m, 1H, Ar), 7.25 – 
7.23 (m, 1H, Ar), 7.23 – 7.20 (m, 1H, Ar), 6.60 – 6.57 (m, 1H, Ar), 2.35 (s, 3H, 8). 
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79 5-Bromo-1H-indole-3-carbaldehyde 
  
To ice cold DMF (9.56 mℓ) was added POCl3 (4.66 mℓ, 51.0 mmol) and allowed to stir for 15 
minutes. To this was added 5-bromo-1H-indole 60 (1000 mg, 5.10 mmol) and allowed to stir 
for 1 hour. The temperature was then increased to 40 °C and allowed to stir for another 
hour. The reaction was then cooled to RT and then poured onto ice. Aqueous NaOH was 
then added to pH 6. The reaction was then stirred overnight. The precipitate was then 
collected by filtration and washed with water. This was then dried under high vacuum to yield 
a white solid (1010 mg, 88%). 1H NMR (400 MHz, DMSO) δ 9.92 (s, 1H, 5), 8.34 (s, 1H, 4), 
8.21 (d, J = 1.9 Hz, 1H, 3), 7.49 (d, J = 8.6 Hz, 1H, 1), 7.40 (dd, J = 8.6, 2.0 Hz, 1H, 2). 
78 5-Bromo-3-(2-nitrovinyl)-1H-indole 
 
To a solution of 79 (300 mg, 1.34 mmol) and ammonium acetate (305 mg, 4.02 mmol) was 
added nitromethane (18 mℓ) and set to reflux for 1 hour. The solvent was then removed in 
vacuo, washed with ice cold water and extracted with EtOAc (3 x 50 mℓ). The combined 
organic layers were washed with brine, dried with MgSO4 and filtered. The crude was 
purified by flash chromatography (1:2 EtOAc:Hexanes) to yield an orange powder (201 mg, 
56.2%). Rf = 0.54 (1:1 EtOAc:Hexanes). 
1H NMR (400 MHz, DMSO) δ 8.44 – 8.33 (m, 4.0 
Hz, 1H), 8.29 – 8.24 (m, 1H), 8.23 – 8.18 (m, 1H), 8.13 – 8.02 (m, 1H), 7.55 – 7.43 (m, 1H), 
7.42 – 7.33 (m, 1H). 
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80 Tert-butyl 5-bromo-3-formyl-1H-indole-1-carboxylate 
 
To a solution of 79 (200 mg, 0.892 mmol) in THF (40.0 mℓ) was added Boc2O (272 mg, 1.25 
mmol) and a single crystal of DMAP. After the reaction was allowed to stir for 16 hours at 
room temperature, the solvent was removed in vacuo. The crude was partitioned with water 
and extracted with EtOAc (3 x 50 mℓ). The combined organic layers washed with brine, dried 
with MgSO4 and filtered. The crude was purified using gravity chromatography (1:4 
EtOAc:Hexanes) to yield a clear oil (257 mg, 88.9%). Rf = 0.80 (1:1 EtOAc:Hexanes). 
1H 
NMR (400 MHz, DMSO) δ 10.07 (s, 1H, 5), 8.72 (s, 1H, 4), 8.27 (d, J = 2.0 Hz, 1H, 3), 8.06 
(d, J = 8.9 Hz, 1H, 1), 7.62 (dd, J = 8.9, 2.0 Hz, 1H, 2), 1.66 (s, 9H, 6). 
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Modelling SpdSyn − 2PT9 
Protein preparation 
Standard dynamics cascade #1 
Minimisation 1   Equilibration 
Algorithm SD   Steps 10000 
Max Steps 5000   Time step 0.001 
RMS gradient 0.1   Target temp 300 
Energy change 0   Save results frequency 100 
Constraints 
 
  Adjust velocity frequency 50 
  
 
  
  
Minimisation 2 
 
  Production  
Algorithm CG   Steps 10000 
Max Steps 5000   Time step 0.001 
RMS gradient 0.0001   Target temp 300 
Energy change 0   Temperature coupling decay 5 
  
  Save results frequency 1 
  
 
    
Heating 
 
  Implicit Solvent model DDDE 
Steps 20000   Electrostatics Spherical cut-off 
Initial temp 0.001      
Target temp 300   
 
Adjust velocity frequency 50    Fixed atom constrains: all non-hydrogen atoms 
Save results frequency 100     
 
Standard dynamics cascade #2 
Minimisation 1     Equilibration   
Algorithm SD   Steps 10000 
Max Steps 5000   Time step 0.001 
RMS gradient 0.1   Target temp 300 
Energy change 0   Save results frequency 100 
Constraints 
 
  Adjust velocity frequency 50 
  
 
   
 
Minimisation 2 
 
  Production  
Algorithm CG   Steps 100 
Max Steps 5000   Time step 0.001 
RMS gradient 0.0001   Target temp 300 
Energy change 0   Temperature coupling decay 5 
Constraints 
 
  Save results freq 1 
  
 
  Implicit Solvent model DDDE 
Heating 
 
    
 
Steps 2000   Electrostatics Spherical cut-off 
Initial temp 0.001     
Target temp 300   
 
Adjust velocity frequency 50    Fixed atom constrains: all non-hydrogen atoms 
Save results frequency 100   
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Solvation   
Solvation model Explicit periodic boundary 
Radius of Sphere 20.0 
Centre of Mass 
 
Minimum Distance From Boundary 7.0 
Cell Shape Orthorhombic 
Add Counterion TRUE 
Salt Concentration 0.145 
Random Seed 314159 
Cation Type Sodium 
Anion Type Chloride 
 
Minimisation   
Algorithm Smart Minimizer 
Max Steps 200000 
RMS Gradient 0.1 
Energy Change 0 
Save Results Frequency 0 
Implicit Solvent Model None 
Non-bond List Radius 14.0 
Non-bond Higher Cut-off Distance 12.0 
Non-bond Lower Cut-off Distance 12.0 
Electrostatics Spherical Cut-off 
Kappa 0.34 
Order 4 
 
Positive control – 4MCHA redock 
CDOCKER      
Top Hits 10 Advanced 
 
Pose Cluster Radius 10 Forcefield CHARMm 
Random conformations 10 Use full potential FALSE 
Dynamic Steps 1000 Grid Extension 8 
Dynamic target temperature 1000 Ligand Partial Charge Method 
Momany-
Rone 
Include Electrostatic Interactions True Random number seed 314159 
Orientations to refine  Final Minimisation 
Full 
Potential 
Maximum bad orientations 800 
Final Minimisation Gradient 
Tolerance 
0 
Orientation vdW Energy Threshold 300 
  
Simulated Annealing True 
  
Heating Steps 2000 
  
Heat Target Temperature 700 
  
Cooling Steps 5000 
  
Cooling Target Temperature 300 
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vHTS – Pharmacophore method 
Build 3D database 
Conformation method BEST 
Number of conformations 150 
Advanced settings Default 
 
Search 3D database 
Input database Sigma Max Hits 300 
Align ligands True Output All conformations 
Search Method Best Descriptors True 
 
CDOCKER      
Top Hits 10 Advanced 
 
Pose Cluster Radius  Forcefield CHARMm 
Random conformations 100 Use full potential FALSE 
Dynamic Steps 1000 Grid Extension 
 
Dynamic target temperature 1000 
Ligand Partial Charge 
Method 
Momany-Rone 
Include Electrostatic Interactions True Random number seed 314159 
Orientations to refine 20 Final Minimisation Full Potential 
Maximum bad orientations 800 
Final Minimisation 
Gradient Tolerance 
0 
Orientation vdW Energy Threshold 300 
  
Simulated Annealing True 
  
Heating Steps 2000 
  
Heat Target Temperature 700 
  
Cooling Steps 5000 
  
Cooling Target Temperature 300 
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Modelling SpdSyn − 2I7C  
Protein preparation 
Standard dynamics cascade   
Minimisation 1 
 
  Equilibration 
 
Algorithm SD   Steps 10000 
Max Steps 5000   Time step 0.001 
RMS gradient 0.1   Target temp 300 
Energy change 0   Adjust velocity frequency 50 
Constraints 
 
  Save results frequency 100 
  
 
    
 
Minimisation 2 
 
  Production 
 
Algorithm CG   Steps 1000 
Max Steps 5000   Time step 0.001 
RMS gradient 0.0001   Target temp 300 
Energy change 0   Temperature coupling decay 5 
Constraints 
 
  Save results frequency 1 
  
 
    
 
Heating 
 
  Implicit Solvent model GBSW 
Steps 2000     
 
Initial temp 0.001   Electrostatics Spherical cut-off 
Target temp 300     
 
Adjust velocity frequency 50   Fixed atom constrains: all non-hydrogen atoms 
Save results frequency 100     
 
Solvation 
 
Solvation model Explicit periodic boundary 
Radius of Sphere 20 
Centre of Mass 
 
Minimum Distance From Boundary 7 
Cell Shape Orthorhombic 
Add Counterion TRUE 
Salt Concentration 0.145 
Random Seed 314159 
Cation Type Sodium 
Anion Type Chloride 
 
Minimisation 
 
Algorithm Smart Minimizer 
Max Steps 40000 
RMS Gradient 0 
Energy Change 0 
Save Results Frequency 0 
Implicit Solvent Model None 
Non-bond List Radius 14 
Non-bond Higher Cut-off Distance 12 
Non-bond Lower Cut-off Distance 12 
Electrostatics Particle Mesh Ewald 
Kappa 0.34 
Order 4 
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CDOCKER 
 
  
 
Top Hits 10 Advanced 
 
Pose Cluster Radius 
 
Forcefield CHARMm 
Random conformations 30 Use full potential FALSE 
Dynamic Steps 1000 Grid Extension 8 
Dynamic target temperature 1000 Ligand Partial Charge Method 
Momany-
Rone 
Include Electrostatic Interactions TRUE Random number seed 314159 
Orientations to refine 15 Final Minimisation 
Full 
Potential 
Maximum bad orientations 800 
Final Minimisation Gradient 
Tolerance 
0 
Orientation vdW Energy Threshold 300 
  
Simulated Annealing TRUE 
  
Heating Steps 2000 
  
Heat Target Temperature 700 
  
Cooling Steps 5000 
  
Cooling Target Temperature 300 
  
 
Positive control – AdoDATO redock 
CDOCKER       
Top Hits 10 Advanced   
Pose Cluster Radius 
 
Forcefield CHARMm 
Random conformations 30 Use full potential FALSE 
Dynamic Steps 1000 Grid Extension 8 
Dynamic target temperature 1000 Ligand Partial Charge Method 
Momany-
Rone 
Include Electrostatic Interactions TRUE Random number seed 314159 
Orientations to refine 15 Final Minimisation 
Full 
Potential 
Maximum bad orientations 800 
Final Minimisation Gradient 
Tolerance 
0 
Orientation vdW Energy Threshold 300 
  
Simulated Annealing TRUE 
  
Heating Steps 2000 
  
Heat Target Temperature 700 
  
Cooling Steps 5000 
  
Cooling Target Temperature 300 
  
 
Hotspot guided screen - LibDock 
LibDock 
Number of hotspots 100 Input ChemDB 
Docking Tolerance 0.25 Conformation method None 
Docking Pre-set 
High-
Quality 
Minimisation algorithm Do not minimise 
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CDocking of 1600 LibDock results 
CDOCKER 
 
    
Top Hits 1 Advanced 
 
Pose Cluster Radius 
 
Forcefield CHARMm 
Random conformations 45 Use full potential FALSE 
Dynamic Steps 1000 Grid Extension 8 
Dynamic target temperature 1000 Ligand Partial Charge Method 
Momany-
Rone 
Include Electrostatic Interactions TRUE Random number seed 314159 
Orientations to refine 15 Final Minimisation 
Full 
Potential 
Maximum bad orientations 800 
Final Minimisation Gradient 
Tolerance 
0 
Orientation vdW Energy Threshold 300 
  
Simulated Annealing TRUE 
  
Heating Steps 2000 
  
Heat Target Temperature 700 
  
Cooling Steps 5000 
  
Cooling Target Temperature 300 
  
 
SpdSyn docking parameters for designed compounds 
CDOCKER 
 
  
 
Top Hits 10 Advanced 
 
Pose Cluster Radius 
 
Forcefield CHARMm 
Random conformations 30 Use full potential FALSE 
Dynamic Steps 1000 Grid Extension 8 
Dynamic target temperature 1000 Ligand Partial Charge Method 
Momany-
Rone 
Include Electrostatic Interactions TRUE Random number seed 314159 
Orientations to refine 10 Final Minimisation 
Full 
Potential 
Maximum bad orientations 800 
Final Minimisation Gradient 
Tolerance 
0 
Orientation vdW Energy Threshold 300 
  
Simulated Annealing TRUE 
  
Heating Steps 2000 
  
Heat Target Temperature 700 
  
Cooling Steps 5000 
  
Cooling Target Temperature 300 
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Modelling PFT − 2R2L 
PFT protein preparation 
Standard dynamics cascade 
Minimisation 1 
 
  Equilibration 
 
Algorithm SD   Steps 1000 
Max Steps 500   Time step 0.001 
RMS gradient 0.1   Target temp 300 
Energy change 0   Save results frequency 100 
Constraints 
 
  Adjust velocity frequency 50 
     
Minimisation 2 
 
  Production 
 
Algorithm CG   Steps 10000 
Max Steps 500   Time step 0.001 
RMS gradient 0.0001   Target temp 300 
Energy change 0   Temperature coupling decay 5 
Constraints    Save results frequency 100 
       
 
Heating    Implicit Solvent model DDDE 
Steps 2000     
 
Initial temp 0.001   Electrostatics Spherical cut-off 
Target temp 300      
Adjust velocity frequency 50   Fixed atom constrains: all non-hydrogen atoms 
Save results frequency 100      
 
Solvation 
Solvation model Explicit periodic boundary 
Radius of Sphere 20.0 
Centre of Mass 
 
Minimum Distance From Boundary 7.0 
Cell Shape Orthorhombic 
Add Counterion TRUE 
Salt Concentration 0.145 
Random Seed 314159 
Cation Type Sodium 
Anion Type Chloride 
 
Minimisation 
Algorithm Smart Minimizer 
Max Steps 20000 
RMS Gradient 0.1 
Energy Change 0 
Save Results Frequency 0 
Implicit Solvent Model GB 
Nonbonded List Radius 14.0 
Nonbonded Higher Cut-off Distance 12.0 
Nonbonded Lower Cut-off Distance 12.0 
Electrostatics Spherical Cut-off 
Kappa 0.34 
Order 4 
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2R2L docking protocols 
CDOCKER 
Top Hits 10 Advanced 
 
Pose Cluster Radius 
 
Forcefield CHARMm 
Random conformations 16 Use full potential FALSE 
Dynamic Steps 1000 Grid Extension 8 
Dynamic target temperature 1000 Ligand Partial Charge Method 
Momany-
Rone 
Include Electrostatic Interactions TRUE Random number seed 314159 
Orientations to refine 10 Final Minimisation 
Full 
Potential 
Maximum bad orientations 800 
Final Minimisation Gradient 
Tolerance 
0 
Orientation vdW Energy Threshold 300 
  
Simulated Annealing TRUE 
  
Heating Steps 2000 
  
Heat Target Temperature 700 
  
Cooling Steps 5000 
  
Cooling Target Temperature 300 
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